



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## The uptake and metabolism of amino acids, and their unique role in the biology of pathogenic trypanosomatids

**Citation for published version:**

Marchese, L, Nascimento, JDF, Damasceno, FS, Bringaud, F, Michels, PAM & Silber, AM 2018, 'The uptake and metabolism of amino acids, and their unique role in the biology of pathogenic trypanosomatids' *Pathogens*, vol. 7, no. 2, 36. DOI: 10.3390/pathogens7020036

**Digital Object Identifier (DOI):**

[10.3390/pathogens7020036](https://doi.org/10.3390/pathogens7020036)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

Pathogens

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



Review

# The Uptake and Metabolism of Amino Acids, and Their Unique Role in the Biology of Pathogenic Trypanosomatids

Letícia Marchese <sup>1,†</sup>, Janaina de Freitas Nascimento <sup>1,†</sup>, Flávia Silva Damasceno <sup>1,†</sup>, Frédéric Bringaud <sup>2</sup>, Paul A. M. Michels <sup>3</sup>  and Ariel Mariano Silber <sup>1,\*</sup>

<sup>1</sup> Laboratory of Biochemistry of Tryps—LaBTryps, Department of Parasitology, Institute for Biomedical Sciences, University of Sao Paulo, Av. Lineu Prestes, 1374, São Paulo 05508-000, SP, Brazil; lets.marchese@gmail.com (L.M.); janaina\_biomed@hotmail.com (J.d.F.N.); flaviadamasceno@usp.br (F.S.D.)

<sup>2</sup> Laboratoire de Microbiologie Fondamentale et Pathogénicité (MFP), Université de Bordeaux, CNRS UMR-5234, 146, rue Léo Saignat, Zone Nord, Bâtiment 3A, 33076 Bordeaux, France; frederic.bringaud@u-bordeaux.fr

<sup>3</sup> Centre for Immunity, Infection and Evolution and Centre for Translational and Chemical Biology, School of Biological Sciences, Ashworth Laboratories, Charlotte Auerbach Road, The University of Edinburgh, Edinburgh EH9 3FL, UK; paul.michels@ed.ac.uk

\* Correspondence: asilber@usp.br; Tel.: +55-11-3091-7335

† These authors contributed equally to this work.

Received: 5 March 2018; Accepted: 29 March 2018; Published: 1 April 2018




**Abstract:** *Trypanosoma brucei*, as well as *Trypanosoma cruzi* and more than 20 species of the genus *Leishmania*, form a group of flagellated protists that threaten human health. These organisms are transmitted by insects that, together with mammals, are their natural hosts. This implies that during their life cycles each of them faces environments with different physical, chemical, biochemical, and biological characteristics. In this work we review how amino acids are obtained from such environments, how they are metabolized, and how they and some of their intermediate metabolites are used as a survival toolbox to cope with the different conditions in which these parasites should establish the infections in the insects and mammalian hosts.

**Keywords:** amino acid metabolism; amino acid uptake; bioenergetics; stress management; autophagy; host-parasite interaction

## 1. Introduction

Trypanosomes are a group of flagellated protists living in a wide range of associations with other organisms, ranging from mutualism to parasitism. Inside this group we can find two genera which include species that are pathogenic to humans: *Trypanosoma* and *Leishmania*. The genus *Trypanosoma* groups two species causing human diseases: *Trypanosoma cruzi* and *Trypanosoma brucei*; in contrast, the genus *Leishmania* comprises more than twenty species affecting human health. All these pathogens have a complex life cycle involving several mammalian species and insects, which are responsible for the main mechanisms of transmission among mammals. Therefore, the life cycles of these parasites involve the establishment of the infection and survival inside different hosts. The different territories that these parasites should colonize inside each kind of host determine the need for a flexible and quickly adaptable metabolism to deal not only with their energy requirements, but also with a variety of stressing conditions predominant in the different environments in which these organisms live [1].

Briefly, the life cycles of *T. cruzi*, *T. brucei* and *Leishmania* spp. are schematized in Figure 1 and can be summarized as follows:



**Figure 1.** Life cycle of TriTryps parasites (*T. brucei*, *T. cruzi* and *Leishmania* spp.). The names of cell forms are abbreviated as A: amastigote, BSF: bloodstream trypomastigote, E: epimastigote, IE: intracellular epimastigote, M: metacyclic, P: promastigote, PCF: procyclic, and T: trypomastigote (adapted from [2]).

(a) *T. cruzi*, the causative agent of Chagas disease, infects the insect midgut after a bloodmeal on an infected mammal, having the non-replicative, infective trypomastigote forms circulating in its blood. In the triatomine gut, these trypomastigotes will differentiate into the replicative (non-infective for mammals) epimastigote forms, which are able to colonize the insect midgut. In the posterior region of the digestive tube, parasites differentiate into the infective, non-replicative metacyclic trypomastigotes [3]. During a next bloodmeal, the triatomine insect will defecate, expelling metacyclic trypomastigotes, which enter into contact with the skin or mucosa of the mammal being bitten. The parasites internalize into this new host through wounds in the skin or exposed mucosa, and must invade cells to reach the cytosol where they differentiate into replicative forms denominated amastigotes [4]. After several cycles of cell division, amastigotes differentiate into a transient replicative intracellular stage named intracellular epimastigotes [5], and, finally, these epimastigote-like forms differentiate into the infective trypomastigotes which burst from the infected cells into the extracellular environment. Trypomastigotes can have two fates, to infect neighbor cells or to reach the bloodstream. Once they reach the bloodstream they can infect other cells in neighboring or distant tissues, or they can be taken up by a new insect which will transmit them to other mammals [6].

(b) *T. brucei* is transmitted by the obligatory blood-feeding tsetse flies. The tsetse takes up bloodstream forms (BSF) of *T. brucei* during a bloodmeal on an infected mammal [7]. Two types of BSF can be distinguished on the basis of morphological, biochemical, and biological characteristics: the long-slender BSF, and the stumpy BSF. Long-slender BSF are replicative, and are responsible for the long-term parasitemia in the mammalian host. When long-slender BSF reach a certain population density, which is sensed through a secreted “stumpy induction factor” (SIF), they differentiate into the non-replicative stumpy forms [8]. These latter BSF forms are the only ones that are able to differentiate into the replicative procyclic forms (PCF) inside the insect and survive in the conditions present in the insect midgut [9]. PCF replicate and initiate their migration to the salivary gland. During this journey, they undergo differentiation into procyclic epimastigotes, a process that is completed once the salivary gland is reached [10]. Upon having colonized the salivary gland, they finally differentiate into the infective, non-dividing metacyclic forms, which will be inoculated in a new mammalian host during the next bloodmeal of the insect. Metacyclics will differentiate into long-slender BSF in order to replicate in the bloodstream to establish the infection. Eventually, BSF can cross the blood brain barrier and reach the central nervous system [11].

(c) *Leishmania* spp. are transmitted by female phlebotomine sandflies which become infected when they take their bloodmeal on an infected mammal [12]. During the bloodmeal, phlebotomines ingest infected macrophages, which are lysed by hydrolytic enzymes present in the insect digestive tube. The released amastigotes differentiate into proliferative promastigotes, which start to replicate in the midgut. Upon nutrient depletion and low pH, promastigotes differentiate into non-replicative, infective metacyclic promastigotes, which accumulate mostly in the stomodeal valve. During a next bloodmeal, these metacyclic forms will be inoculated into the mammalian host [13]. Components of the sandfly saliva can function as attractors for the host macrophages, which migrate to the region of the bite and phagocytize the *Leishmania* parasites [14]. Once inside the parasitophorous vacuole, metacyclic promastigotes can differentiate into replicative amastigotes. These amastigotes secrete a series of proteins that can modulate, or even subvert, the role of lysosomal-derived lytic enzymes, allowing the parasites to customize the vacuole as an adequate niche for replicating and establishing the infection [15]. The infection can spread to other phagocytic cells directly through the release of infective amastigotes from the macrophages. Additionally, other phagocytic host cells can become infected by the uptake of *Leishmania*-infected cells: intracellular amastigotes are able to induce in their host cells an apoptosis-like process causing their phagocytosis that allows the amastigotes to infect a new cell [15]. Cells infected with *Leishmania* spp. can be ingested by a (non-infected) sandfly, which will be able to transmit it to a new mammalian host.

As mentioned above, *T. brucei*, *T. cruzi*, and *Leishmania* spp. have insects and mammals as hosts. Their biology, the niches they colonize inside each host, and the mechanisms used against the host defenses have similarities and differences. For example, *T. brucei* is transiently present in the insect midgut: once they establish the infection they colonize the salivary gland. *Leishmania* spp. colonize the midgut and the proboscis of the insect, and is inoculated when the insect regurgitates during their bloodmeal. Differently, *T. cruzi* transit through the entire digestive tube, and eventually colonizes its entire epithelium, including the terminal portion, and the infected parasites are expelled with the faeces. In the mammalian host, the replicative stages of *Leishmania* spp. and *T. cruzi* are the amastigotes, which are strictly intracellular. However, the amastigotes of *Leishmania* spp. are intracellularly located in a parasitophorous vacuole in phagocytic cells (mostly macrophages), while *T. cruzi* (which is able to invade almost any nucleated cell) is transiently present in a parasitophorous vacuole, and then escapes to the host cell's cytosol. Differently, *T. brucei* is strictly extracellular, and was classically assumed to being able to colonize the bloodstream and the central nervous system [11,16]. More recently, their ability to survive in the skin and the extracellular interstices of fat cells in adipose tissue was shown [17]. The indicated similarities and differences between these groups of organisms probably determined that each one evolved its metabolism to survive in the different environments they colonize. In this respect, amino acid metabolism is crucial for these parasites far beyond their conventional roles as

sources of carbon and energy, and building blocks of proteins. In this review, we have compiled information about the relevance of amino acid transport and metabolism for involvement in critical biological processes during the life cycle of these parasites, such as the establishment of the infection within the mammalian and insect hosts, differentiation, modulation of the cell cycle and resistance to extreme stress conditions.

A note on the nomenclature used: When genome sequencing of trypanosomatid organisms was initiated, one reference strain (or species, in the case of *Leishmania*) was chosen for each of three human diseases caused by trypanosomatids (sleeping sickness, Chagas disease, and leishmaniasis). The term TriTryps was then introduced to refer to *T. brucei*, *T. cruzi*, and *L. major* in most of comparative studies among these species. Subsequently, the term TriTryps has been adopted to refer to the entire range of human pathogenic trypanosomatids and will be used in this sense in this paper. In the case of amino acids, the conventional three-letter code is used to refer to the L-isomers from the beginning of the text without being specifically spelled in full at the first mention. All other abbreviations are used after first giving the full term followed by introducing the abbreviation between parentheses. Finally, to avoid confusion about names and identities of enzymes, we followed the IUBMB recommendations for biochemical texts: they are identified firstly by both their more common name and their EC number. In most of cases, an abbreviation is introduced to make the text more readable, and this abbreviation is used further. A complete list of all enzymes cited in the text, as well as their abbreviations and EC numbers, are found in Supplementary Table 1.

## 2. Amino Acid Uptake

### 2.1. Amino Acid Transporters and the Identification of Their Putative Genes in Trypanosomatids

Metabolite transport systems allow entry of all essential nutrients into the cells, initially to the cytosol and, subsequently, into the respective organelles. This is, in fact, the initial step of any metabolic pathway, allowing the incorporation of exogenous sources of carbon, nitrogen, sulfur, and phosphorus [18,19]. The substrates of transporters have been classified into eight categories: 1: inorganic solutes; 2: carbohydrates; 3: amino acids and derivatives; 4: bases and derivatives; 5: vitamins, cofactors, signaling molecules and their precursors; 6: drugs, dyes, sterols, and toxic substances; 7: macromolecules; and 8: miscellaneous compounds [19].

With the advent of genome sequencing of TriTryps it has been possible to identify an enormous variety of coding sequences for amino acid transporters [20]. These genes are spread throughout the chromosomes, in multiple loci. One of the first attempts to identify genes encoding amino acid transporters (AAT) in trypanosomatids focused on a family grouping of H<sup>+</sup>/amino acid symporters, the AAAP family (amino acid/auxin permease, TC 2.A.18). This family is part of the electrochemical potential-driven transporters and includes permeases transporting multiple or single amino acids [21,22]. Some transporters are encoded by single-copy genes, such as the *T. brucei* AAT11 and AAT12 (TbAAT11 and TbAAT12), others comprise gene families with multiple copies, such as TbAAT5 (six copies) and TbAAT7 (11 copies). This diversity is also reflected in the origin of the AAT genes. For example, AAT11, 12, 15, and 21 have been proposed to be orthologs present in *T. cruzi*, *T. brucei*, and *L. major*, derived from a common ancestor. Differently, *Lm*AAT1 seems to have originated by tandem duplication in *L. major*, whereas *Tc*AAT32/*Tc*AAT36 might have appeared by transpositive duplication in *T. cruzi* [22,23].

As will be discussed later in this review, various AAT/AAAP have been characterized and related to particular roles beyond uptake of amino acids as nutrients, such as osmotic control, differentiation and infection. However, a considerable number of members of both groups still remain uncharacterized. In this context, genetic tools have been used in attempts to identify the specific function of transporters in trypanosomatids, especially the ones related to drug resistance. For example, two independent RNAi library screens performed in BSF *T. brucei* indicated that the amino acid transporter TbAAT6 is most likely responsible for the uptake of DL- $\alpha$ -difluoromethylornithine (DFMO, also commercially known



as eflornithine), because its knockdown conferred resistance against this drug [24–26]. The application of RNAi screens in trypanosomatids is limited to *T. brucei*, the only species of this family in which the RNAi machinery has been extensively used for reverse genetic approaches [27]. Predictably, the development of high-throughput CRISPR-Cas9 for use in other trypanosomatids will facilitate the discovery and characterization of novel amino acid transporters [28].

## 2.2. Biochemical Characterization of Amino Acid Transporters

Amino acids are available in both mammalian and insect hosts of TriTryps at different concentrations and these metabolites can be consumed as energy source, what occurs mainly when they colonize insect vectors [29–31]. Amino acid transporters with a broad range of affinities and specificities have been described for TriTryps, probably reflecting the broad range of concentrations in which amino acids are present in the different hosts. In this review, we will approach the biochemically-described transport systems according to the representative groups of TriTryps.

### 2.2.1. *Trypanosoma brucei*

Early studies of amino acid transport showed that *T. b. gambiense* BSF take up different amino acids, such as Ala, Arg, Asp, Glu, Gly, Leu, Lys, Met, Phe, Ser, Thr, and the non-proteinogenic amino acid ornithine (Orn). In these studies, the authors showed that, in most cases, such uptake was mediated by a membrane-associated transport system, but these systems were not fully characterized [32–34]. Initially, it was suggested that, based on their specificities, the transport systems formed discrete sets (collectively named *loci*), each one able to take up different amino acids. Five different loci were described: locus A transports Lys and, by binding Glu and Arg, stimulate Lys uptake; locus B transports Thr, Gly, and Ala; locus C transports Glu, this transport being inhibited by the binding of Phe, Met, or Thr; locus D transports Met and Phe; and locus E transports Arg and Lys, this transport being inhibited by its binding of Met and Phe [34]. Later, the Thr transport in *T. brucei* BSF was assessed at Thr concentrations close to those of the rat's plasma, indicating a single transporter instead of a locus [35]. Almost simultaneously, Cys transport was described in the context of the design of a medium for axenic cultivation of BSF. Duzsenko and collaborators [36] showed that these parasites efficiently incorporated Cys, but not cystine (oxidized Cys form).

It has been shown that Pro is a main carbon source for PCF grown in glucose-depleted conditions [37–39]. In the hemolymph of tsetse flies (*Glossina* species) Pro can reach concentrations as high as 60 mM, which was assumed to be used by *T. brucei* parasites during the infection [2,40]. This reinforced the interest in the characterization of Pro uptake in PCF of *T. b. brucei*. The kinetic characterization of Pro uptake pointed to a single high affinity active transporter ( $K_M$  0.02 mM) inhibited by Ala and Cys [41]. It was also shown that the  $V_{max}$  value in parasites cultivated in glucose-depleted SDM80 medium was 2.6 times higher than that in parasites grown in glucose-rich SDM79 medium, indicating that Pro transport is down-regulated in the presence of glucose [38]. More recently, the RNAi library screening approach allowed the identification of the transporter responsible for uptake of the drug DFMO, which is TbAAT6, a low affinity transporter of neutral amino acids, including Pro, Gly, and Trp [42]. It is noteworthy that the biochemical characteristics (affinity and substrate specificity) reported for TbAAT6 expressed in *Xenopus laevis* oocytes and the PCF Pro transport system are markedly different [38,41,42]. In addition, TbAAT6 knockdown did not affect the growth of PCF in glucose-depleted conditions and Pro uptake rates, but it resulted in reduced sensitivity to DFMO [42]. This supports the view that *T. brucei*, like *T. cruzi* and *Leishmania* spp. (see below), expresses high-affinity and low-affinity Pro transport systems, the former being probably responsible for Pro metabolism in glucose-depleted conditions and at low Pro concentrations, and the latter (TbAAT6) being responsible for DFMO uptake.

Met transport systems have also been characterized in *T. b. brucei* [43,44]. Met uptake in both BSF and PCF of *T. b. brucei* occurs by a relatively high affinity ( $K_M$  0.03 mM), proton-motive force dependent system and is inhibited by Leu, Phe, and Trp. However, in BSF Met, uptake showed a

broader inhibition profile: D-Met, Leu, and Gln also inhibited Met uptake efficiently. These data suggest that different transporters are operative in the two stages [44]. Interestingly, low-affinity Met transporters with similar kinetic properties ( $K_M > 1$  mM) have been described for *T. b. brucei* and *T. b. rhodesiense* BSF [43].

More recently, other members of the AAT family have been characterized. TbAAT5-3 and TbAAT16-1 have been heterologously expressed, showing high affinity for Arg and Lys (in both cases  $K_M$  in the low  $\mu$ M range) and high selectivity (including stereoselectivity, the D-isomer does not affect the transport). Peculiarly, down-regulation of these transporters affected BSF growth, demonstrating they are essential for the parasites [45]. In addition, it has been shown that *T. brucei* has two high-affinity Orn transporters, TbAAT10-1 and TbAAT2-4. TbAAT10-1 is selective for Orn, whereas TbAAT2-4 transports both Orn and His, which is consistent with inhibition of TbAAT2-4-mediated Orn uptake in the presence of high extracellular His levels. Orn uptake by both transporters is important for growth of BSF *T. brucei*, probably due to their role in providing Orn for polyamine biosynthesis [46].

### 2.2.2. *Trypanosoma cruzi*

The study of amino acid uptake in *T. cruzi* was initiated with the demonstration that Arg and Lys uptake was mediated by transport systems [47–49]. Lys transport was described as being performed by three different systems, based on their sensitivity to neutral amino acids, with one of them being inhibited by Phe and Tyr, another by Pro, Ala, Met, and Cys, and the last one by Gly and branched-chain amino acids (BCAA), respectively [47]. Four of these amino acids that inhibit Lys transport (Gly, Val, Met, and Ala) have also been shown to be inhibitors of Arg transport [48]. The existence of these transport systems was also confirmed by Goldberg in *T. cruzi* epimastigotes [49], who proposed that Met is an inhibitor of both transporters, and Lys is an inhibitor of Arg uptake and vice versa. More recently, two Arg transport systems were fully characterized, a high-affinity transporter specific for Arg and a low-affinity transporter ( $K_M$  value for Arg 70-fold higher than that of the high-affinity system), which is inhibited by Met and, to a lesser extent, by Gly, Lys, and Tyr [50,51]. Later, a gene encoding a cationic amino-acid transporter, *TcAAP7*, was identified in *T. cruzi*. It was biochemically characterized as a Lys permease through heterologous expression and through overexpression in epimastigotes. No kinetic parameters were reported for the recombinantly expressed *TcAAP7* protein, but the transport activity in epimastigotes showed a  $K_M$  of 23  $\mu$ M. Interestingly, when epimastigotes were subjected to starvation in PBS supplemented with either glucose or Pro, Lys uptake was increased, whereas in Lys-supplemented PBS Lys uptake was considerably decreased. These data indicate the existence of an energy-dependent, substrate-sensing mechanism that regulates Lys transport [52].

A gene encoding an Arg permease (*TcAAP411/TcAAP3*) was identified, and the biochemical characterization of the protein showed an activity with kinetic parameters compatible with the high-affinity Arg transporter previously characterized by Pereira and coworkers [53]. The influence of *TcAAP3* in Arg metabolism was also studied, showing that the intracellular Arg concentration increases and arginine kinase is significantly down-regulated in parasites that overexpressed *TcAAP3* [54]. Recently, a novel transporter (*TcCAT1.1*) has been characterized, which was able to transport both Arg and Orn, although it showed high affinity for Arg and low affinity for Orn [55].

Pro uptake was also investigated in *T. cruzi*. The kinetic analysis indicated the presence of two relatively low-affinity active transport systems (named systems A and B) with different affinities. System A is  $H^+$  dependent, whereas system B is presumably dependent on ATP hydrolysis. System A is inhibited by Trp, Gly, Leu, Met, Cys, and Ala, while Cys, Ala, and Val inhibit system B [56]. A low affinity Pro carrier (*TcAAP24*, the *TbAAT6* ortholog), transporting both the L- and D-Pro enantiomers, has more recently been characterized [57]. This unusual lack of stereospecificity for Pro can be related to the reported expression of a Pro racemase in *T. cruzi* and *Trypanosoma vivax* (but not in *T. brucei* and *Leishmania* spp.) [58].

The transport of two anionic amino acids, Asp and Glu, in *T. cruzi* was described to be mediated by at least two different systems with maximal activities at lower pH [59,60]. Asp uptake occurs with

the same high affinity and specificity (only inhibited by Glu) in the epimastigote and trypomastigote forms. Glu transport, which was shown to be H<sup>+</sup> dependent, occurs with 10-times less affinity than Asp, and was inhibited by Asp, Ala, Gln, Asn, and Met [60]. Notably, the rate of Asp uptake in epimastigotes increases upon nutrient starvation of the parasites [59], while such starvation had no effect on Glu uptake [60].

The transport of His and Gln, two amino acids metabolically related to Glu, was also characterized. His uptake is performed by a medium-affinity, highly specific, active system [61]. In contrast, the highly-specific Gln transporter can be considered of low affinity, with a  $K_M$  value in the mM range (similar to that of system A for Pro transport). Like the Glu transport system, both His and Gln uptake are H<sup>+</sup> dependent and do not compete with other amino acids [Damasceno, F.S., Barisón, M.J., et al., submitted]. The transport of  $\gamma$ -aminobutyric acid (GABA), another Glu-related metabolite, showed kinetic parameters close to those of Glu uptake, but involves a different mechanism. GABA uptake is the only Na<sup>+</sup>-dependent amino acid transport characterized so far [60,62].

Cys uptake is mediated by a high-affinity system, showing an increased  $V_{max}$  under nutrient starvation and in stationary growth phase. Cys uptake seemed to be highly specific, since none of the amino acids tested (Pro, Ser, Gly, Met, Arg, Glu) significantly affected its transport rate [63].

The uptake of all BCAA (Val, Ile, and Leu) was shown to be performed by the same transport system, with relevant differences in affinity ( $K_M^{Ile}$  470  $\mu$ M,  $K_M^{Leu}$  940  $\mu$ M,  $K_M^{Val}$  1960  $\mu$ M) and velocities. The system is H<sup>+</sup> dependent and highly specific, since no other amino acids than the branched ones were able to decrease their incorporation [64].

### 2.2.3. *Leishmania* spp.

The transport of Met was the first one studied in *Leishmania* spp. by Mukkada and Simon [65]. In promastigotes of *L. tropica*, this uptake occurs through a single system, following Michaelis-Menten kinetics. After 10 min of Met uptake, only 20% of this amino acid is metabolized, mainly to Met sulfoxide and cystathionine [65]. In addition, D-Met and some neutral amino acids (Ala and BCAA), as well as internal pools of Met, Lys, and Tyr, were able to inhibit Met transport [66]. Mukkada and collaborators [67] were also pioneers in the characterization of Pro transport in *Leishmania*, describing it as an active system with broad specificity, and inhibited by Ala, Met, and Val. Later, Bonay and Cohén [68] proposed the existence of two Na<sup>+</sup>-independent neutral amino-acid (including Met) transporters in *Leishmania*, one being more specific for Ala and Pro uptake and the other more specific for Phe and Leu uptake. The energy driving Pro transport in the *L. donovani* promastigotes was determined as being a proton-motive force comprising a transmembrane pH gradient and electrical potential [69]. Later, it was established that although the uptake of Pro has an optimal pH in the neutral region (7.0–7.5), its dependence on the electrochemical potential is constant over the entire pH range tested [70]. The pH dependence of Pro transport in *L. donovani* was also seen in intracellular forms. Different from promastigotes, in which uptake is inhibited at an acidic pH, that in amastigotes has an optimum at pH 5.5. Nonetheless, as in promastigotes, Pro transport is driven by the proton-motive force [71]. Another study showed that the uptake of Pro can occur by passive transport when this amino acid is the growth rate-limiting carbon and energy source in glucose-free conditions [72]. It is also regulated by the extracellular pH [71], with different kinetics compared to that operating in promastigotes grown and assayed at pH 7.0 [73]. The differences found in the transport of Pro between *L. donovani* life-cycle stages suggest that Pro can be captured by more than one system. This was confirmed by the identification of three different Pro transport systems: a cation-dependent (system A) and a cation-independent (system B) transporter in promastigotes, and a single cation-independent transporter in amastigotes (system C) [74]. The A and C systems have an optimum pH in the acidic range (pH 6.0 and 5.0, respectively); they are less specific for Pro and able to mediate uptake of several other amino acids. In contrast, system B is less sensitive to the extracellular pH and is more specific for Pro, while only Ala, Cys, Gln, and Gly inhibit it more than 50% [74].



Also biochemically characterized in *L. donovani* promastigotes is an Arg transporter that showed a high affinity and specificity, a Na<sup>+</sup> dependence and pH sensitivity with an optimum pH at 7.5 [75]. Two more amino-acid transport systems were characterized in *L. amazonensis*. First, a single Glu transport system was found in promastigotes, which was shown to be energy dependent, sensitive to the extracellular H<sup>+</sup> concentration (pH optimum at 6.0) and insensitive to K<sup>+</sup> and Na<sup>+</sup> and susceptible to inhibition by Gln, Asp, Asn, Ala, and Met [76]. Ser uptake was also characterized in *L. amazonensis* promastigotes and amastigotes. Its kinetic analysis showed a single transport system with similar characteristics in both forms, i.e., a medium affinity and pH responsiveness (pH optimum at 7.5). Similarly to what was observed for the Glu transport system, it was not affected by K<sup>+</sup> or Na<sup>+</sup>, and was inhibited by other amino acids, in this case, Ala, Cys, Gly, Thr, and Val [77].

Some genes annotated as putatively-encoding amino-acid transporters were functionally characterized, allowing to provide a molecular identity to some of the biochemically-characterized systems. A neutral amino-acid transporter (LbAAP24), which was shown to transport mainly Pro and Ala, was identified and characterized by heterologous expression. It appeared to be a transporter with low affinity and high specificity for Pro and with an optimum pH at 6.5, identifying it as a promastigote-specific transport system A. Interestingly, LbAAP24 plays a critical role in amino-acid homeostasis and in hypotonic stress resistance [78]. Subsequently, an active and highly-specific, high-affinity Arg transporter (LdAAP3) was identified and characterized, with kinetic parameters similar to those of the system described by Kandpal et al. [79]. In addition, like for LdAAP24, a role was shown for LdAAP3 in maintaining Arg homeostasis in promastigotes [80]. This regulation was also reported in *L. amazonensis* [81,82].

Finally, transporter LdAAP7 was identified and characterized as a Lys-specific permease in *L. donovani*. Biochemical analysis of LdAAP7, heterologously expressed and in promastigotes, revealed similar kinetic parameters for Lys uptake ( $K_M$  7  $\mu$ M and 3  $\mu$ M, respectively), however, different pH dependencies (pH optimum at 4.5 and 6.5, respectively) were found. In both cases, Lys uptake was highly specific and seemed to be regulated by the intracellular Lys pool. Its overexpression in promastigotes did not increase Lys transport. Furthermore, no uptake of Lys was observed in stationary phase promastigotes, in agreement with the notion that, until now, Lys seems not to be involved in other processes than the synthesis of proteins [52].

All amino acid transporters and systems that have been characterized in TriTryps are summarized in Table 1.

**Table 1.** Biochemically-characterized amino acid transport systems and their genes in TriTryps.

Amino Acid	<i>T. brucei</i>	<i>T. cruzi</i>	<i>Leishmania</i> spp.	Gene Name
Proline <sup>a</sup>	Two systems [38,41,42]	Two systems [54]	Three systems [72]	<i>TbAAT6</i> [40]
				<i>TcAAP24</i> [55]
				<i>LmAAP24</i> [76]
Glutamate		One system [60]	One system [76]	
Glutamine		One system (Damasceno et al., submitted)		
Isoleucine, Leucine and Valine <sup>b</sup>		One system [64]		
Aspartate		One system [59]		
Arginine <sup>c</sup>		Two systems [48,49]	One system [73]	<i>TbAAT5-3</i> [45]
				<i>TcAAAP411/TcAAP3</i> and <i>TcCAT1.1</i> [51,53]
				<i>LdAAP3</i> and <i>LaAAP3</i> [75,79–82]

Table 1. Cont.

Amino Acid	<i>T. brucei</i>	<i>T. cruzi</i>	<i>Leishmania</i> spp.	Gene Name
Ornithine <sup>d</sup>				<i>TbAAT10-1</i> and <i>TbAAT2-4</i> [46] <i>TcCAT1.1</i> [55]
Histidine <sup>e</sup>		One system [61]		<i>TbAAT2-4</i> [46]
Methionine	Two systems [43,44]		One system [65,66]	
Lysine <sup>f</sup>		One system [52]	One system [52]	<i>TbAAT16-1</i> [45] <i>TcAAP7</i> [52] <i>LmAAP7</i> [52]
Threonine	One system [35]			
Cysteine	One system [36]	One system [63]		
Serine			One system [77]	

<sup>a</sup> *T. brucei* is auxotrophic for Pro [39], <sup>b</sup> TriTryps are auxotrophic for branched-chain amino acids [83–85], <sup>c</sup> TriTryps are auxotrophic for Arg [85,86], <sup>d</sup> *T. brucei* and *T. cruzi* are auxotrophic for Orn [2,87–89], <sup>e</sup> *T. cruzi* is auxotrophic for His [61,86], <sup>f</sup> TriTryps are auxotrophic for Lys [52,90,91].

### 3. Amino Acid Metabolism in TriTryps

#### 3.1. Proline


Pro can be catabolized by enzymes of the tricarboxylic acid (TCA) cycle after its conversion into Glu through two enzymatic steps [2,38,92–96]. Pro catabolism was characterized in some detail in *T. cruzi* and *T. brucei*. It initiates via Pro dehydrogenase (PRODH, EC 1.5.99.8), which produces pyrroline-5-carboxylate (P5C) using FAD as an electron acceptor. As previously shown for other systems [97,98], PRODH-derived FADH<sub>2</sub> is able to transfer electrons to the ubiquinone pool in the electron transport chain of trypanosomes [95]. In aqueous medium, P5C is converted through a non-enzymatic reaction to its open form glutamate- $\gamma$ -semialdehyde (GSA) which is oxidized to Glu by a P5C dehydrogenase (P5CDH, EC 1.5.1.12) with a concomitant reduction of NAD(P)<sup>+</sup> [96,99,100] (Figure 2).

Among the TriTryps, *T. brucei* was the first organism in which the first Pro oxidation step was characterized. As described for Pro uptake, the activity of TbPRODH in PCF is downregulated by the presence of glucose. Accordingly, in PRODH-deficient cell lines, the absence of glucose is lethal. Even more, it was shown that Pro is the only amino acid able to sustain the growth of PCF in a medium without glucose. In addition, the absence of glucose induces a 1000-fold increase of oligomycin sensitivity, which is explained by the oxidative phosphorylation dependency for ATP production when Pro is the major carbon source consumed by PCF [38]. Later, Mantilla et al. [39] showed that the second step of Pro catabolism is also essential for PCF in glucose-depleted conditions. Although P5CDH deficiency was not lethal in glucose-rich medium, TbP5CDH knockdown cells showed a slower growth rate than parental cells and a diminished mitochondrial membrane potential and capacity for ATP synthesis when cultured in medium without glucose. Remarkably, it was shown that the integrity of the Pro–Glu pathway is important for the PCF to survive in the tsetse fly midgut, a necessary condition for establishing infection in the tsetse vector.

The Pro–Glu pathway was also addressed in *T. cruzi*. It was shown that TcPRODH is a FAD-dependent Pro oxidoreductase, which is able to reduce cytochrome c in an antimycin-sensitive manner [95]. This enzyme is up-regulated in intracellular epimastigotes, consistent with previous reports on its importance for differentiation of these forms to trypomastigotes [101]. P5CDH in *T. cruzi* was identified and characterized as a component of the inner mitochondrial membrane. It is able to reduce both NAD<sup>+</sup> and NADP<sup>+</sup>, although the enzyme has a higher affinity for NAD<sup>+</sup>. TcP5CDH is up-regulated in the infective stages (trypomastigotes and metacyclic trypomastigotes) and sustains

energetically *T. cruzi* growth and the process of infecting host cells [96]. In contrast, the characterization of Pro catabolism in *Leishmania* spp. has not been performed yet, although two of its steps are known to also exist in *Leishmania* metabolism through genome data and by ancient and recent metabolic studies [2,30,92,102,103].

In addition to taking it up, most of organisms can synthesize Pro *de novo*. The most common biosynthesis pathway occurs from Glu through its phosphorylation to  $\gamma$ -glutamyl phosphate by  $\gamma$ -glutamyl kinase ( $\gamma$ GK, EC 2.7.2.11), transferring a phosphoryl group from ATP to Glu. Then,  $\gamma$ -glutamyl phosphate is reduced to GSA by  $\gamma$ -glutamyl phosphate reductase (GPR, EC 1.2.1.41), with the simultaneous oxidation of NADPH [104,105]. In most higher eukaryotes,  $\gamma$ GK and GPR activities are provided by the bifunctional enzyme P5C synthase [106,107] (P5CS, EC not assigned) and its product, GSA, is non-enzymatically converted into P5C, which serves as a substrate for P5C reductase (P5CR, EC 1.5.1.2) to produce Pro using NADPH or NADH as electron donors [108–111].



**Figure 2.** Metabolism of histidine, proline, glutamate, and glutamine. Enzymes: HAL: histidine ammonia lyase (EC 4.3.1.3); UH: urocanate hydratase (EC 4.2.1.49); IP: imidazolone propionase (EC 3.5.2.7); FG: formimidoylglutamase (EC 3.5.3.8); PRAC: proline racemase (EC 5.1.1.4); P5CR: pyrroline-5-carboxylate reductase (EC 1.5.1.2); P5CS: pyrroline-5-carboxylate synthase (EC not assigned); PRODH: proline dehydrogenase (EC 1.5.99.8); P5CDH: pyrroline-5-carboxylate dehydrogenase (EC 1.5.1.12); GDH: glutamate dehydrogenase (EC 1.4.1.3); GS: glutamine synthetase (EC 6.3.1.2); GF6PA: glutamine fructose-6-phosphate aminotransferase (EC 2.6.1.16); CPS: carbamoyl-phosphate synthase (EC 6.3.3.5); GMPS: GMP synthase (EC 6.3.5.2); ALAT: alanine aminotransferase (EC 2.6.1.2); TAT: tyrosine aminotransferase (EC 2.6.1.5); GlnAT: glutamine aminotransferase (EC 2.6.1.15). Metabolites: Pyr: pyruvate, Ala: L-alanine, XMP: xanthosine monophosphate, Glu: L-glutamate, D-F6-P: D-fructose 6-phosphate. The question mark (?) indicates unknown step.

Alternatively, Pro might also be produced from Orn, connecting its metabolism to Arg metabolism through Orn aminotransferase (OAT, EC 2.6.1.13), which can provide GSA and Glu by transferring the amino group of Orn to  $\alpha$ -ketoglutarate ( $\alpha$ -KG) in a pyridoxal-5-phosphate-dependent reversible reaction [112]. However, there is as yet no biochemical evidence for the OAT enzyme in

trypanosomatids, nor has a putative gene encoding such an enzyme been detected [20], and the urea cycle is not operative in these protists [102,113].

*T. brucei* is auxotrophic for Pro [39], whereas *T. cruzi* is capable of producing Pro in its cytosol from Glu via P5CS and P5CR. Interestingly, this Pro production in *T. cruzi* is NADPH-dependent and is regulated by the cytosolic pools of this cofactor (Marchese et al., unpublished data). Little is known about Pro biosynthesis in *Leishmania* spp., but it should be remarked that their genomes contain candidate genes for P5CS and P5CR [2,102]. In addition, Pro was not essential for growth of promastigotes in NM defined medium, strongly indicating that the biosynthetic pathway for this amino acid can be operative in these *Leishmania* [85].

Like some bacteria, the trypanosome species *T. cruzi* and *T. vivax* can interconvert L- and D-Pro through a Pro racemase (PRAC, EC 5.1.1.4) [58,114]. The first eukaryotic PRAC was identified as secreted in the culture medium by *T. cruzi* [115]. The *T. cruzi* genome encodes two isoforms of TcPRACs with different kinetic properties, one secreted, and one remaining intracellularly [116,117]. The role of D-Pro, and the interconversion between L- and D-Pro by the TcPRAC have not yet been completely elucidated, although there are some clues about the role of the enzyme in different aspects of the biology of *T. cruzi*, as will be discussed later in this review.

### 3.2. Glutamine, Histidine, and Glutamate

Glu can be considered a metabolic hub, which can be produced from a variety of metabolic sources (such as His, Gln, Pro, or the TCA cycle intermediate  $\alpha$ -KG). In addition, it can be a precursor for these metabolites in most cells. Once Glu is available inside the cells, it can be reversibly converted into  $\alpha$ -KG by the enzyme Glu dehydrogenase (GDH, EC 1.4.1.3) [118,119], transferring the amino group to  $H_2O$  (forming  $NH_4^+$ ), thus participating in energy metabolism [93,120]. Moreover,  $\alpha$ -KG can be converted into malate, and further into pyruvate through the malic enzymes [121]. Alternatively, the amino group can be removed from Glu to be transferred to pyruvate by an Ala aminotransferase (ALAT, EC 2.6.1.2) or a Tyr aminotransferase (TAT, EC 2.6.1.5) generating Ala and  $\alpha$ -KG, respectively [122]. Remarkably,  $\alpha$ -KG can be aminated to produce Glu, a mechanism to detoxify the excess of  $NH_4^+$  produced by amino acid consumption. As mentioned, the amino group can be transferred to pyruvate or other keto-acids serving as substrates for the ALAT or TAT, to allow the recovery of  $\alpha$ -KG, critical for keeping the TCA cycle working (Figure 2).

Glu is also produced through the catabolism of other amino acids, such as Pro (as described above), His, and Gln. His can be converted into Glu through a four-enzymatic-steps degradation pathway [61]. The first step of His catabolism involves the formation of urocanate and  $NH_4^+$  catalyzed by His ammonia lyase (HAL, EC 4.3.1.3). Next, urocanate hydratase (UH, EC 4.2.4.9) converts urocanate in 4-imidazolone-5-propionate (IPA) that is hydrolyzed by imidazolone propionase (IP, EC 3.5.2.7) resulting in N-formimino-L-glutamate. The last step involves the formation of Glu and formamide through a formimidoylglutamase (FG, EC 3.5.3.8) (Figure 2).

According to the TriTryp genome database, *T. cruzi* is the only trypanosomatid containing genes for the four-step pathway converting His into Glu. This is in agreement with the capacity of *T. cruzi* to completely oxidize His, forming  $CO_2$  [61]. Transcriptomic data have shown that the first two enzymes of the His degradation pathway are primarily expressed in the invertebrate host stages [123]. Accordingly, an increase of the levels of urocanate, the product of the first step of His degradation, has been reported for stationary phase epimastigotes [124].

The availability of Gln depends on its uptake from the culture medium (Damasceno et al., unpublished data) and its biosynthesis catalyzed by Gln synthetase (GS, EC 6.3.1.2), which uses Glu and  $NH_4^+$  as precursors, in a reaction that requires ATP. Incidentally, GS activity participates in the  $NH_4^+$  detoxification and, probably through the resulting control of the low pH, in the parasite exit from the parasitophorous vacuole inside the host [125].

Gln can participate as nitrogen donor in the hexosamine pathway by the enzyme Gln fructose-6-phosphate aminotransferase (GF6PA, EC 2.6.1.16) (our unpublished data), as well as in

the pyrimidine biosynthesis by the enzyme carbamoyl-phosphate synthase [126,127] (CPS EC 6.3.3.5) and in the GMP synthesis through the action of the enzyme GMP synthase [128] (GMPS, EC 6.3.5.2). Moreover, Gln is a substrate for the enzyme Gln aminotransferase (GlnAT, EC 2.6.1.15) that transfers the amino group from Gln to pyruvate, generating Ala and  $\alpha$ -ketoglutaramate [129].

*Leishmania* can take Glu up from the culture medium [76] and oxidize it intracellularly by the TCA cycle, thus contributing to the energy metabolism [102]. Additionally, in *Leishmania* spp., Glu can be converted into Gln by a GS [130], as occurs in *T. cruzi*, using Glu and  $\text{NH}_4^+$  as substrates. Moreover, the importance of the enzyme GF6PA (which uses Gln as substrate, and participates in the hexosamine pathway) was demonstrated. Promastigote GF6PA null mutants are unable to proliferate inside macrophages [131].

### 3.3. Arginine and Ornithine


Arg forms, in most eukaryotes, one of the central metabolic nodes, connecting the urea cycle with Glu/Pro metabolism through its conversion to Orn by an arginase (ARG, EC 3.5.3.1) and then to GSA/P5C by OAT. As explained above, the oxidation of P5C by P5CDH yields Glu, which connects with the TCA cycle through  $\alpha$ -KG. This makes it crucial for cell viability since it is a precursor of Orn, urea, NO, polyamines (see below), and other amino acids, such as Pro [132]. When arginase is present, a major metabolic fate of Arg is the synthesis of polyamines. It happens through a complex pathway that involves four steps. First, Arg is converted into Orn through the action of an arginase (ARG, EC 3.5.3.1). Orn is then decarboxylated in a reaction catalyzed by Orn decarboxylase (ODC, EC 4.1.1.17), generating putrescine. Next, spermidine synthase (SPDS, EC 2.5.1.16) adds an aminopropyl group to putrescine, finally generating spermidine. The last step uses a decarboxylated S-adenosylmethionine as an aminopropyl donor, which is an outcome of the action of the enzyme S-adenosylmethionine decarboxylase (AdoMetDC, EC 4.1.1.50). In mammals, there is a fifth step in which spermidine is converted to spermine [133].

Interestingly, in *T. brucei* and *Leishmania* spp. this latter step is not present, while *T. cruzi*, in turn, seems to have lost the ODC coding sequence and is auxotroph for diamines [134]. In trypanosomatids, spermidine can be used to synthesize the redox agent trypanothione, which is specific to these organisms [135]. This synthesis occurs through a two-step pathway mediated by a single enzyme, the trypanothione synthetase (TRYPSY, EC 6.3.1.9) [136–138]. Trypanothione, in turn, can be reduced by the homolog of glutathione reductase, the trypanothione reductase (TRYPRD, EC 1.8.1.12) [139,140] (Figure 3).

In *Leishmania* spp. the catabolism of Arg involves its conversion to Orn and urea, catalyzed by ARG. *Lm*ARG is compartmentalized in peroxisome-related organelles, named glycosomes [141,142], differently from its mammalian counterparts, in which one isoform is present in the cytosol and the other one in mitochondria [143]. The other enzymes involved to polyamine biosynthesis are cytosolic. Therefore, Arg seems to be taken up from the extracellular medium, converted into Orn within glycosomes, after which Orn goes back to the cytosol where it becomes a precursor in polyamine biosynthesis. However, when *Lm*ARG is expressed without its glycosomal-targeting signal, it localizes as an active enzyme to the cytosol where it is able to restore the synthesis of polyamines in ARG-knockout cell lines of *L. mexicana* promastigotes [141]. In *L. major* and *L. tropica*, expression and enzymatic activity of *Lm*ARG were found to be higher in promastigote cells during their logarithmic growth than in the stationary phase [144]. Promastigotes of *L. mexicana* and *L. donovani* ARG-null mutants are auxotrophic for polyamines and require supplementation of Orn or putrescine to grow. However, deletion of ARG had no effect on amastigotes proliferation in spleens of infected mice [141,145]. Interestingly, transcriptomics and metabolomics analyses of promastigote and amastigote ARG-null mutants revealed a tight regulation of the expression of genes associated with Pro and polyamine metabolism, as well as the levels of metabolites associated with this pathway. These results strongly suggest a metabolic regulon controlled by ARG expression [82].



*T. cruzi* and *T. brucei* use Arg in different ways than *Leishmania* spp. In the case of *T. brucei*, a metabolomics analysis of BSF showed the lack of ARG activity [88]. Additionally, the only gene encoding a putative ARG encodes an enzymatically non-functional version of ARG [146], pointing to the absence of a canonical mechanism to produce Orn from Arg. This fact would explain the relevance of Orn uptake by AAT10-1 and AAT2-4 in this parasite [46]. Interestingly, it has been shown that both parasites possess an Arg kinase (ArgK, EC 2.7.3.3) that can reversibly phosphorylate Arg to phospho-Arg (P-Arg) using ATP. P-Arg contributes to the management of the energetic metabolism in these parasites, acting like an energy backup when restoration of ATP levels is needed [51,147]. Furthermore, by measuring Arg uptake and the expression and activity levels of ArgK in different life-cycle stages, a connection between Arg metabolism and cell proliferation has been proposed for *T. cruzi* [148,149]. In *T. brucei* there are three isoforms of ArgK, being localized in the flagellum (*TbAK1*), the mitochondrion (*TbAK2*), and the cytosol (*TbAK3*). Although all isoforms are expressed throughout the life cycle of these parasites, higher ArgK activities have been detected in the BSF, suggesting a major role of P-Arg in the energy metabolism of this life-cycle stage [150]. More recently, it has been shown that the flagellar isoform of ArgK is essential for *T. brucei* infectivity of the tsetse fly, although the exact mechanism still remains to be elucidated [151].




**Figure 3.** Metabolism of arginine and ornithine. **Enzymes:** ArgK: arginine kinase (EC 2.7.3.3); ARG: arginase (EC 3.5.3.1); ODC: ornithine decarboxylase (EC 4.1.1.17); SPDS: spermidine synthase (EC 2.5.1.16); SMS: spermine synthase (EC 2.5.1.2); TRYPsy: trypanothione synthase (EC 6.3.1.9). **Metabolite:** DecAdoMet: decarboxylated S-adenosyl methionine.

### 3.4. Branched-Chain Amino Acids

Ile, Leu, and Val, the BCAA are biosynthesized only by plants and fungi among the eukaryotic organisms [83,84]. Indeed, there is evidence that BCAA are also essential in the TriTryp parasites. However, they seem to be able to catabolize them all [85,89,152–154]. The catabolic pathway of BCAA involves several enzymatic steps, some in common for all three amino acids and others specific for some of them. The first enzymatic reaction consists of the deamination of the BCAA producing the derived 2-oxo acid of the corresponding amino acid:  $\alpha$ -ketoisocaproic acid,  $\alpha$ -keto- $\beta$ -methylvaleric acid, and  $\alpha$ -ketoisovaleric acid are produced from Leu, Ile, and Val, respectively. Usually, in

eukaryotes this deamination is catalyzed by specific dehydrogenases, producing  $\text{NH}_3/\text{NH}_4^+$  (ValDH, EC 1.4.1.8; LeuDH, EC 1.4.1.9) [155,156] or by branched-chain aminotransferases (BCATs, EC 2.6.1.42), pyridoxal phosphate-dependent enzymes that usually use  $\alpha$ -KG as the acceptor for the amino group (leading to the formation of Glu) [157,158]. The BCATs might be located in the cytosol and the mitochondrion. The following enzymatic step is performed by a mitochondrial dehydrogenase complex, named branched-chain  $\alpha$ -keto-acid dehydrogenase complex (BCKDC), which is constituted by three enzymes: E1, E2, and E3 (EC 1.2.4.4; EC 2.3.1.168; EC 1.8.1.14, respectively) [83]. The complex catalyzes the oxidative and irreversible decarboxylation of the three BCKDC, producing the acetyl-CoA derivatives isovaleryl-CoA, 3-methylbutyryl-CoA, and isobutyryl-CoA, and also NADH and  $\text{CO}_2$ . Remarkably, all these products can be substrates of acyl-CoA dehydrogenases (ACADs, EC 1.3.8.7) as happens with the acyl-CoA derived from the  $\beta$ -oxidation of fatty acids in the mitochondrial matrix [159–161]. From this step forward, the pathways resemble some of those of fatty-acid oxidation, resulting in end products that can be introduced into the TCA cycle. The complete oxidation of Leu generates acetoacetate and acetyl-CoA (both ketogenic compounds), Val generates succinyl-CoA (glucogenic), and Ile produces propionyl-CoA and acetyl-CoA (glucogenic and ketogenic compounds, respectively) [83] (Figure 4).



**Figure 4.** Metabolism of BCAAs. **Enzymes:** BCATs: branched-chain aminotransferases (EC 2.6.1.42); BCKDC: branched-chain  $\alpha$ -keto acid dehydrogenase complex (E1: EC 1.2.4.4; E2: EC 2.3.1.168 and E3: EC 1.8.1.14); ACADs: acyl-CoA dehydrogenases (EC 1.3.8.7). **Metabolites:**  $\alpha$ -KG:  $\alpha$ -ketoglutarate, Glu: L-glutamate, CoA: coenzyme A.


The first studies on BCAA catabolism in TriTryps were performed on *T. cruzi* and *L. donovani*, demonstrating that the insect forms are able to metabolize Leu through the TCA cycle [162,163]. Leu is the most studied BCAA in TriTryps, since it has been described as a precursor of sterol and fatty-acid biosynthesis in *Leishmania* spp., *T. cruzi*, and *T. brucei*, although the latter species prefers acetate as a precursor [164–167]. Noteworthy, glucose and Thr are also main carbon sources used by *T. brucei* PCF for acetyl-CoA and lipid biosynthesis [94,168,169].

BCAT genes have been predicted in *T. brucei* and *Leishmania* spp. genomes [20]. Surprisingly, the *T. cruzi* genome lacks a putative BCAT gene, although *T. cruzi* epimastigotes are able to fully oxidize BCAA [170]. This dilemma was recently solved by showing the unusual BCAT activity displayed by the *T. cruzi* TAT and ALAT [171]. Putative genes encoding BCKDC and ACAD are also present in the

TriTryp genome database, which were recently characterized in our laboratory (Manchola, N. C. et al., Ornitz, O. O. S. et al., unpublished data).

### 3.5. Asparagine and Aspartate

As mentioned above, Asp is transported into *T. cruzi* epimastigote and trypomastigote cells [59] and is important for the metacyclogenesis process [172]. Moreover, Asp is converted to oxaloacetate by the enzyme aspartate aminotransferase [118] (ASAT, EC 2.6.1.1), and participates in ATP production through the TCA cycle and subsequent oxidative phosphorylation [93]. *T. cruzi* and *T. brucei* present two isoforms of the enzyme Asp aminotransferase, one being cytosolic (cASAT) and the other one mitochondrial (mASAT). In *T. brucei*, the cASAT is constitutively expressed and mASAT is down-regulated in BSF, whereas in *T. cruzi* the mASAT is expressed along the whole life cycle and the cASAT is specifically expressed during the mammalian stages [173,174]. Asp can also be synthesized from the TCA cycle intermediate oxaloacetate and by deamination of Asn (Figure 5).



**Figure 5.** Metabolism of asparagine, aspartate and alanine. **Enzymes:** AS: asparagine synthetase (EC 6.3.1.1); ASN: asparaginase (EC 3.5.1.1); AdesS: adenylosuccinate synthetase (EC 6.3.4.4); ACT: aspartate carbamoyl transferase (EC 2.1.3.2); ASAT: aspartate aminotransferase (EC 2.6.1.1); ALAT: alanine aminotransferase (EC 2.6.1.2); TAT: tyrosine aminotransferase (EC 2.6.1.5); AlaR: alanine racemase (EC 5.1.1.1). **Metabolites:** α-KG: α-ketoglutarate, Glu: L-glutamate, Gln: L-glutamine.


It has been shown that, in *T. brucei* BSF, Asp is a precursor of pyrimidine biosynthesis through the enzymes Asp carbamoyl transferase (ACT, EC 2.1.3.2) and adenylosuccinate synthetase [175] (AdesS, EC 6.3.4.4). Asp can also be converted into Asn by the enzyme Asp ammonia ligase (EC 6.3.1.1) which catalyzes the formation of Asn from Asp and NH<sub>4</sub><sup>+</sup>, or Asn synthetase (AS, EC 6.3.1.1), that could use either NH<sub>4</sub><sup>+</sup> or Gln (EC 6.3.5.4) as nitrogen donors, both reactions being ATP-dependent. Additionally, this parasite becomes auxotrophic for Asn when AS expression is knocked down [176].

*Leishmania* is able to synthesize both Asp and Asn from oxaloacetate by a mitochondrial ASAT and an AS [102]. Asp can support growth and Asn is non-essential when the parasites are cultivated in the presence of glucose [85]. Similarly as to what occurs in *T. cruzi* and *T. brucei*, *Leishmania* also has an active AS which can use NH<sub>4</sub><sup>+</sup> or Gln as nitrogen donors. This enzyme is not essential for parasite growth, infectivity, or survival in normal cultivation conditions [177]. More recently, an asparaginase (ASN, EC 3.5.1.1) has been characterized in *Leishmania*. This enzyme converts Asn into Asp and ammonia [178]. ASN was also demonstrated to be involved in conferring resistance to the drug amphotericin B in both amastigote and promastigote forms grown in axenic conditions [179].

### 3.6. Cysteine and Methionine

Met metabolism is involved in the biosynthesis of Cys, phospholipids, and polyamines [173,180]. Catabolism and biosynthesis of Met are connected by two regeneration cycles. The first catabolic

step is common to both Met regeneration cycles: it produces S-adenosylmethionine (AdoMet) from Met and ATP by S-adenosylmethionine synthetase (AdoMetS, EC 2.5.1.6), also named Met adenosyltransferase. From this point, AdoMet can be a methyl donor for several methyltransferases (MTs, EC 2.1.1.-), such as Cys 5-methyltransferase (CMT, EC 2.1.1.37), the major common byproduct is S-adenosylhomocysteine [180,181] (AdoHcys). From AdoHcys formation, the catabolism of Met can generate propionyl-CoA (a precursor of succinyl-CoA) via the degradation to  $\alpha$ -ketobutyrate ( $\alpha$ -KB) [182,183], through five enzymatic steps. The last three steps are performed by S-adenosylhomocysteine hydrolase (AdoHcysHD, EC 3.3.1.1), cystathionine  $\beta$ -synthase (CBS, EC 4.2.1.22), and cystathionine  $\gamma$ -lyase (CGL, EC 4.4.1.1), producing, respectively, homocysteine, cystathionine, and  $\alpha$ -KB together with Cys. One of the Met regeneration cycles is completed by the conversion of homocysteine to Met by four enzymes, i.e., betaine-homocysteine S-methyltransferase (BHMT, EC 2.1.1.5), homocysteine S-methyltransferase (HMT, EC 2.1.1.10), and either Met synthase (MetH, EC 2.1.1.13) or cobalamin-independent Met synthase [180,184] (MetE, EC 2.1.1.14). Homocysteine itself can be catabolized by homocysteine desulfurase (HD, EC 4.4.1.2), forming sulfide,  $\alpha$ -KB, and  $\text{NH}_4^+$  [185] (Figure 6).



**Figure 6.** Metabolism of methionine and cysteine. **Enzymes:** AdoMetS: S-adenosylmethionine synthetase (EC 2.5.1.6); MTs: methyltransferases (EC 2.1.1.-); AdoHcysHD: S-adenosylhomocysteine hydrolase (EC 3.3.1.1); CBS: cystathionine  $\beta$ -synthase (EC 4.2.1.22); CBL: cystathionine  $\beta$ -lyase (EC 4.4.1.8); CGL: cystathionine  $\gamma$ -lyase (EC 4.4.1.1); CGS: cystathionine  $\gamma$ -synthase (EC 2.5.1.48); BHMT: betaine-homocysteine S-methyltransferase (EC 2.1.1.5); HMT: homocysteine S-methyltransferase (EC 2.1.1.10); MetH: methionine synthase (EC 2.1.1.13); MetE: methionine synthase (EC 2.1.1.14); AdoMetDC: AdoMet decarboxylase (EC 4.1.1.50); SPDS: spermidine synthase (EC 2.5.1.16); SMS: spermine synthase (EC 2.5.1.22); MTAP: 5-methylthioadenosine phosphorylase (EC 2.4.2.28); MTAPi: 5-methylthioribose 1-phosphate isomerase (EC 5.3.1.23); MTAN: 5-methylthioadenosine nucleosidase (EC 3.2.2.16); MTRK: 5-methylthioribose kinase (EC 2.7.1.100); ASAT: aspartate aminotransferase (EC 2.6.1.1); MGL: methionine  $\gamma$ -lyase (EC 4.4.1.11); MSR: methionine sulfoxide reductase (EC 1.8.4.13/1.8.4.14); CD: cysteine disulfurase (EC 2.8.1.7); CS: cysteine synthase (EC 2.5.1.47); SAT: serine acetyltransferase (EC 2.3.1.30); HD: homocysteine desulfurase (EC 4.4.1.2). **Metabolites:**  $\alpha$ -KB:  $\alpha$ -ketobutyrate, Ser: L-serine. Question mark (?) indicates unknown step.

As already mentioned, AdoMet can also undergo decarboxylation, initiating the other Met regeneration cycle [185,186]. This decarboxylation is performed by AdoMetDC producing

decarboxylated AdoMet (DecAdoMet), which is an aminopropyl donor in the polyamine biosynthesis [187]. In mammals, this catalytic step is rate-limiting in the polyamine formation [188]. The aminopropyl moiety can be transferred to putrescine or spermidine yielding, respectively, spermidine or spermine by SPDS or SMS [180]. The reactions catalyzed by the latter two enzymes also produce 5-methyl thioadenosine, which is converted directly to 5-methylthioribose 1-phosphate by 5-methylthioadenosine phosphorylase (MTAP, EC 2.4.2.28), or through two steps performed by 5-methylthioadenosine nucleosidase (MTAN, EC 3.2.2.16) and 5-methylthioribose kinase (MTRK, EC 2.7.1.100). Next, 5-methylthioribulose 1-phosphate is formed from 5-methylthioribose 1-phosphate by 5-methylthioribose 1-phosphate isomerase (MTAPi, EC 5.3.1.23). Two more steps lead to the production of  $\alpha$ -ketomethiobutyrate (KMTB); the intermediates have been identified, but the enzymes/reaction mechanisms involved have not yet been fully elucidated [185]. Finally, the regeneration of Met from KMTB occurs through the activity of an aromatic amino acid transaminase [189]. In addition, Met can be catabolized to methanethiol and  $\alpha$ -KB by Met  $\gamma$ -lyase (MGL, EC 4.4.1.11) [185,186] and to Met sulfoxide (MetSO) by Met sulfoxide reductases (MSRs): Met (S)-S-oxide reductase (MSR-A, EC 1.8.4.13) and Met (R)-S-oxide reductase (MSR-B, EC 1.8.4.14), which produce two enantiomers, R-MetO and S-MetO, respectively [190] (Figure 6).

The first step of Met catabolism has been extensively studied in *L. infantum*. AdoMetS activity was measured in promastigotes and shown to be higher in lag and early-log phases of growth [191]. The genomic DNA of the parasite has two identical genes encoding AdoMetS. Through kinetic studies made with the heterologously-expressed enzyme it was shown that it was insensitive to the expected allosteric inhibition by AdoMet [192]. Two other enzymatic steps in Met metabolism were also studied in *Leishmania* spp.: (i) the decarboxylation of AdoMet, and (ii) the Met oxidation. The decarboxylation of AdoMet is performed by an AdoMetDC. In *Leishmania* spp., one gene encoding this enzyme was found, but, additionally, a copy annotated as a putative AdoMetDC-like proenzyme (AdoMetDCL) could be found, as in other trypanosomatids [193–195]. In *L. donovani* the knockout of the AdoMetDC gene led to spermidine auxotrophy [196]. In addition, structural and functional characterization of AdoMetDCL in *L. donovani* was performed, evidencing that it binds AdoMet and putrescine and may play an essential role in polyamine biosynthesis [195]. The oxidation of Met is performed by a MRS-A. This enzyme has been characterized in *L. major* where the genome encodes one functional copy for the cytosolically located *LmMRS-A*. Parasites knocked out for *LmMRS-A* exhibited increased sensitivity to  $H_2O_2$ . However, this protein is not essential for pathogenesis *in vivo* [197].

Initially, in BSF of *T. b. brucei*, different Met catabolic enzymes were identified: activities of AdoMetDC [198], AdoMetS, AdoHcysHD, CBS, and several MTs (guanidinoacetate N-methyltransferase-GAMT, EC 2.1.1.2; Gly N-methyltransferase-GNMT, EC 2.1.1.20; HMT; and Meth) were described. Yarlett and Bacchi also demonstrated that the AdoMet concentration is 50-fold higher in BSF isolated from rats treated with DFMO than from untreated rats [199]. Subsequently, the kinetic characterization of AdoMetS activity was performed in these parasites, evidencing the presence of two isoforms and a weak inhibition by the AdoMet product when compared to the corresponding mammalian enzyme [200]. Another study by Bacchi and coworkers [201] showed that these parasites are able to metabolize Met into intermediates of the polyamine and methyltransferases pathways. The AdoMetDC activity was initially described as being insensitive to putrescine and  $Mg^{2+}$  [198]. However, Tekwani et al. [202] showed a strong activation by putrescine when cell-free extracts were dialyzed, similarly as to what occurs with AdoMetDC from mammalian cells. Like other trypanosomatids, *T. brucei* has a gene encoding an active AdoMetDC and a catalytically-inactive version of AdoMetDC (“prozyme”) which is able to form a high-affinity heterodimer stimulating the AdoMetDC activity [193,203]. In *T. brucei* the next (and last) metabolic step after AdoMet decarboxylation can be performed by the ASAT, which also has catalytic activity of an ALAT [173,174,189].

Met oxidation was also investigated in *T. brucei*: cloning, bacterial expression, and characterization of a MSR-A has been reported that is expressed in both BSF and PCF stages [204]. Recently, two more



MSRs from *T. brucei* were characterized, a cytosolic one homologous to the MSR-A family, and a mitochondrial one, with sequence motifs typical of MSR-Bs. Interestingly, a reduced expression of *TbMSR-A* gave rise to an increased susceptibility to exogenous  $H_2O_2$ , while elevated expression levels resulted in more resistance to oxidative imbalance [205].

In *T. cruzi*, the first study of Met metabolism reported the cloning of putative genes of AdoMetDC and AdoHcysHD, as well as the expression and kinetic characterization of their proteic products [206,207]. Like in *T. brucei*, TcAdoMetDC is stimulated by putrescine [206] and by a prozyme [203]. Still in the same way as in *T. brucei*, the cytosolic TcASAT regenerates Met from KMTB [174]. Lastly, two genes encoding TcMSR-As were cloned and the proteins expressed and characterized. The MSR-A activity was also detected in cytosolic extracts of replicative stages (epimastigotes and amastigotes). Furthermore, the overexpression of one of the isoforms in epimastigotes increased the resistance of these cells to oxidative imbalance generated by exogenous  $H_2O_2$  [204].

Beyond its role as a sulfur group-containing building block for proteins, Cys is crucial for the biosynthesis of the reducing agent trypanothione in trypanosomatids. In fact, Cys has been shown to be essential for cell viability in BSF *T. brucei* and addition of this amino acid to the culture medium enabled, axenically, culture of this life-cycle stage [36,208,209]. In contrast, *L. major* and *L. mexicana* promastigotes are able to grow in the absence of Cys [85,210], suggesting that a Cys biosynthesis pathway probably exists in these organisms.

As mentioned above, Cys can be synthesized by using Met as a precursor via the reverse transsulfuration pathway. This pathway involves the enzymes CBS and CGL. Alternatively, Cys biosynthesis can also be achieved via Ser acetyltransferase (SAT, EC 2.3.1.30) which catalyzes the conversion of Ser to O-acetylserine (OAS) and Cys synthase [211] (CS, EC 2.5.1.47) (Figure 6), which catalyzes the addition of a sulfide group to O-acetylserine (OAS). *T. cruzi* and *L. major* seem to be the only unicellular organisms studied to date that contain both active pathways and the biological relevance of this redundancy for Cys biosynthesis remains to be elucidated. The characterization of these pathways in *T. cruzi* has shown that CBS has a higher activity in epimastigotes, whereas CS is active both in epimastigotes and amastigotes. Regarding their expression, both CBS and CGL have been shown to be more expressed in the insect-stage epimastigote whilst CS is more abundant in the mammalian-stage amastigote, suggesting a developmental regulation of the reverse transsulfuration pathway in this organism [212,213]. Noticeably, the genome of *T. brucei* contains putative coding sequences only for CBS and CGL, but the reverse transsulfuration pathway remains uncharacterized in this organism.


In *L. braziliensis* amastigotes, CS levels and activity were increased together with CBS and CGL, whereas CBS is more active in promastigotes. The overexpression of either CBS or CS in *L. braziliensis* promastigotes increased the resistance of these parasites to oxidative imbalance, in agreement with the role of Cys as an anti-oxidant and its participation as a precursor of trypanothione biosynthesis [214]. CGL was also characterized in *L. major* and *L. mexicana*, where it was shown to have a cytosolic localization in promastigotes [215]. SAT and CS are also present in the cytosol, forming a complex that would have an increased activity compared to the individual enzymes, as suggested by *in vitro* studies in which *L. major* and *L. donovani* CS stimulate their respective SAT activities [179,210,216], similarly as previously observed in plants [217].

Cys can be also catabolized through the action of Cys desulhydrase (CD, EC 2.8.1.7), which converts Cys into  $H_2S$ ,  $NH_3$ , and pyruvate. This enzyme has only been characterized in *L. major*, being able to specifically use Cys as a substrate [216]. Cys can also be converted back to Met via cystathionine  $\beta$ -lyase (CBL, EC 4.4.1.8) and cystathionine  $\gamma$ -synthase (CGS, EC 2.5.1.48) but, to date, this pathway has not been characterized in any of the trypanosomatids.

### 3.7. Other Amino Acids: Phenylalanine, Tryptophan, Tyrosine, Serine, Glycine, Threonine, Alanine, and Lysine

#### 3.7.1. Aromatic Amino Acids (Phe, Trp and Tyr)

Trypanosomatids are auxotrophic for aromatic amino acids and depend on their uptake from the extracellular environment [85,91]. Once imported, these amino acids are metabolized in aromatic acids by pathways that vary among these organisms. *T. cruzi* has two enzymes involved in the catabolism of aromatic amino acids: TcTAT that produces  $\alpha$ -oxoacids, and an aromatic L-2 hydroxyacid dehydrogenase (TcAHADH, EC 1.1.1.337) that converts  $\alpha$ -oxoacids into  $\alpha$ -hydroxyacids using NADH [218,219] (Figure 7). TcTAT is only expressed in epimastigotes, where it can transaminate Phe, Trp, and Tyr, as well as Ala, Leu, Ile, Val, Glu, and Met using pyridoxal phosphate (PLP) as a cofactor, with a preference for Tyr [171,218,220–222]. Not much is known about TcAHADH, which belongs to the malate dehydrogenases family, although it does not have any MDH activity [223].



**Figure 7.** Metabolism of tyrosine, tryptophan and phenylalanine. **Enzymes:** PAH: phenylalanine hydroxylase (EC 1.14.16.1); TAT: tyrosine aminotransferase (EC 2.6.1.5); ASAT: aspartate aminotransferase (EC 2.6.1.1); AHADH: aromatic L-2-hydroxyacid dehydrogenase (EC 1.1.1.337). **Metabolites:**  $\alpha$ -KG:  $\alpha$ -ketoglutarate, Glu: L-glutamate,  $H_4B$ : Tetrahydrobiopterin,  $H_2B$ : Dihydrobiopterin. Question mark (?) indicates unknown step (adapted from [224]).

In *L. donovani*, transaminases are active, having most amino acids as amino group donors and both  $\alpha$ -KG and pyruvate as preferred acceptor co-substrates [225,226]. In addition, a broad-specificity aminotransferase (BSAT, EC 2.6.1.1) has been identified, able to transaminate all aromatic amino acids, as well as Asp, Met, Leu and, with a lower activity, Ala in *L. mexicana* [227,228]. Similarly to *T. cruzi*, *Leishmania* spp. also have a TAT, which is able to transaminate aromatic amino acids and Met using pyruvate as an amino group acceptor. However, it does not have ALAT activity [129]. There is no AHADH in *Leishmania* spp. in agreement with the absence of aromatic products excreted in culture media [224,228]. Finally, *Leishmania* contains a Phe hydroxylase (PAH, EC 1.14.16.1) that can convert Phe into Tyr using tetrahydrofolate as a co-substrate [229].


In *T. brucei*, conversion of Phe into phenylpyruvate, as well as Tyr into p-hydroxyphenylpyruvate and p-hydroxyphenyllactate, the latter reaction being NADH-dependent, has been demonstrated.

Indoleacetate, indolepyruvate, and tryptophol have been detected as products of Trp catabolism [230–232]. Additionally, several studies reported that products of aromatic amino-acid metabolism were increased in urine and blood of animals infected with *T. b. gambiense* and *T. b. evansi* [233–235]. Furthermore, it has been demonstrated that indolepyruvate can modulate the immune response in infected mice [236], which points to a role for aromatic amino acids in the successful establishment of an infection by *T. brucei*.

So far, no homolog of TAT has been found in *T. brucei*. Instead, it has been recently shown that the aromatic ketoacids resulting from Phe, Tyr, and Trp metabolism are products of the activity of the cytosolic ASAT in BSF *T. brucei* [174]. Furthermore, aromatic amino acids play an important role in Met recycling, where they act as the major amino group donor to  $\alpha$ -ketomethiobutyrate to yield Met [173,189].

### 3.7.2. Glycine and Serine

Both Ser and Gly metabolic pathways can contribute to folate metabolism, as well as to Cys and Met synthesis. In the former process, tetrahydrofolate (THF) is used as a co-substrate in a reversible reaction with Ser catalyzed by Ser hydroxymethyltransferase (SHMT, EC 2.1.2.1) resulting in 5,10-methylene tetrahydrofolate (5,10-MTHF) and Gly [237]. 5,10-MTHF is an important precursor in the thymidylate and Met synthesis, and it can also be synthesized in the mitochondrion from Gly and THF through the action of the Gly cleavage complex (GCC) [238] (Figure 8).



**Figure 8.** Metabolism of serine, glycine and threonine. **Enzymes:** CBS: cystathionine  $\beta$ -synthase (EC 4.2.1.22); SAT: serine acetyltransferase (EC 2.3.1.30); SHMT: serine hydroxymethyltransferase (EC 2.1.2.1); TDH: threonine dehydrogenase (EC 1.1.1.406); ThrS: threonine synthase (EC 4.2.3.1); HSK: homoserine kinase (EC 2.7.1.39); AKCT: 2-amino-3-ketobutyrate CoA-transferase (EC 2.3.1.29); GCC-P: glycine decarboxylase (EC 1.4.4.2); GCC-T: tetrahydrofolate aminomethyltransferase (EC 2.1.2.10); GCC-L: dihydrolypoamide dehydrogenase (EC 1.8.1.4). **Metabolites:** A-CoA: acetyl coenzyme A, CoA: coenzyme A, THF: tetrahydrofolate, 5,10-MTHF: 5-10-methylene tetrahydrofolate.

The first evidence that Ser could be metabolized in trypanosomatids was provided by Hampton, when analyzing the incorporation of radioactivity from both uniformly-labeled Ser and Ser-1- $^{14}\text{C}$ . Labeled carbons were incorporated in all fractions except nucleic acids. In addition, a large production of radio-labeled  $\text{CO}_2$  was detected when *T. cruzi* epimastigotes were incubated with Ser-1- $^{14}\text{C}$  [47]. Cys, Ala, Gly, as well as Glu and Asp, can also be products of Ser metabolism [239]. Later, SHMT

activity was demonstrated in *T. cruzi*, *Trypanosoma rangeli* and *Leishmania* spp., with *T. cruzi* having the highest activity of this enzyme [240].

Two isoforms of SHMT have been characterized in *Leishmania*, one being cytosolic and the other one mitochondrial [241]. In the presence of Ser, both isoforms have been shown to be dispensable for cell growth in *L. major*. However, gene knock-out of one or both of the SHMT isoforms is lethal in the absence of Ser [242].

The *T. cruzi* genome contains a single SHMT gene, which encodes the cytosolic isoform and uses pyridoxal phosphate (PLP) as a cofactor [243]. In contrast, no SHMT gene is present in the *T. brucei* genome, which suggests that *T. brucei* depends only on GCC to synthesize 5,10-MTHF.

GCC is a complex formed by four subunits: a Gly decarboxylase that is known as P-protein (GCC-P, EC 1.4.4.2), a tetrahydrofolate aminomethyltransferase known as Gly synthase or T-protein (GCC-T, EC 2.1.2.10), a dihydrolipoamide dehydrogenase known as L-protein (GCC-L, EC 1.8.1.4), and an H-protein which contains a lipoamide prosthetic group. There are putative homologs for the four subunits of the complex encoded in the *L. major*, *T. brucei*, and *T. cruzi* genomes. In *Leishmania* spp., subunit P is localized in the mitochondrion and its knockout in amastigotes caused a delay in the progress of an infection in mice [244]. In *T. brucei* and *T. cruzi*, L-protein is the best-characterized GCC subunit and it catalyzes the formation of 5,10-MTHF in a NAD-dependent reaction. In *T. brucei* this enzyme is localized in the mitochondrion and, accordingly, it is more expressed in the procyclic form. However, the L-protein has been shown to be essential in both insect and mammalian stages of the parasite [245–249]. In *T. cruzi* this enzyme has been investigated as a potential drug target since it is inactivated by free radicals derived from phenol and its mRNA is up-regulated in cell lines resistant to benznidazole [250–253].

### 3.7.3. Threonine

In *T. brucei* PCF, Thr is the most-consumed amino acid regardless of the growth conditions, with a consumption rate comparable to that of glucose [38,254]. However, Thr cannot sustain growth of the parasite *in vitro* since it is converted into other metabolites, including the excreted acetate and Gly end products, which are not or poorly used for energy production in trypanosomatids [38]. Thr is first reduced by Thr dehydrogenase (TDH, EC 1.1.1.103) into amino-oxobutyrate, which is converted into acetyl-CoA and Gly by 2-amino-3-ketobutyrate CoA-transferase (AKCT, EC 2.3.1.29). Then, acetyl-CoA is converted into acetate by acetate:succinate CoA-transferase (ASCT, EC 2.8.3.8), or acetyl-CoA thioesterase [168,255] (ACH, EC 3.1.2.3). In *in vitro* conditions, Thr, via acetyl-CoA, is the preferred source of carbon for fatty-acid and sterol synthesis [169,256]. Interestingly, expression of TDH is down-regulated in a phosphoenolpyruvate carboxykinase (PEPCK) null background probably as a consequence of the redirection of the metabolic flux towards acetate production, suggesting that a metabolite of this latter pathway participates in the control [169] (Figure 8).

*Leishmania* spp. and *T. cruzi* genomes do not contain genes encoding enzymes for the Thr degradation pathway, suggesting that these parasites are not able to catabolize this amino acid [169]. This is consistent with Thr being one of the major components of the amino-acid pool in *L. tropica* promastigotes [257].

Thr can be synthesized *de novo* from Asp in a multistep pathway that involves aspartokinase (AspK, EC 2.7.2.4), Asp semialdehyde dehydrogenase (AspSD, EC 1.2.1.11), and homoserine dehydrogenase (HSD, EC 1.1.1.3), which culminates in homoserine production. Homoserine is then phosphorylated by homoserine kinase (HSK, EC 2.7.1.39) and the resulting O-phospho-homoserine is finally converted into Thr by Thr synthase (ThrS, EC 4.2.3.1) (Figure 8). *Leishmania* spp. genomes encode all enzymes of this pathway, and the conversion of Asp into Thr has been demonstrated in *L. mexicana* [258]. However, it has recently been reported that the absence of Thr in the culture medium increases the doubling time of promastigotes, whilst it decreases the cellular protein content and size, suggesting that the Thr *de novo* biosynthetic pathway is not sufficient for optimal parasite growth [85]. Interestingly, the *T. brucei* genome only encodes the last two steps of the pathway and an HSK has been

characterized. Growth of the PCF HSK-null mutant is compromised in the absence of Thr and rescued by the addition of homoserine [259]. Incidentally, the tsetse fly microbiota includes two species of bacteria—*Soldalis glossinidius* and *Wigglesworthia glossinidia*—producing homoserine, which could be a source of Thr in the *T. brucei* PCF *in vivo*, explaining why the last two steps of the pathway have been retained.

#### 3.7.4. Alanine

Ala constitutes the majority of the free amino acid pool in trypanosomes [260,261] and *Leishmania* spp. [257]. It has been demonstrated in *Leishmania* that approximately 90% of the free Ala pool corresponds to the L-isomer. The remaining part is formed by D-Ala that is synthesized by the activity of the Ala racemase [262] (AlaR, EC 5.1.1.1). Putative coding sequences for Ala racemase are present in both the *T. cruzi* and *T. brucei* genomes, but they still remain uncharacterized. Extracellular Ala uptake has been demonstrated in *T. b. gambiense* [33] and *L. donovani* [78]. It can also be synthesized by different pathways in trypanosomatids. In fact, Frydman and collaborators used <sup>13</sup>C-nuclear magnetic resonance to investigate Ala pools in *T. cruzi* epimastigotes. They were able to identify two distinct pools: one originated from glucose metabolism and the other one from a different source [263].

In addition to uptake and synthesis, Ala is also excreted by trypanosomatids [264]. Actually, the levels of this amino acid are increased in the serum, but not in tissues of mammals infected with *T. b. gambiense* and *T. brucei* [265–267]. In PCF *T. brucei*, Ala is the main excreted product from Pro metabolism when cells are grown in the absence of glucose. As mentioned earlier, the excreted Ala is the product of the amination of pyruvate through the action of transaminases. The main known sources of pyruvate are the conversion of malic acid through the mitochondrial or cytosolic malic enzymes or the production from phosphoenolpyruvate by pyruvate kinase [94] (PK, EC 2.7.1.40). *T. brucei* has a coding sequence for a putative mitochondrial ALAT, of which expression has been detected in both the cytosol of both the PCF and BSF. It specifically transaminates Ala using  $\alpha$ -KG as an amino acceptor, generating pyruvate and Glu (Figure 5). Down-regulation of *Tb*ALAT induces a strong growth defect of the PCF trypanosomes in glucose-depleted conditions, which confirms that ALAT activity is essential for the viability of the parasite in the insect vector, where the availability of glucose is limited [129,268,269].

In *T. cruzi* and *L. donovani*, ALAT is expressed throughout all stages of the life cycle, but higher expression levels have been observed in amastigote stages [270]. TcALAT is localized in both the mitochondrion and the cytosol [129]. The poorly specific TcTAT is also localized in the cytosol and, therefore, the cytosolic pool of Ala/pyruvate might be regulated by the combined activity of these two enzymes. Furthermore, as previously mentioned, in *T. cruzi* epimastigotes Ala can also be generated as a product of Ser metabolism [239].

#### 3.7.5. Lysine

Trypanosomatids are unable to synthesize Lys and rely on uptake to obtain this amino acid [52,90,91]. Accordingly, Lys has been shown to be essential for cell growth in *Leishmania* [85].

In summary, a list of enzymes that use amino acids as substrates and their respective genes' accession numbers in TriTryps is detailed in Table 2.



**Table 2.** Genes annotated as encoding relevant amino acid metabolism enzymes in TriTryps.

Amino Acid	Enzymes	Genes *			Characterization
		<i>T. brucei</i>	<i>T. cruzi</i>	<i>L. major</i>	
Ala	ALAT	Tb927.1.3950	TcCLB.506529.420●	LmjF12.0630	[129,269]
	AlaR	Tb927.5.1280●	TcCLB.509767.90●	LmjF.23.1480	[262]
	TAT	-	(see aromatic AA)	-	-
Arg	ARG	-	-	LmjF.35.1480	[141]
	ArgK	Tb927.9.6210	TcCLB.482369.29	-	[51,148,150]
Aromatic AA	ASAT/BSAT	Tb927.10.3660	TcCLB.503841.70	LmjF.35.0820	[171,174,228]
	TAT	-	TcCLB.508535.50	LmjF.36.2360	[129]
Asn	ASN	-	TcCLB.504147.110●	LmjF.36.4430●	-
Asp	AS	Tb927.7.1110	TcCLB.503899.90●	LmjF.26.0830●	[176]
	ASAT	-	(see aromatic AA)	-	-
	mASAT	Tb927.11.5090	TcCLB.510945.70	LmjF.24.0370●	[174]
BCAA	BCAT	Tb927.2.4590●	-	LmjF27.2030●	-
	TAT/ASAT	-	(see aromatic AA)	-	-
Cys	CGS	Tb11.v5.0869●	TcCLB.510741.10●	LmjF14.0460	[215]
	CD	-	-	LmjF.32.2640	[216]
Gln	GLNAT	Tb927.10.11970	TcCLB.503747.10●	LmjF.33.1330●	[129]
	GF6PA	Tb927.7.5560●	TcCLB.510303.200	LmjF.06.0950	[131]; Crispim et al., unpublished data
	CPS	Tb927.5.3800●	TcCLB.508373.10	LmjF.16.0590	[126,127]
	GMPS	Tb927.7.2100	TcCLB.508085.10●	LmjF.22.0110●	[128]
Glu	GDH	Tb927.9.5900●	TcCLB.505843.10	LmjF.15.1010●	[119]
	GS	Tb927.7.4970●	TcCLB.503405.10	LmjF.06.0370	[125,130]
	P5CS	-	TcCLB.509067.70●	LmjF.32.3140●	-
	TAT/ASAT	-	(see aromatic AA)	-	-
	GCC-P	Tb927.7.1910●	TcCLB.510911.50●	LmjF26.0030	[244]
His	HAL	-	TcCLB.506247.220	-	[61]
Lys	-	-	-	-	-
Met	AdoMetS	Tb927.6.4840	TcCLB.506945.160●	LmjF.30.3500	[189,191]
	MSR	Tb427.08.550●	TcCLB.510855.10●	LmjF.07.1140●	-
Pro	PRODH	Tb927.7.210	TcCLB.506411.30	LmjF.26.1610	[38,95]; Ferraz et al., unpublished data
	PRAC	-	TcCLB.430737.10●	-	-
Phe	PAH	-	-	LmjF.28.1280	[229]
Ser	SHMT-L	-	-	LmjF.28.2370	[241]
	SHMT-S	-	TcCLB.510407.90	LmjF.14.1320	[241,243]
	SAT	-	TcCLB.510879.80	LmjF.34.2850	[210,216]
Thr	CBS	Tb11.02.5400●	TcCLB.508241.140	LmjF17.0250	[210,212]
	TDH	Tb927.6.2790	TcCLB.507923.10●	-	[169]

●Putative genes

\* Accession numbers from reference strains: *T. brucei* TREU927, *T. cruzi* CL Brener Esmeraldo-like (except HAL) and *L. major* strain Friedlin.

## 4. Non-Obvious Roles of Amino Acids

### 4.1. Host-Parasite Interaction

*T. cruzi*, along its life cycle, needs to adapt to different nutrients available in the different environments: the bloodstream, the intracellular environments in the different tissues it can invade in the mammalian host, and the different parts of the midgut in the insect vector. Epimastigotes in the early exponential growth phase (*in vitro*) are equipped with the complete set of glycolytic enzymes and, in fact, they obtain energy from glucose catabolism. However, it is not known if this is possible inside the insect midgut, since relevant quantities of free sugars in this environment have not been demonstrated so far [271]. However, the availability of amino acids has been well demonstrated [272,273] and the ability of epimastigotes to catabolize these metabolites is well understood, as previously described. In addition to their role in the parasite's bioenergetics, it was demonstrated that some of these amino acids have relevance in the survival of the epimastigotes during the nutritional, redox, osmotic, and thermal stresses that they suffer in the midgut [274,275]. For example, Pro participates in the parasite's resistance to thermal stress, while both Pro and Glu contribute to resistance to the nutritional stress and redox imbalance [276,277]. Additionally, His was shown to extend parasite survival in nutritional stress conditions, such as that experienced by epimastigotes during the colonization of the triatomine midgut [61].

Nutritional stress also plays a functional role in *T. cruzi*'s life cycle. Metacyclogenesis, i.e., the differentiation of the proliferative non-infective epimastigotes into the non-proliferative infective metacyclic trypomastigotes, is triggered when the epimastigotes are starved [172], followed by exposure to a supply of nutrients, notably some amino acids. To analyze this process in more detail, Contreras and collaborators developed a minimum medium for *in vitro* induction of metacyclogenesis. They investigated the effect of individually adding 10 different L-amino acids to artificial triatomine urine. In this study, Pro was the only amino acid able to support an approximately 90% efficient differentiation [172], although subsequent experiments showed that Gln and Asn were also able to induce metacyclogenesis, with efficiencies similar to that of Pro [278]. Interestingly, it was shown that the consumption of amino acids continued after completion of metacyclogenesis [279].

Since the next differentiation step, of the non-dividing metacyclic trypomastigotes into proliferating amastigotes occurs exclusively in the intracellular environment, invasion of host cells by the trypomastigotes should be considered a crucial step for establishing the infection in the mammal. The parasite requires energy for this host-cell invasion [280]. It was shown that this energy can be provided by Pro, its metabolite P5C and, to a lesser extent, Glu, because these compounds were shown to make the mammalian host-cells infection much more efficient [96,279].

Trypomastigote forms derived from a previous mammalian host-cell infection are, most of the time, present in the glucose-rich bloodstream, and are able to consume this compound for their energy metabolism [281]. Once the parasites establish the infection in the cytosol of the host cells as amastigotes, they go through a metabolic switch to preferably consume the intracellular pools of amino acids, mainly Pro, as carbon and energy source. In fact, the intracellular environment is poor in glucose and amastigotes are unable to take this sugar up from an environment at concentrations below the millimolar range [281], despite the fact that amastigotes can take up and metabolize glucose when available at high concentrations [282]. It was also demonstrated that amastigotes can acquire fatty acids from the host to support infection [283,284].

As mentioned earlier, the metabolism of amino acids occurs with the production of  $\text{NH}_4^+$  as a result of the transfer of the amino group to  $\text{H}_2\text{O}$  [185]. As *T. cruzi* does not have a functional urea cycle [113], the detoxification of the accumulated  $\text{NH}_4^+$  occurs through its metabolism to form non-toxic metabolites, notably through its incorporation into  $\alpha$ -KG to form Glu. However, a high consumption of  $\alpha$ -KG to deal with  $\text{NH}_4^+$  accumulation could compromise the functioning of the TCA cycle. Thus,  $\alpha$ -KG is regenerated by a transamination reaction in which pyruvate is the main amino group acceptor, yielding also Ala [122]. As the accumulation of Ala can be detrimental as well, we proposed and

recently demonstrated that the enzyme GS can contribute to the detoxification of  $\text{NH}_4^+$ . In fact, GS has its highest activity in the amastigote stage and we showed its participation in the regulation of the  $\text{NH}_4^+$  release during the transient residence of *T. cruzi* in the parasitophorous vacuole [125]. The acidic pH of this vacuole is critical for the parasite differentiation from trypomastigotes to amastigotes and for the release of the amastigotes into the host-cell cytosol, a *sine qua non* condition for the establishment of the intracellular infection [285]. Moreover, it was recently shown that intracellular parasite forms possess transmembrane transporters their in acidic organelles to sequester the ammonium resulting from amino-acid metabolism. This system enhances the parasite's resistance to starvation and osmotic stress [286].

The intracellular epimastigote is a transient stage between amastigote and trypomastigote, and expresses some of the trypomastigote surface proteins, probably as an early adaptation to the needs that trypomastigotes, the next stage, will face [5]. As such, its ability to transport glucose from the medium (which is, in this case, the host-cell cytosol) is not surprising [281]. However, it was shown that among all the stages analyzed so far, intracellular epimastigotes are those with the highest specific activities of Pro uptake, PRODH and P5CDH, i.e., the enzymes involved in the oxidation of Pro to Glu. This increase of Pro uptake serves probably to compensate for a decrease of the intracellular stocks of free Pro due to its catabolism [95,96,101,281]. Even more, when the infection happens in a Pro-poor environment, the total number of released trypomastigotes, as well as the differentiation from intracellular epimastigotes to trypomastigotes, are compromised, indicating that Pro is involved not only in the intracellular proliferation of the parasites, but also in their differentiation [101]. In addition, different studies suggested that the Pro-dependent enzyme TcPRAC is involved in cellular differentiation and invasion [117,287] and in the development of the parasite's resistance to the host proteolytic enzymes through the incorporation of D-Pro into parasite proteins [288]. Remarkably, the secreted isoform of TcPRAC, an enzyme having Pro as a substrate, is an effective mitogen for host B lymphocytes, favoring parasite evasion of specific immune responses [115,116]. This activity is dependent on the exposure of a transient epitope in the ligand-free enzyme [289]. Consequently, the mitogen activity would be regulated by the availability of Pro in the mammalian host blood.

*T. brucei* also alternates between its mammalian host and insect vector and adapts its metabolism to the availability of nutrients in these different environments. The BSF use glucose as an energy source that is abundant in the mammalian blood [30,290,291]. Interestingly, it was recently shown that, in spite of the existence of a fully-functional Gln biosynthesis pathway in long-slender BSF, the supply of external Gln is essential for the BSF's survival and replication (Damasceno et al., unpublished data). Little is known about the differentiation process from metacyclic forms to the replicative long-slender BSF. However, some more information is available on the differentiation process from long-slender BSF to the non-proliferative and insect-infective stumpy BSF. This process is dependent on the parasitemia level and on the concentration of the stumpy-induction factor (SIF) [292]. Although still of unknown identity, it has been shown that SIF is a low molecular weight soluble molecule produced by the parasite [8]. Transformation to the stumpy form induces a partial metabolic reprogramming including the upregulation of various mitochondrial processes, like the induction of ASCT expression with consequent acetate production. This likely creates a pre-adaptive condition to the next stage: the infection of the insect vector [293]. Within approximately 15 minutes after the tsetse has taken up stumpy BSF parasites during the blood meal, glucose from the host's blood has been consumed [294]. In the midgut of the fly, Pro, the most abundant amino acid in the tsetse flies which energetically supports the flight process [268], becomes the main energy source for PCF, as well as, to a lesser extent, Thr. In fact, the need of a fully-functional Pro metabolic pathway for *T. brucei* survival in the insect's midgut and to support establishment of the fly's infection was recently shown [38,39,94]. Similarly, *in vitro* transformation from BSF to PCF involves addition of citrate/cis-aconitate to the differentiation medium, which lacks glucose and is rich in Pro and Gln, and a change in temperature, which, together, stimulate mitochondrial development, including the expression of TCA cycle enzymes [295,296].

*Leishmania* spp. classically present two stages: amastigote (in the mammalian host) and promastigote (in the insect vector). Proliferative promastigotes, in turn, can differentiate into non-proliferative, infective metacyclic promastigotes, which are morphologically similar to the proliferative ones [297]. The exponentially-growing promastigote expresses an enzymatic arsenal to metabolize disaccharides, probably an adaptation to the diet of sandflies, which can feed on nectar and aphid honeydew. Promastigotes face varying environmental conditions, like the physical and chemical changes due to, respectively, the temperature and the nutritional habit of the sandfly [298]. Comparative proteomic and metabolomic analyses of a mutant promastigote line with inability to transport glucose suggest that Pro is a main carbon source used for energy metabolism and gluconeogenesis [103]. The amastigote is the proliferative form and replicates inside the phagolysosomal compartment of macrophages using mainly sugars as energy source, although it presents a reduced uptake and rate of metabolism when compared to the promastigote form [299].

In fact, *Leishmania* spp. differentiate from the extracellular procyclic promastigotes to metacyclic promastigotes in the sandfly and then to the intracellular amastigotes in the mammalian host. Similar to *T. cruzi*, this transformation means an extreme change in environment, from the sand fly midgut to the acidic interior of the phagolysosome. This process is accompanied by a metabolic switch in which the parasite changes from the high use of sugars and amino acids as carbon and energy sources to a form with a globally-reduced metabolism still based on the preferential use of sugars [300]. In fact, the use of amino acids available in the phagolysosome appears to be detrimental, since it would necessitate increased activity of the TCA cycle and respiratory chain resulting in oxygen stress for which the parasites are highly susceptible in this environment [301].

*In vitro* differentiation of *Leishmania* spp. involves changes in temperature and pH [302], but the function of amino acids in inducing cell differentiation is still to be elucidated. Diaz and collaborators investigated the role of the L-amino acids Ala, Cys, Met, Glu, Gln, Pro, and Trp in inducing chemotaxis, which has been proposed to be essential for cell differentiation. In this study, Glu, Gln, Met, and Trp had both positive and negative effects on chemotaxis depending on the amino acid concentration, suggesting the existence of some sort of sensing mechanism in *Leishmania* [303].

Arg plays a crucial role in the host-parasite interplay [304,305]: a mechanism in which *Leishmania* senses extracellular levels of Arg has been shown to impact on parasite viability inside the macrophage. The role of Arg during mammalian host-cell infection was studied in some detail. Arg is the substrate of the inducible nitric oxide synthase (iNOS), a major effector of the immune system producing the potent microbicidal NO, and which has an increased expression in activated macrophages [306]. Arg is also a substrate for the enzyme ARG which, in both amastigotes and promastigotes, is found within glycosomes, suggesting that the pool and trafficking of Arg is under control in these parasites [307]. Infection with *L. major* resulted in an additional increase of the parasite's Arg catabolism through ARG, producing two effects: diminishing the availability of free Arg as a substrate of the iNOS, and re-directing this metabolite to the production of Orn and polyamines in the host cells. Interestingly, upon diminished levels of Arg, the parasite upregulates the expression of the Arg "transceptor" AAP3, to increase the uptake of the amino acid and compensate for the effect of its diminished levels inside the host-cells [80,308,309]. In summary, inhibition of arginase activity results in diminished Arg catabolism, decreased polyamine synthesis, and subsequently-reduced parasite growth [310], whereas at the host side the amino acid Arg is the substrate to produce nitric oxide for combating the parasite [305,309,311,312]. This metabolic balance can decide between death or survival of the parasite.

#### 4.2. Role of Amino Acids in the Regulation of Autophagy and Apoptosis

As part of the attention being paid to "non-canonical roles" (i.e., beyond their involvement in the cell bioenergetics or protein synthesis) of amino acids in trypanosomatids, efforts have been made to elucidate their possible participation in regulating processes in these organisms, such as autophagy and cell death. Schmidt and Butikofer used PCF *T. brucei* expressing GFP-tagged *TbAtg8.1* and *TbAtg8.2* to investigate the conditions in which autophagy is induced in this organism.

Atg8 is a cytosolic protein that, upon initiation of the autophagy process, is cleaved and modified by the addition of a phosphatidylethanolamine (PE) anchor. This modification relocates Atg8 to the developing phagophore membrane that will give rise to the autophagosomes, which will eventually fuse with the lysosome [313–315]. The authors found that when PCF experiences nutrient starvation, *TbAtg8.1-GFP* and *TbAtg8.2-GFP* presented a punctal appearance, spread throughout the cytoplasm. However, addition of His prevented the relocation of the fluorescently-tagged proteins to puncta and autophagy [316]. As previously mentioned, *T. brucei* does not have the canonic His degradation pathway and, although the mechanism by which this amino acid protects trypanosomes from autophagy is still to be elucidated, it is very likely that it is a direct effect of His and not of a product of its catabolism. Conversely, among the amino acids are not only those that protect against autophagy, but also ones that, by the trypanosome's starvation for them, induce the process, similarly to what has been reported for other eukaryotes. For example, He and collaborators described that amino acid starvation can trigger autophagy independently of the AMP-activated-Protein-Kinase-mediated energy sensing mechanisms [317,318]. Further studies are required to unravel the details of the pathways involved.

A more explicit mechanism has been proposed to explain the role of Arg in protecting *T. cruzi* from apoptosis. Piacenza and collaborators found that Arg prevents the formation of patterns associated with the programmed cell death process as DNA fragmentation and inhibition of [<sup>3</sup>H]-thymidine incorporation when epimastigotes are exposed to apoptotic stimuli. Furthermore, Arg stimulates the mammalian host's production of NO, which is a known apoptosis regulator [319] and polyamine synthesis that sustains parasite proliferation [320]. Similarly, the absence of Arg in culture media has been associated with oxidative stress, increase in reactive oxygen species production, decrease in polyamine synthesis, and induction of programmed cell death in *L. donovani* promastigotes [321].

#### 4.3. Osmotic Control by Amino Acids

Amino acids, besides being precursors of essential compounds, such as polypeptides and polyamines, also function as osmolytes used by the TriTryps to cope with the osmotic stress that they face along their life cycles. When insect forms colonize the digestive tract of their invertebrate hosts, they encounter extreme fluctuations in osmolarity caused by the regular feeding of the bugs and, particularly in the case of metacyclic forms of *T. cruzi*, by the composition of the triatomine rectal contents [322–325]. In the vertebrate hosts, the parasites still face osmotic fluctuations, since different tissues are exposed to high or low osmolarity fluids in their physiological or pathological conditions [326,327]. Therefore, osmoregulation is essential for the completion of the biological cycle by the TriTryps.

Osmotic control in trypanosomatids is mainly performed by two types of organelles: the acidocalcisomes in all trypanosomatids and in *T. cruzi* the contractile vacuole complex [328,329]. Acidocalcisomes are electron-dense acidic organelles that are rich in calcium and polyphosphates [330]. The contractile vacuole complex is a bipartite structure composed of a network of microtubules and vesicles named the spongione, surrounding a central vacuole, or bladder [331]. This bladder swells when it accumulates excess water from the cytosol, which is eventually expelled from the cell after the bladder comes into contact with the plasma membrane [332]. In *T. cruzi*, the hydrolysis or synthesis of polyphosphates inside the acidocalcisomes occurs in response to hypoosmotic or hyperosmotic stress conditions, respectively [333]. In *L. major* the acidocalcisomal content also changes under hypoosmotic stress, changing its levels of sodium and chlorine [334]. In *T. brucei*, the role of acidocalcisomes in osmoregulation has been demonstrated in a mutant cell line deficient in polyphosphate production that became sensitive to osmotic stress [335].

Pools of amino acids in TriTryps also provide a reservoir of osmolytes for cells to use during osmotic stress. Under hypoosmotic stress, amino acids are mobilized for an intensive efflux to exhibit a regulatory volume response [336–338]. This efflux occurs through an anion channel, mobilizing uncharged and acidic amino acids, a mechanism that accounts for approximately 50% of the regulatory



volume decrease [328]. Epimastigote, amastigote, and trypomastigote forms of *T. cruzi* released Glu, Gly, and, mainly, Ala and Pro [337], while promastigotes of *L. major* released Glu, Gly, Ser, and mainly Ala, which is also the major amino acid released by amastigotes of *L. donovani* [336,338]. The importance of amino acids as osmolytes was also evidenced in hypoosmotic and hyperosmotic stresses, by noticing an increase of the catabolism or biosynthesis under the respective stress conditions that serves to maintain the cytosolic ionic strength [339,340].

More recently, Inbar et al. have shown that Pro and Ala act differently in the face of hypoosmotic stress in *L. donovani*, with Pro only influencing the rate of volume decrease, while Ala is involved in controlling the extent of swelling. The authors also suggested that the regulatory volume decrease is mediated by Pro, either through its flow along with the water flow, or associated with activation of a water channel, possibly aquaporin 1 [78].

All functions of amino acids that have been described in TriTryps and mentioned in this review are summarized in Table 3.

**Table 3.** Functions associated to amino acids in TriTryps.

Amino Acid	Function	<i>T. brucei</i>	<i>T. cruzi</i>	<i>Leishmania</i> spp.	References
Ala	Osmotic control				[336–338]
	Polyamine biosynthesis				[134,136]
Arg	Establishment of infection				[306]
	Apoptosis protection				[320]
Asn	Energy management				[51,148,149]
	Metacyclogenesis				[278]
Asp	Metacyclogenesis				[172]
	Pyrimidine biosynthesis				[175]
Cys	Mitochondrial ATP synthesis				[93]
	Trypanothione synthesis				[214]
Gln	Pyrimidine biosynthesis				[126,127]
	Hexosamine biosynthesis				Crispim et al., unpublished; [131]
Glu	Metacyclogenesis				Damasceno et al., submitted
	Osmotic control				[336–338]
Gly	Metacyclogenesis				[172]
	Mitochondrial ATP synthesis				[93,121]
His	Resistance to oxidative stress				[277]
	Resistance to nutritional stress				[277]
Leu	Osmotic control				[336–338]
	Resistance to nutritional stress				[61]
Met	Autophagy protection				[316]
	Sterol biosynthesis				[165,167]
Pro	Fatty acid biosynthesis				[165]
	Polyamine biosynthesis				[173]
Ser	Resistance to oxidative stress				[197,204,205]
	Mitochondrial ATP synthesis				[2,38,39,92,95,96]
Thr	Carbon source				[2,30,38,103]
	Cell differentiation				[101,172]
Tyr	Cell invasion				[96,279,337]
	Osmotic control				[337]
Val	Resistance to oxidative stress				[276]
	Resistance to thermal stress				[276]
Ile	Resistance to nutritional stress				[276]
	Osmotic control				[336,338]
Phe	Carbon source				[169,256]

## 5. Concluding Remarks

TriTryps transit during their life cycle through different environments, thus being exposed to variations in their nutritional situations and challenged by a variety of stress conditions. Amino acids are present at different concentrations and ratios in each of the environments and exert different roles in the parasites in the successive life-cycle stages. Amino acids are a group of metabolites with an amazing diversity in their physicochemical properties. In fact, most of physicochemical conditions of any cellular or subcellular microenvironment (such as pH, redox potential, osmolarity) could be created or regulated by using different combinations of amino acids and their intermediate metabolites. In addition to being taken up or synthesized for their role as constituents of proteins, amino acids participate in a myriad of biological processes, such as cell bioenergetics, the regulation of cell cycle, regulation of cell volume, mechanisms of cell survival (autophagy) and death, differentiation, and cell

invasion. Even more, in some cases, the regulation of amino acids and their metabolism can subvert the host immune response. The regulation of these activities is dependent on several factors, mainly their uptake, degradation, and biosynthesis. These activities can also be determined by the accumulation of intermediate metabolites, which, in many cases, were shown to be much more than inert entities in the route from precursor to the product of a metabolic pathway. A more detailed knowledge on this intricate metabolic network is necessary to improve our understanding of the biology of these organisms.

**Supplementary Materials:** The following item is available online at <http://www.mdpi.com/2076-0817/7/2/36/s1>, **Table S1**. Enzymes mentioned in the text with their respective abbreviations, EC numbers, and references to figures.

**Acknowledgments:** This work was supported by: Fundação de Amparo à Pesquisa do Estado de São Paulo grants 2016/06034-2 and 2017/16553-0 (awarded to AMS), Conselho Nacional de Pesquisas Científicas e Tecnológicas (CNPq) grant 308351/2013-4 (awarded to AMS), and the Research Council United Kingdom Grand Challenges Research Funder under grant agreement ‘A Global Network for Neglected Tropical Diseases’ grant number MR/P027989/1. FB is supported by the Centre National de la Recherche Scientifique (CNRS), the Université de Bordeaux, the Agence Nationale de la Recherche (ANR) through the GlycoNov grants of the “Générique” call and the Laboratoire d’Excellence (LabEx) ParaFrap ANR-11-LABX-0024. PM acknowledges the University of Edinburgh’s BBSRC Grand Challenges Research Fund Impact Acceleration Account Scheme for grants BB GC IAA 16/17 – PM and BB GC IAA 17/18 – PM, which enabled collaboration with AMS resulting in the preparation of this manuscript.

**Author Contributions:** LM, JFN, and FSD compiled and organized the information, designed, and produced all tables and figures. LM, JFN, FSD, and AMS wrote essential parts of this manuscript. FB, PM, and AMS contributed to revision and edition of the manuscript. LM, JFN, FSD, PM, and AMS conceived the topic, scope and the general organization of the MS. AMS made the final revision and edition.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

- Rodrigues, J.C.F.; Godinho, J.L.P.; de Souza, W. Biology of human pathogenic trypanosomatids: Epidemiology, lifecycle and ultrastructure. In *Proteins and Proteomics of Leishmania and Trypanosoma*; Springer: Dordrecht, The Netherlands, 2014; Volume 74, pp. 1–42.
- Bringaud, F.; Barrett, M.P.; Zilberstein, D. Multiple roles of proline transport and metabolism in trypanosomatids. *Front. Biosci. (Landmark Ed.)* **2012**, *17*, 349–374. [[CrossRef](#)] [[PubMed](#)]
- Garcia, E.S.; Genta, F.A.; De Azambuja, P.; Schaub, G.A. Interactions between intestinal compounds of triatomines and *Trypanosoma cruzi*. *Trends Parasitol.* **2010**, *26*, 499–505. [[CrossRef](#)] [[PubMed](#)]
- De Souza, W.; de Carvalho, T.M.U.; Barrias, E.S. Review on *Trypanosoma cruzi*: Host cell interaction. *Int. J. Cell Biol.* **2010**, *2010*, 1–18. [[CrossRef](#)] [[PubMed](#)]
- Almeida-de-Faria, M.; Freymüller, E.; Colli, W.; Alves, M.J.M.; Freymu, E. *Trypanosoma cruzi*: Characterization of an intracellular epimastigote-like form. *Exp. Parasitol.* **1999**, *92*, 263–274. [[CrossRef](#)] [[PubMed](#)]
- Alves, M.J.M.; Colli, W. *Trypanosoma cruzi*: Adhesion to the host cell and intracellular survival. *IUBMB Life* **2007**, *59*, 274–279. [[CrossRef](#)] [[PubMed](#)]
- Ponte-Sucré, A. An overview of *Trypanosoma brucei* infections: An intense host–parasite interaction. *Front. Microbiol.* **2016**, *7*. [[CrossRef](#)] [[PubMed](#)]
- Mony, B.M.; Matthews, K.R. Assembling the components of the quorum sensing pathway in African trypanosomes. *Mol. Microbiol.* **2015**, *96*, 220–232. [[CrossRef](#)] [[PubMed](#)]
- Silvester, E.; McWilliam, K.; Matthews, K. The cytological events and molecular control of life cycle development of *Trypanosoma brucei* in the mammalian bloodstream. *Pathogens* **2017**, *6*, 29. [[CrossRef](#)] [[PubMed](#)]
- Rotureau, B.; Van Den Abbeele, J. Through the dark continent: African trypanosome development in the tsetse fly. *Front. Cell. Infect. Microbiol.* **2013**, *3*, 1–7. [[CrossRef](#)] [[PubMed](#)]
- Mogk, S.; Boßelmann, C.M.; Mudogo, C.N.; Stein, J.; Wolburg, H.; Duszenko, M. African trypanosomes and brain infection—The unsolved question. *Biol. Rev.* **2017**, *92*, 1675–1687. [[CrossRef](#)] [[PubMed](#)]
- Bates, P.A. Transmission of *Leishmania* metacyclic promastigotes by phlebotomine sand flies. *Int. J. Parasitol.* **2007**, *37*, 1097–1106. [[CrossRef](#)] [[PubMed](#)]

13. Dostálová, A.; Volf, P. *Leishmania* development in sand flies: Parasite-vector interactions overview. *Parasit. Vectors* **2012**, *5*, 276. [[CrossRef](#)] [[PubMed](#)]
14. Lestinova, T.; Rohousova, I.; Sima, M.; de Oliveira, C.I.; Volf, P. Insights into the sand fly saliva: Blood-feeding and immune interactions between sand flies, hosts, and *Leishmania*. *PLoS Negl. Trop. Dis.* **2017**, *11*, e0005600. [[CrossRef](#)] [[PubMed](#)]
15. Podinovskaia, M.; Descoteaux, A. *Leishmania* and the macrophage: A multifaceted interaction. *Future Microbiol.* **2015**, *10*, 111–129. [[CrossRef](#)] [[PubMed](#)]
16. Geiger, A.; Bossard, G.; Sereno, D.; Pissarra, J.; Lemesre, J.-L.; Vincendeau, P.; Holzmüller, P. Escaping deleterious immune response in their hosts: Lessons from trypanosomatids. *Front. Immunol.* **2016**, *7*. [[CrossRef](#)] [[PubMed](#)]
17. Tanowitz, H.B.; Scherer, P.E.; Mota, M.M.; Figueiredo, L.M. Adipose tissue: A safe haven for parasites? *Trends Parasitol.* **2017**, *33*, 276–284. [[CrossRef](#)] [[PubMed](#)]
18. Higgins, C.F. ABC transporters: From microorganisms to man. *Annu. Rev. Cell Biol.* **1992**, *8*, 67–113. [[CrossRef](#)] [[PubMed](#)]
19. Saier, M.H. A functional-phylogenetic classification system for transmembrane solute transporters. *Microbiol. Mol. Biol. Rev.* **2000**, *64*, 354–411. [[CrossRef](#)] [[PubMed](#)]
20. El-Sayed, N.M.; Myler, P.J.; Blandin, G.; Berriman, M.; Crabtree, J.; Aggarwal, G.; Caler, E.; Renauld, H.; Worthey, E.A.; Hertz-Fowler, C.; et al. Comparative genomics of trypanosomatid parasitic protozoa. *Science* **2005**, *309*, 404–409. [[CrossRef](#)] [[PubMed](#)]
21. Young, G.B.; Jack, D.L.; Smith, D.W.; Saier, M.H. The amino acid/auxin: Proton symport permease family. *Biochim. Biophys. Acta* **1999**, *1415*, 306–322. [[CrossRef](#)]
22. Bouvier, L.A.; Silber, A.M.; Galvão Lopes, C.; Canepa, G.E.; Miranda, M.R.; Tonelli, R.R.; Colli, W.; Alves, M.J.M.; Pereira, C.A. Post genomic analysis of permeases from the amino acid/auxin family in protozoan parasites. *Biochem. Biophys. Res. Commun.* **2004**, *321*, 547–556. [[CrossRef](#)] [[PubMed](#)]
23. Jackson, A.P. Origins of amino acid transporter loci in trypanosomatid parasites. *BMC Evol. Biol.* **2007**, *7*, 1–17. [[CrossRef](#)] [[PubMed](#)]
24. Baker, N.; Alford, S.; Horn, D. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. *Mol. Biochem. Parasitol.* **2011**, *176*, 55–57. [[CrossRef](#)] [[PubMed](#)]
25. Schumann Burkard, G.; Jutzi, P.; Roditi, I. Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. *Mol. Biochem. Parasitol.* **2011**, *175*, 91–94. [[CrossRef](#)] [[PubMed](#)]
26. Vincent, I.M.; Creek, D.; Watson, D.G.; Kamleh, M.A.; Woods, D.J.; Wong, P.E.; Burchmore, R.J.S.; Barrett, M.P. A molecular mechanism for eflornithine resistance in African trypanosomes. *PLoS Pathog.* **2010**, *6*, 1–9. [[CrossRef](#)] [[PubMed](#)]
27. Ngô, H.; Tschudi, C.; Gull, K.; Ullu, E. Double-stranded RNA induces mRNA degradation in *Trypanosoma brucei*. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 14687–14692. [[CrossRef](#)] [[PubMed](#)]
28. Beneke, T.; Madden, R.; Makin, L.; Valli, J.; Sunter, J.; Gluenz, E. A CRISPR Cas9 high-throughput genome editing toolkit for kinetoplastids. *R. Soc. Open Sci.* **2017**, *4*, 170095. [[CrossRef](#)] [[PubMed](#)]
29. Tielens, A.G.M.; Van Hellemond, J.J. Differences in energy metabolism between Trypanosomatidae. *Parasitol. Today* **1998**, *14*, 265–271. [[CrossRef](#)]
30. Bringaud, F.; Rivière, L.; Coustou, V. Energy metabolism of trypanosomatids: Adaptation to available carbon sources. *Mol. Biochem. Parasitol.* **2006**, *149*, 1–9. [[CrossRef](#)] [[PubMed](#)]
31. Tielens, A.G.M.; van Hellemond, J.J. Surprising variety in energy metabolism within Trypanosomatidae. *Trends Parasitol.* **2009**, *25*, 482–490. [[CrossRef](#)] [[PubMed](#)]
32. Voorheis, H.P. Amino-acid transport in *Trypanosoma brucei*. *Trans. R. Soc. Trop. Med. Hyg.* **1971**, *65*, 241–242. [[CrossRef](#)]
33. Clark Southworth, G.; Read, C.P. Absorption of some amino acids by the haemoflagellate, *Trypanosoma gambiense*. *Comp. Biochem. Physiol. Part A Physiol.* **1972**, *41*, 905–911. [[CrossRef](#)]
34. Hansen, B.D. *Trypanosoma gambiense*: Membrane transport of amino acids. *Exp. Parasitol.* **1979**, *48*, 296–304. [[CrossRef](#)]
35. Fricker, S.P.; Jones, S.E.M.; Clive Ellory, J.; Angus, J.M.; Klein, R.A. Threonine uptake in *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* **1984**, *11*, 215–223. [[CrossRef](#)]

36. Duszenko, M.; Ferguson, M.A.; Lamont, G.S.; Rifkin, M.R.; Cross, G.A. Cysteine eliminates the feeder cell requirement for cultivation of *Trypanosoma brucei* bloodstream forms in vitro. *J. Exp. Med.* **1985**, *162*, 1256–1263. [[CrossRef](#)] [[PubMed](#)]
37. Geigy, R.; Huber, M.; Weinman, D.; Wyatt, G.R. Demonstration of trehalose in the vector of African trypanosomiasis: The tsetse fly. *Acta Trop.* **1959**, *16*, 255–262. [[PubMed](#)]
38. Lamour, N.; Riviere, L.; Coustou, V.; Coombs, G.H.; Barrett, M.P.; Bringaud, F.F.F. Proline metabolism in procyclic *Trypanosoma brucei* is down-regulated in the presence of glucose. *J. Biol. Chem.* **2005**, *280*, 11902–11910. [[CrossRef](#)] [[PubMed](#)]
39. Mantilla, B.S.; Marchese, L.; Casas-Sánchez, A.; Dyer, N.A.; Ejeh, N.; Biran, M.; Bringaud, F.; Lehane, M.J.; Acosta-Serrano, A.; Silber, A.M. Proline metabolism is essential for *Trypanosoma brucei brucei* survival in the tsetse vector. *PLoS Pathog.* **2017**, *13*, 1–29. [[CrossRef](#)] [[PubMed](#)]
40. Bursell, E. The role of proline in energy metabolism. In *Energy Metabolism in Insects*; Springer: Boston, MA, USA, 1981; pp. 135–154.
41. L’Hostis, C.; Geindre, M.; Deshusses, J. Active transport of L-proline in the protozoan parasite *Trypanosoma brucei brucei*. *Biochem. J.* **1993**, *291*, 297–301. [[CrossRef](#)] [[PubMed](#)]
42. Mathieu, C.; Salgado, A.G.; Wirdnam, C.; Meier, S.; Grotemeyer, M.S.; Inbar, E.; Mäser, P.; Zilberstein, D.; Sigel, E.; Bütikofer, P.; et al. *Trypanosoma brucei* eflornithine transporter AAT6 is a low-affinity low-selective transporter for neutral amino acids. *Biochem. J.* **2014**, *463*, 9–18. [[CrossRef](#)] [[PubMed](#)]
43. Goldberg, B.; Rattendi, D.; Lloyd, D.; Yarlett, N.; Bacchi, C.J. Kinetics of methionine transport and metabolism by *Trypanosoma brucei brucei* and *Trypanosoma brucei rhodesiense*. *Arch. Biochem. Biophys.* **2000**, *377*, 49–57. [[CrossRef](#)] [[PubMed](#)]
44. Hasne, M.P.; Barrett, M.P. Transport of methionine in *Trypanosoma brucei brucei*. *Mol. Biochem. Parasitol.* **2000**, *111*, 299–307. [[CrossRef](#)]
45. Mathieu, C.; Macêdo, J.P.; Hürlimann, D.; Wirdnam, C.; Haindrich, A.C.; Grotemeyer, M.S.; González-Salgado, A.; Schmidt, R.S.; Inbar, E.; Mäser, P.; et al. Arginine and lysine transporters are essential for *Trypanosoma brucei*. *PLoS ONE* **2017**, *12*, 1–23. [[CrossRef](#)] [[PubMed](#)]
46. Macedo, J.P.; Currier, R.B.; Wirdnam, C.; Horn, D.; Alsford, S.; Rentsch, D. Ornithine uptake and the modulation of drug sensitivity in *Trypanosoma brucei*. *FASEB J.* **2017**, *31*, 4649–4660. [[CrossRef](#)] [[PubMed](#)]
47. Hampton, J.R. Lysine uptake in cultured *Trypanosoma cruzi*: Interactions of competitive inhibitors. *J. Protozool.* **1970**, *17*, 597–600. [[CrossRef](#)] [[PubMed](#)]
48. Hampton, J.R. Arginine transport in the culture form of *Trypanosoma cruzi*. *J. Protozool.* **1971**, *18*, 701–703. [[CrossRef](#)] [[PubMed](#)]
49. Goldberg, S.S.; Pereira, A.A.S.; Chiari, E.; Mares-Guia, M.; Gazzinelli, G. Comparative kinetics of arginine and lysine transport by epimastigotes and trypomastigotes from two strains of *Trypanosoma cruzi*. *J. Protozool.* **1976**, *23*, 179–186. [[CrossRef](#)]
50. Canepa, G.E.; Silber, A.M.; Bouvier, L.A.; Pereira, C.A. Biochemical characterization of a low-affinity arginine permease from the parasite *Trypanosoma cruzi*. *FEMS Microbiol. Lett.* **2004**, *236*, 79–84. [[CrossRef](#)] [[PubMed](#)]
51. Pereira, C.A.; Alonso, G.D.; Paveto, M.C.; Flawiá, M.M.; Torres, H.N. L-arginine uptake and L-phosphoarginine synthesis in *Trypanosoma cruzi*. *J. Eukaryot. Microbiol.* **1999**, *46*, 566–570. [[CrossRef](#)] [[PubMed](#)]
52. Inbar, E.; Canepa, G.E.; Carrillo, C.; Glaser, F.; Grotemeyer, M.S.; Rentsch, D.; Zilberstein, D.; Pereira, C.A. Lysine transporters in human trypanosomatid pathogens. *Amino Acids* **2012**, *42*, 347–360. [[CrossRef](#)] [[PubMed](#)]
53. Carrillo, C.; Canepa, G.E.; Giacometti, A.; Bouvier, L.A.; Miranda, M.R.; de los Milagros Camara, M.; Pereira, C.A. *Trypanosoma cruzi* amino acid transporter TcAAAP411 mediates arginine uptake in yeasts. *FEMS Microbiol. Lett.* **2010**, *306*, 97–102. [[CrossRef](#)] [[PubMed](#)]
54. Miranda, M.R.; Sayé, M.; Bouvier, L.A.; de los Milagros Cámara, M.; Montserrat, J.; Pereira, C.A. Cationic amino acid uptake constitutes a metabolic regulation mechanism and occurs in the flagellar pocket of *Trypanosoma cruzi*. *PLoS ONE* **2012**, *7*, 3–9. [[CrossRef](#)] [[PubMed](#)]
55. Henriques, C.; Miller, M.P.; Catanho, M.; De Carvalho, T.M.U.; Krieger, M.A.; Probst, C.M.; De Souza, W.; Degraeve, W.; Amara, S.G. Identification and functional characterization of a novel arginine/ornithine transporter, a member of a cationic amino acid transporter subfamily in the *Trypanosoma cruzi* genome. *Parasites Vectors* **2015**, *8*, 1–18. [[CrossRef](#)] [[PubMed](#)]

56. Silber, A.M.; Tonelli, R.R.; Martinelli, M.; Colli, W.; Alves, M.J.M. Active transport of L-proline in *Trypanosoma cruzi*. *J. Eukaryot. Microbiol.* **2002**, *49*, 441–446. [[CrossRef](#)] [[PubMed](#)]
57. Saye, M.; Miranda, M.R.; Di Girolamo, F.; De Los Milagros Cámara, M.; Pereira, C.A. Proline modulates the *Trypanosoma cruzi* resistance to reactive oxygen species and drugs through a novel D, L-proline transporter. *PLoS ONE* **2014**, *9*. [[CrossRef](#)] [[PubMed](#)]
58. Caballero, Z.C.; Costa-Martins, A.G.; Ferreira, R.C.; P Alves, J.M.; Serrano, M.G.; Camargo, E.P.; Buck, G.A.; Minoprio, P.; Teixeira, G.M.M. Phylogenetic and syntenic data support a single horizontal transference to a *Trypanosoma* ancestor of a prokaryotic proline racemase implicated in parasite evasion from host defences. *Parasites Vectors* **2015**, *8*, 1–18. [[CrossRef](#)] [[PubMed](#)]
59. Canepa, G.E.; Bouvier, L.A.; Urias, U.; Miranda, M.R.; Colli, W.; Alves, M.J.M.; Pereira, C.A. Aspartate transport and metabolism in the protozoan parasite *Trypanosoma cruzi*. *FEMS Microbiol. Lett.* **2005**, *247*, 65–71. [[CrossRef](#)] [[PubMed](#)]
60. Silber, A.M.; Rojas, R.L.G.; Urias, U.; Colli, W.; Alves, M.J.M. Biochemical characterization of the glutamate transport in *Trypanosoma cruzi*. *Int. J. Parasitol.* **2006**, *36*, 157–163. [[CrossRef](#)] [[PubMed](#)]
61. Barisón, M.J.; Damasceno, F.S.; Mantilla, B.S.; Silber, A.M. The active transport of histidine and its role in ATP production in *Trypanosoma cruzi*. *J. Bioenerg. Biomembr.* **2016**, *48*, 437–449. [[CrossRef](#)] [[PubMed](#)]
62. Galvez Rojas, R.L.; Ahn, I.Y.; Suárez Mantilla, B.; Sant’Anna, C.; Pral, E.M.F.; Silber, A.M. The uptake of GABA in *Trypanosoma cruzi*. *J. Eukaryot. Microbiol.* **2015**, *62*, 629–636. [[CrossRef](#)] [[PubMed](#)]
63. Canepa, G.E.; Bouvier, L.A.; Miranda, M.R.; Uttaro, A.D.; Pereira, C.A. Characterization of *Trypanosoma cruzi* L-cysteine transport mechanisms and their adaptive regulation. *FEMS Microbiol. Lett.* **2009**, *292*, 27–32. [[CrossRef](#)] [[PubMed](#)]
64. Manchola, N.C.; Rapado, L.N.; Barison, M.J.; Silber, A.M. Biochemical characterization of branched chain amino acids uptake in *Trypanosoma cruzi*. *J. Eukaryot. Microbiol.* **2015**, *63*, 299–308. [[CrossRef](#)] [[PubMed](#)]
65. Mukkada, A.J.; Simon, M.W. *Leishmania tropica*: Uptake of methionine by promastigotes. *Exp. Parasitol.* **1977**, *42*, 87–96. [[CrossRef](#)]
66. Simon, M.W.; Mukkada, A.J. *Leishmania tropica*: Regulation and specificity of the methionine transport system in promastigotes. *Exp. Parasitol.* **1977**, *42*, 97–105. [[CrossRef](#)]
67. Law, S.S.; Mukkada, A.J. Transport of L-proline and its regulation in *Leishmania tropica* promastigotes. *J. Protozool.* **1979**, *26*, 295–301. [[CrossRef](#)] [[PubMed](#)]
68. Bonay, P.; Cohen, E. Neutral amino acid transport in *Leishmania* promastigotes. *Biochim. Biophys. Acta* **1983**, *731*, 222–228. [[CrossRef](#)]
69. Zilberstein, D.; Dwyer, D.M. Protonmotive force-driven active transport of D-glucose and L-proline in the protozoan parasite *Leishmania donovani*. *Proc. Natl. Acad. Sci. USA* **1985**, *82*, 1716–1720. [[CrossRef](#)] [[PubMed](#)]
70. Zilberstein, D.; Philosoph, H.; Gepstein, A. Maintenance of cytoplasmic pH and proton motive force in promastigotes of *Leishmania donovani*. *Mol. Biochem. Parasitol.* **1989**, *36*, 109–117. [[CrossRef](#)]
71. Glaser, T.A.; Mukkada, A.J. Proline transport in *Leishmania donovani* amastigotes: Dependence on pH gradients and membrane potential. *Mol. Biochem. Parasitol.* **1992**, *51*, 1–8. [[CrossRef](#)]
72. Ter Kuile, B.H.; Opperdoes, F.R. A chemostat study on proline uptake and metabolism of *Leishmania donovani*. *J. Protozool.* **1992**, *39*, 555–558. [[CrossRef](#)] [[PubMed](#)]
73. Zilberstein, D.; Gepstein, A. Regulation of L-proline transport in *Leishmania donovani* by extracellular pH. *Mol. Biochem. Parasitol.* **1993**, *61*, 197–205. [[CrossRef](#)]
74. Mazareb, S.; Fu, Z.Y.; Zilberstein, D. Developmental regulation of proline transport in *Leishmania donovani*. *Exp. Parasitol.* **1999**, *91*, 341–348. [[CrossRef](#)] [[PubMed](#)]
75. Kandpal, M.; Fouce, R.B.; Pal, A.; Guru, P.Y.; Tekwani, B.L. Kinetics and molecular characteristics of arginine transport by *Leishmania donovani* promastigotes. *Mol. Biochem. Parasitol.* **1995**, *71*, 193–201. [[CrossRef](#)]
76. Paes, L.S.; Galvez Rojas, R.L.; Daliry, A.; Floeter-Winter, L.M.; Ramirez, M.I.; Silber, A.M. Active transport of glutamate in *Leishmania (Leishmania) amazonensis*. *J. Eukaryot. Microbiol.* **2008**, *55*, 382–387. [[CrossRef](#)] [[PubMed](#)]
77. Dos Santos, M.G.; Paes, L.S.; Zampieri, R.A.; da Silva, M.F.L.; Silber, A.M.; Floeter-Winter, L.M. Biochemical characterization of serine transport in *Leishmania (Leishmania) amazonensis*. *Mol. Biochem. Parasitol.* **2009**, *163*, 107–113. [[CrossRef](#)] [[PubMed](#)]



78. Inbar, E.; Schlisselberg, D.; Suter-Grotemeyer, M.; Rentsch, D.; Zilberstein, D. A versatile proline/alanine transporter in the unicellular pathogen *Leishmania donovani* regulates amino acid homeostasis and osmotic stress responses. *Biochem. J.* **2013**, *449*, 555–566. [[CrossRef](#)] [[PubMed](#)]
79. Shaked-Mishan, P.; Suter-Grotemeyer, M.; Yoel-Almagor, T.; Holland, N.; Zilberstein, D.; Rentsch, D. A novel high-affinity arginine transporter from the human parasitic protozoan *Leishmania donovani*. *Mol. Microbiol.* **2006**, *60*, 30–38. [[CrossRef](#)] [[PubMed](#)]
80. Darlyuk, I.; Goldman, A.; Roberts, S.C.; Ullmarr, B.; Rentsch, D.; Zilberstein, D. Arginine homeostasis and transport in the human pathogen *Leishmania donovani*. *J. Biol. Chem.* **2009**, *284*, 19800–19807. [[CrossRef](#)] [[PubMed](#)]
81. Castilho-Martins, E.A.; da Silva, M.F.L.; dos Santos, M.G.; Muxel, S.M.; Floeter-Winter, L.M. Axenic *Leishmania amazonensis* promastigotes sense both the external and internal arginine pool distinctly regulating the two transporter-coding genes. *PLoS ONE* **2011**, *6*. [[CrossRef](#)] [[PubMed](#)]
82. Aoki, J.I.; Muxel, S.M.; Zampieri, R.A.; Acuña, S.M.; Fernandes, J.C.R.; Vanderlinde, R.H.; Sales, M.C.O.P.; Floeter-Winter, L.M. L-arginine availability and arginase activity: Characterization of amino acid permease 3 in *Leishmania amazonensis*. *PLoS Negl. Trop. Dis.* **2017**, *11*, 1–19. [[CrossRef](#)] [[PubMed](#)]
83. Harper, A.; Miller, R.; Block, K. Branched-chain amino acid metabolism. *Annu. Rev. Nutr.* **1984**, *4*, 409–454. [[CrossRef](#)] [[PubMed](#)]
84. Curien, G.; Biou, V.; Mas-Droux, C.; Robert-Genthon, M.; Ferrer, J.L.; Dumas, R. Amino acid biosynthesis: New architectures in allosteric enzymes. *Plant Physiol. Biochem.* **2008**, *46*, 325–339. [[CrossRef](#)] [[PubMed](#)]
85. Nayak, A.; Akpunarlieva, S.; Barrett, M.; Burchmore, R. A defined medium for *Leishmania* culture allows definition of essential amino acids. *Exp. Parasitol.* **2018**, *185*, 39–52. [[CrossRef](#)] [[PubMed](#)]
86. Chaudhary, K.; Roos, D.S. Protozoan genomics for drug discovery. *Nat. Biotechnol.* **2005**, *23*, 1089–1091. [[CrossRef](#)] [[PubMed](#)]
87. Canepa, G.E.; Carrillo, C.; Miranda, M.R.; Sayé, M.; Pereira, C.A. Arginine kinase in *Phytomonas*, a trypanosomatid parasite of plants. *Comp. Biochem. Physiol. B Biochem. Mol. Biol.* **2011**, *160*, 40–43. [[CrossRef](#)] [[PubMed](#)]
88. Vincent, I.M.; Creek, D.J.; Burgess, K.; Woods, D.J.; Burchmore, R.J.S.; Barrett, M.P. Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against *Trypanosoma brucei*. *PLoS Negl. Trop. Dis.* **2012**, *6*. [[CrossRef](#)] [[PubMed](#)]
89. Berriman, M.; Ghedin, E.; Hertz-Fowler, C.; Blandin, G.; Renauld, H.; Bartholomeu, D.C.; Lennard, N.J.; Caler, E.; Hamlin, N.E.; Haas, B.; et al. The genome of the African trypanosome *Trypanosoma brucei*. *Science* **2005**, *309*, 416–422. [[CrossRef](#)] [[PubMed](#)]
90. Guttman, H.N. Patterns of methionine and lysine biosynthesis in the Trypanosomatidae during growth. *J. Protozool.* **1967**, *14*, 267–271. [[CrossRef](#)] [[PubMed](#)]
91. Opperdoes, F.R.; Butenko, A.; Flegontov, P.; Yurchenko, V.; Lukeš, J. Comparative metabolism of free-living *Bodo saltans* and parasitic trypanosomatids. *J. Eukaryot. Microbiol.* **2016**, *63*, 657–678. [[CrossRef](#)] [[PubMed](#)]
92. Krassner, S.M.; Flory, B. Proline metabolism in *Leishmania donovani* promastigotes. *J. Protozool.* **1972**, *19*, 682–685. [[CrossRef](#)] [[PubMed](#)]
93. Sylvester, D.; Krassner, S.M.; In, P.M. Proline metabolism in *Trypanosoma cruzi* epimastigotes. *Comp. Biochem. Physiol. Part B Biochem.* **1976**, *55*, 443–447. [[CrossRef](#)]
94. Coustou, V.; Biran, M.; Breton, M.; Guegan, F.; Rivière, L.; Plazolles, N.; Nolan, D.; Barrett, M.P.; Franconi, J.M.; Bringaud, F.; et al. Glucose-induced remodeling of intermediary and energy metabolism in procyclic *Trypanosoma brucei*. *J. Biol. Chem.* **2008**, *283*, 16343–16354. [[CrossRef](#)] [[PubMed](#)]
95. Paes, L.S.; Suárez Mantilla, B.; Zimbres, F.M.; Pral, E.M.F.; Diogo de Melo, P.; Tahara, E.B.; Kowaltowski, A.J.; Elias, M.C.; Silber, A.M. Proline dehydrogenase regulates redox state and respiratory metabolism in *Trypanosoma cruzi*. *PLoS ONE* **2013**, *8*. [[CrossRef](#)] [[PubMed](#)]
96. Mantilla, B.S.; Paes, L.S.; Pral, E.M.F.; Martil, D.E.; Thiemann, O.H.; Fernández-Silva, P.; Bastos, E.L.; Silber, A.M. Role of  $\Delta^1$ -pyrroline-5-carboxylate dehydrogenase supports mitochondrial metabolism and host-cell invasion of *Trypanosoma cruzi*. *J. Biol. Chem.* **2015**, *290*, 7767–7790. [[CrossRef](#)] [[PubMed](#)]
97. Johnson, A. B. Strecker The interconversion of glutamic acid and proline. *J. Biol. Chem.* **1962**, *237*, 1876–1882. [[PubMed](#)]
98. Phang, J.M.; Yeh, G.C.; Hagedorn, C.H. The intercellular proline cycle. *Life Sci.* **1981**, *28*, 53–58. [[CrossRef](#)]

99. Vogel, H.J.; Davis, J. Glutamic g-semialdehyde and  $\Delta$ 1-pyrroline-5-carboxylic acid, intermediates in the biosynthesis of proline. *J. Am. Chem. Soc.* **1952**, *74*, 109–112. [[CrossRef](#)]
100. Strecker, H.J. The interconversion of glutamic acid and proline. *J. Biol. Chem.* **1960**, *235*, 3218–3223. [[CrossRef](#)]
101. Tonelli, R.R.; Silber, A.M.; Almeida-de-Faria, M.; Hirata, I.Y.; Colli, W.; Alves, J.M. L-proline is essential for the intracellular differentiation of *Trypanosoma cruzi*. *Cell. Microbiol.* **2004**, *6*, 733–741. [[CrossRef](#)] [[PubMed](#)]
102. Opperdoes, F.R.; Coombs, G.H. Metabolism of *Leishmania*: Proven and predicted. *Trends Parasitol.* **2007**, *23*, 149–158. [[CrossRef](#)] [[PubMed](#)]
103. Akpunarlieva, S.; Weidt, S.; Lamasudin, D.; Naula, C.; Henderson, D.; Barrett, M.; Burgess, K.; Burchmore, R. Integration of proteomics and metabolomics to elucidate metabolic adaptation in *Leishmania*. *J. Proteom.* **2017**, *155*, 85–98. [[CrossRef](#)] [[PubMed](#)]
104. Hayzer, D.J.; Leisinger, T. Proline biosynthesis in *Escherichia coli*. *Eur. J. Biochem.* **1982**, *121*, 561–565. [[CrossRef](#)] [[PubMed](#)]
105. Csonka, L.N.; Leisinger, T. Biosynthesis of proline. *EcoSal Plus* **2007**, *2*. [[CrossRef](#)] [[PubMed](#)]
106. Hu, C.A.; Delauney, A.J.; Verma, D.P. A bifunctional enzyme (delta 1-pyrroline-5-carboxylate synthetase) catalyzes the first two steps in proline biosynthesis in plants. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 9354–9358. [[CrossRef](#)] [[PubMed](#)]
107. Turchetto-Zolet, A.C.; Margis-Pinheiro, M.; Margis, R. The evolution of pyrroline-5-carboxylate synthase in plants: A key enzyme in proline synthesis. *Mol. Genet. Genom.* **2009**, *281*, 87–97. [[CrossRef](#)] [[PubMed](#)]
108. Yura, T.; Vogel, H.J. Pyrroline-5-carboxylate reductase of *Neurospora crassa*; partial purification and some properties. *J. Biol. Chem.* **1959**, *234*, 335–338. [[PubMed](#)]
109. Rossi, J.J.; Vender, J.; Berg, C.M.; Coleman, W.H. Partial purification and some properties of  $\Delta$ 1-pyrroline-5-carboxylate reductase from *Escherichia coli*. *J. Bacteriol.* **1977**, *129*, 108–114. [[PubMed](#)]
110. Szoke, A.; Miao, G.H.; Hong, Z.; Verma, D.P. Subcellular location of delta-pyrroline-5-carboxylate reductase in root/nodule and leaf of soybean. *Plant Physiol.* **1992**, *99*, 1642–1649. [[CrossRef](#)] [[PubMed](#)]
111. Murahama, M.; Yoshida, T.; Hayashi, F.; Ichino, T.; Sanada, Y.; Wada, K. Purification and characterization of delta(1)-pyrroline-5-carboxylate reductase isoenzymes, indicating differential distribution in spinach (*Spinacia oleracea* L.) leaves. *Plant Cell Physiol.* **2001**, *42*, 742–750. [[CrossRef](#)] [[PubMed](#)]
112. Delauney, A.J.; Hu, C.A.A.; Kavi Kishor, P.B.; Verma, D.P.S. Cloning of ornithine  $\delta$ -aminotransferase cDNA from *Vigna aconitifolia* by trans-complementation in *Escherichia coli* and regulation of proline biosynthesis. *J. Biol. Chem.* **1993**, *268*, 18673–18678. [[PubMed](#)]
113. Yoshida, N.; Plessmann Camargo, E. Ureotelism and ammonotelism in trypanosomatids. *J. Bacteriol.* **1978**, *136*, 1184–1186. [[PubMed](#)]
114. König, S.; Marco, H.; Gäde, G. D-Proline: Comment to “An overview on D-amino acids”. *Amino Acids* **2018**, *50*, 359–361. [[CrossRef](#)] [[PubMed](#)]
115. Reina-San-Martín, B.; Degrave, W.; Rougeot, C.; Cosson, A.; Chamond, N.; Cordeiro-da-Silva, A.; Arala-Chaves, M.; Coutinho, A.; Minoprio, P. A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase. *Nat. Med.* **2000**, *6*, 890–897. [[PubMed](#)]
116. Chamond, N.; Grégoire, C.; Coatnoan, N.; Rougeot, C.; Freitas-Junior, L.H.; Da Silveira, J.F.; Degrave, W.M.; Minoprio, P. Biochemical characterization of proline racemases from the human protozoan parasite *Trypanosoma cruzi* and definition of putative protein signatures. *J. Biol. Chem.* **2003**, *278*, 15484–15494. [[CrossRef](#)] [[PubMed](#)]
117. Chamond, N.; Goytia, M.; Coatnoan, N.; Barale, J.C.; Cosson, A.; Degrave, W.M.; Minoprio, P. *Trypanosoma cruzi* proline racemases are involved in parasite differentiation and infectivity. *Mol. Microbiol.* **2005**, *58*, 46–60. [[CrossRef](#)] [[PubMed](#)]
118. Cazzulo, J.J.; Juan, S.M.; Segura, E.L. Glutamate dehydrogenase and aspartate aminotransferase in *Trypanosoma cruzi*. *Comp. Biochem. Physiol. B* **1977**, *56*, 301–303. [[CrossRef](#)]
119. Barderi, P.; Campetella, O.; Carlos, A.; Frasc, A.C.C.; Santome, J.A.; Hellman, U.; Pettersson, U.; Cazzulo, J.J. The NADP<sup>+</sup>-linked glutamate dehydrogenase from *Trypanosoma cruzi*: Sequence, genomic organization and expression. *Biochem. J.* **1998**, *330*, 951–958. [[CrossRef](#)] [[PubMed](#)]
120. Cannata, J.J.B.; Frasc, A.C.C.; Cataldi de Flombaum, M.A.; Segura, E.L.; Cazzulo, J.J. Two forms of malic enzyme with different regulatory properties in *Trypanosoma cruzi*. *Biochem. J.* **1979**, *184*, 409–419. [[CrossRef](#)] [[PubMed](#)]

121. Zeledon, R. Comparative physiological studies on four species of hemoflagellates in culture. II. Effect of carbohydrates and related substances and some amino compounds on the respiration. *J. Parasitol.* **1960**, *46*, 541–551. [[CrossRef](#)] [[PubMed](#)]
122. Zelada, C.; Jo, J.; Montemartini, M.; Cazzulo, J.J.; Nowicki, C. Purification and partial structural and kinetic characterization of an alanine aminotransferase from epimastigotes of *Trypanosoma cruzi*. *Mol. Biochem. Parasitol.* **1996**, *79*, 225–228. [[CrossRef](#)]
123. Li, Y.; Shah-Simpson, S.; Okrah, K.; Belew, A.T.; Choi, J.; Caradonna, K.L.; Padmanabhan, P.; Ndegwa, D.M.; Temanni, M.R.; Corrada Bravo, H.; et al. Transcriptome remodeling in *Trypanosoma cruzi* and human cells during intracellular infection. *PLoS Pathog.* **2016**, *12*, 1–30. [[CrossRef](#)] [[PubMed](#)]
124. Barisón, M.J.; Rapado, L.N.; Merino, E.F.; Pral, E.M.F.; Mantilla, B.S.; Marchese, L.; Nowicki, C.; Silber, A.M.; Cassera, M.B. Metabolomic profiling reveals a finely tuned, starvation induced metabolic switch in *Trypanosoma cruzi* epimastigotes. *J. Biol. Chem.* **2017**, *292*, 8964–8977. [[CrossRef](#)] [[PubMed](#)]
125. Crispim, M.; Damasceno, S.; Hernandez, A.; Barison, M.J.; Sauter, I.P.; Pavani, R.S.; Moura, A.S.; Pral, E.M.F.; Cortez, M.; Elias, M.C.; et al. The glutamine synthetase of *Trypanosoma cruzi* is required for its resistance to ammonium accumulation and evasion of the parasitophorous vacuole during host-cell infection. *PLoS Negl. Trop. Dis.* **2018**, *12*, e0006170. [[CrossRef](#)] [[PubMed](#)]
126. Gao, G.; Nara, T.; Nakajima-Shimada, J.; Aoki, T. Novel organization and sequences of five genes encoding all six enzymes for *de novo* pyrimidine biosynthesis in *Trypanosoma cruzi*. *J. Mol. Biol.* **1999**, *285*, 149–161. [[CrossRef](#)] [[PubMed](#)]
127. Hashimoto, M.; Morales, J.; Fukai, Y.; Suzuki, S.; Takamiya, S.; Tsubouchi, A.; Inoue, S.; Inoue, M.; Kita, K.; Harada, S.; et al. Critical importance of the *de novo* pyrimidine biosynthesis pathway for *Trypanosoma cruzi* growth in the mammalian host cell cytoplasm. *Biochem. Biophys. Res. Commun.* **2012**, *417*, 1002–1006. [[CrossRef](#)] [[PubMed](#)]
128. Li, Q.; Leija, C.; Rijo-Ferreira, F.; Chen, J.; Cestari, I.; Stuart, K.; Tu, B.P.; Phillips, M.A. GMP synthase is essential for viability and infectivity of *Trypanosoma brucei* despite a redundant purine salvage pathway. *Mol. Microbiol.* **2015**, *97*, 1006–1020. [[CrossRef](#)] [[PubMed](#)]
129. Marciano, D.; Maugeri, D.A.; Cazzulo, J.J.; Nowicki, C. Functional characterization of stage-specific aminotransferases from trypanosomatids. *Mol. Biochem. Parasitol.* **2009**, *166*, 172–182. [[CrossRef](#)] [[PubMed](#)]
130. Kumar, V.; Yadav, S.; Soumya, N.; Kumar, R.; Kishore, N.; Singh, S. Biochemical and inhibition studies of glutamine synthetase from *Leishmania donovani*. *Microb. Pathog.* **2017**, *107*, 164–174. [[CrossRef](#)] [[PubMed](#)]
131. Naderer, T.; Wee, E.; McConville, M.J. Role of hexosamine biosynthesis in *Leishmania* growth and virulence. *Mol. Microbiol.* **2008**, *69*, 858–869. [[CrossRef](#)] [[PubMed](#)]
132. Morris, S.M. Recent advances in arginine metabolism: Roles and regulation of the arginases. *Br. J. Pharmacol.* **2009**, *157*, 922–930. [[CrossRef](#)] [[PubMed](#)]
133. Pegg, A.E. The function of spermine. *IUBMB Life* **2014**, *66*, 8–18. [[CrossRef](#)] [[PubMed](#)]
134. Ariyanayagam, M.R.; Fairlamb, A.H. Diamine auxotrophy may be a universal feature of *Trypanosoma cruzi* epimastigotes. *Mol. Biochem. Parasitol.* **1997**, *84*, 111–121. [[CrossRef](#)]
135. Ariyanayagam, M.R.; Fairlamb, A.H. Ovothiol and trypanothione as antioxidants in trypanosomatids. *Mol. Biochem. Parasitol.* **2001**, *115*, 189–198. [[CrossRef](#)]
136. Oza, S.L.; Tetaud, E.; Ariyanayagam, M.R.; Warnon, S.S.; Fairlamb, A.H. A single enzyme catalyses formation of trypanothione from glutathione and spermidine in *Trypanosoma cruzi*. *J. Biol. Chem.* **2002**, *277*, 35853–35861. [[CrossRef](#)] [[PubMed](#)]
137. Oza, S.L.; Ariyanayagam, M.R.; Aitcheson, N.; Fairlamb, A.H. Properties of trypanothione synthetase from *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* **2003**, *131*, 25–33. [[CrossRef](#)]
138. Oza, S.L.; Shaw, M.P.; Wyllie, S.; Fairlamb, A.H. Trypanothione biosynthesis in *Leishmania major*. *Mol. Biochem. Parasitol.* **2005**, *139*, 107–116. [[CrossRef](#)] [[PubMed](#)]
139. Jockers-Scherubl, M.C.; Schirmer, R.H.; Krauth-Siegel, R.L. Trypanothione reductase from *Trypanosoma cruzi*. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds. *Eur. J. Biochem.* **1989**, *180*, 267–272. [[CrossRef](#)] [[PubMed](#)]
140. Jones, D.C.; Ariza, A.; Chow, W.H.A.; Oza, S.L.; Fairlamb, A.H. Comparative structural, kinetic and inhibitor studies of *Trypanosoma brucei* trypanothione reductase with *T. cruzi*. *Mol. Biochem. Parasitol.* **2010**, *169*, 12–19. [[CrossRef](#)] [[PubMed](#)]

141. Roberts, S.C.; Tancer, M.J.; Polinsky, M.R.; Michael Gibson, K.; Heby, O.; Ullman, B. Arginase plays a pivotal role in polyamine precursor metabolism in Leishmania: Characterization of gene deletion mutants. *J. Biol. Chem.* **2004**, *279*, 23668–23678. [[CrossRef](#)] [[PubMed](#)]
142. Da Silva, E.R.; da Silva, M.F.L.; Fischer, H.; Mortara, R.A.; Mayer, M.G.; Framesqui, K.; Silber, A.M.; Floeter-Winter, L.M. Biochemical and biophysical properties of a highly active recombinant arginase from *Leishmania (Leishmania) amazonensis* and subcellular localization of native enzyme. *Mol. Biochem. Parasitol.* **2008**, *159*, 104–111. [[CrossRef](#)] [[PubMed](#)]
143. Jenkinson, C.P.; Grody, W.W.; Cederbaum, S.D. Comparative properties of arginases. *Comp. Biochem. Physiol. B Biochem. Mol. Biol.* **1996**, *114*, 107–132. [[CrossRef](#)]
144. Badirzadeh, A.; Taheri, T.; Taslimi, Y.; Abdossamadi, Z.; Heidari-Kharaji, M.; Gholami, E.; Sedaghat, B.; Niyyati, M.; Rafati, S. Arginase activity in pathogenic and non-pathogenic species of *Leishmania* parasites. *PLoS Negl. Trop. Dis.* **2017**, *11*, e0005774. [[CrossRef](#)] [[PubMed](#)]
145. Boitz, J.M.; Gilroy, C.A.; Olenyik, T.D.; Paradis, D.; Perdeh, J.; Dearman, K.; Davis, M.J.; Yates, P.A.; Li, Y.; Riscoe, M.K.; et al. Arginase is essential for survival of *Leishmania donovani* promastigotes but not intracellular amastigotes. *Infect. Immun.* **2017**, *85*. [[CrossRef](#)] [[PubMed](#)]
146. Hai, Y.; Kerkhoven, E.J.; Barrett, M.P.; Christianson, D.W. Crystal structure of an arginase-like protein from *Trypanosoma brucei* that evolved without a binuclear manganese cluster. *Biochemistry* **2015**, *54*, 458–471. [[CrossRef](#)] [[PubMed](#)]
147. Pereira, C.A.; Alonso, G.D.; Torres, H.N.; Flawiá, M.M. Arginine kinase: A common feature for management of energy reserves in African and American flagellated trypanosomatids. *J. Eukaryot. Microbiol.* **2002**, *49*, 82–85. [[CrossRef](#)] [[PubMed](#)]
148. Pereira, C.A.; Alonso, G.D.; Paveto, M.C.; Iribarren, A.; Cabanas, M.L.; Torres, H.N.; Flawiá, M.M. *Trypanosoma cruzi* arginine kinase characterization and cloning. A novel energetic pathway in protozoan parasites. *J. Biol. Chem.* **2000**, *275*, 1495–1501. [[CrossRef](#)] [[PubMed](#)]
149. Pereira, C.A.; Alonso, G.D.; Ivaldi, S.; Silber, A.; Alves, M.J.M.; Bouvier, L.A.; Flawiá, M.M.; Torres, H.N. Arginine metabolism in *Trypanosoma cruzi* is coupled to parasite stage and replication. *FEBS Lett.* **2002**, *526*, 111–114. [[CrossRef](#)]
150. Voncken, F.; Gao, F.; Wadforth, C.; Harley, M.; Colasante, C. The phosphoarginine energy-buffering system of *Trypanosoma brucei* involves multiple arginine kinase isoforms with different subcellular locations. *PLoS ONE* **2013**, *8*. [[CrossRef](#)] [[PubMed](#)]
151. Ooi, C.P.; Rotureau, B.; Gribaldo, S.; Georgikou, C.; Julkowska, D.; Blisnick, T.; Perrot, S.; Subota, I.; Bastin, P. The flagellar arginine kinase in *Trypanosoma brucei* is important for infection in tsetse flies. *PLoS ONE* **2015**, *10*, 1–23. [[CrossRef](#)] [[PubMed](#)]
152. Krassner, S.M.; Flory, B. Essential amino acids in the culture of *Leishmania tarentolae*. *J. Parasitol.* **1971**, *57*, 917–920. [[CrossRef](#)] [[PubMed](#)]
153. Cadavid-Restrepo, G.; Gastardelo, T.S.; Faudry, E.; de Almeida, H.; Bastos, I.M.; Negreiros, R.S.; Lima, M.M.; Assumpção, T.C.; Almeida, K.C.; Ragno, M.; et al. The major leucyl aminopeptidase of *Trypanosoma cruzi* (LAPTc) assembles into a homohexamer and belongs to the M17 family of metalloproteinases. *BMC Biochem.* **2011**, *12*. [[CrossRef](#)] [[PubMed](#)]
154. Timm, J.; Valente, M.; García-Caballero, D.; Wilson, K.S.; González-Pacanowska, D. Structural characterization of acidic M17 leucine aminopeptidases from the TriTryps and evaluation of their role in nutrient starvation in *Trypanosoma brucei*. *mSphere* **2017**, *2*, e00226-16. [[CrossRef](#)] [[PubMed](#)]
155. Ohshima, T.; Nishida, N.; Bakthavatsalam, S.; Kataoka, K.; Takada, H.; Yoshimura, T.; Soda, K.; Esaki, N. The purification, characterization, cloning and sequencing of the gene for a halostable and thermostable leucine dehydrogenase from *Thermoactinomyces intermedius*. *Eur. J. Biochem.* **1994**, *222*, 305–312. [[CrossRef](#)] [[PubMed](#)]
156. Oikawa, T.; Yamanaka, K.; Kazuoka, T.; Kanzawa, N.; Soda, K. Psychrophilic valine dehydrogenase of the antarctic psychrophile, *Cytophaga* sp. KUC-1. *Eur. J. Biochem.* **2001**, *4383*, 4375–4383. [[CrossRef](#)]
157. Bixel, M.G.; Hutson, S.M.; Hamprecht, B. Cellular distribution of branched-chain amino acid aminotransferase isoenzymes among rat brain glial cells in culture. *J. Histochem. Cytochem.* **1997**, *45*, 685–694. [[CrossRef](#)] [[PubMed](#)]
158. Brosnan, J.T.; Brosnan, M.E. Branched-chain amino acids: Metabolism, physiological function, and application. *J. Nutr.* **2006**, *3*, 207s–211s. [[CrossRef](#)]



159. Ikeda, Y.; Tanaka, K. Purification and characterization of isovaleryl coenzyme A dehydrogenase from rat liver mitochondria. *J. Biol. Chem.* **1983**, *258*, 1077–1085. [[PubMed](#)]
160. Pohl, B.; Raichle, T.; Ghisla, S. Studies on the reaction mechanism of general acyl-CoA dehydrogenase: Determination of selective isotope effects in the dehydrogenation of butyryl-CoA. *Eur. J. Biochem.* **1986**, *160*, 109–115. [[CrossRef](#)] [[PubMed](#)]
161. Ghisla, S.; Thorpe, C. Acyl-CoA dehydrogenases: A mechanistic overview. *Eur. J. Biochem.* **2004**, *271*, 494–508. [[CrossRef](#)] [[PubMed](#)]
162. Mancilla, R.; Naquira, C.; Lanás, C. Protein biosynthesis in trypanosomidae. *Exp. Parasitol.* **1967**, *21*, 154–159. [[CrossRef](#)]
163. Blum, J.J. Oxidation of leucine by *Leishmania donovani*. *J. Protozool.* **1991**, *38*, 527–531. [[CrossRef](#)] [[PubMed](#)]
164. Ginger, M.L.; Chance, M.L.; Goad, L.J. Elucidation of carbon sources used for the biosynthesis of fatty acids and sterols in the trypanosomatid *Leishmania mexicana*. *Biochem. J.* **1999**, *342*, 397–405. [[CrossRef](#)] [[PubMed](#)]
165. Ginger, M.L.; Prescott, M.C.; Reynolds, D.G.; Chance, M.L.; Goad, J.L. Utilization of leucine and acetate as carbon sources for sterol and fatty acid biosynthesis by Old and New World *Leishmania* species, *Endotrypanum monterogeii* and *Trypanosoma cruzi*. *Eur. J. Biochem.* **2000**, *267*, 2555–2566. [[CrossRef](#)] [[PubMed](#)]
166. Ginger, M.L.; Chance, M.L.; Sadler, I.H.; Goad, L.J. The biosynthetic incorporation of the intact leucine skeleton into sterol by the trypanosomatid *Leishmania mexicana*. *J. Biol. Chem.* **2001**, *276*, 11674–11682. [[CrossRef](#)] [[PubMed](#)]
167. Nes, C.R.; Singha, U.K.; Liu, J.; Ganapathy, K.; Villalta, F.; Waterman, M.R.; Lepesheva, G.I.; Chaudhuri, M.; Nes, W.D. Novel sterol metabolic network of *Trypanosoma brucei* procyclic and bloodstream forms. *Biochem. J.* **2012**, *443*, 267–277. [[CrossRef](#)] [[PubMed](#)]
168. Riviere, L.; Moreau, P.; Allmann, S.; Hahn, M.; Biran, M.; Plazolles, N.; Franconi, J.-M.; Boshart, M.; Bringaud, F. Acetate produced in the mitochondrion is the essential precursor for lipid biosynthesis in procyclic trypanosomes. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 12694–12699. [[CrossRef](#)] [[PubMed](#)]
169. Millerioux, Y.; Ebikeme, C.; Biran, M.; Morand, P.; Bouyssou, G.; Vincent, I.M.; Mazet, M.; Riviere, L.; Franconi, J.M.; Burchmore, R.J.S.; et al. The threonine degradation pathway of the *Trypanosoma brucei* procyclic form: The main carbon source for lipid biosynthesis is under metabolic control. *Mol. Microbiol.* **2013**, *90*, 114–129. [[PubMed](#)]
170. Montamat, E.E.; Arauzo, S.S.; Blanco, A. Subcellular localization of leucine aminotransferase and a-hydroxyacid dehydrogenase in *Trypanosoma cruzi*. *Mol. Biochem. Parasitol.* **1987**, *22*, 185–193. [[CrossRef](#)]
171. Manchola, N.C.; Silber, A.M.; Nowicki, C. The non-canonical substrates of *Trypanosoma cruzi* tyrosine and aspartate aminotransferases: Branched-chain amino acids. *J. Eukaryot. Microbiol.* **2018**, *65*, 70–76. [[CrossRef](#)] [[PubMed](#)]
172. Contreras, V.T.; Salles, J.M.; Thomas, N.; Morel, C.M.; Goldenberg, S. In vitro differentiation of *Trypanosoma cruzi* under chemically defined conditions. *Mol. Biochem. Parasitol.* **1985**, *16*, 315–327. [[CrossRef](#)]
173. Berger, L.C.; Wilson, J.; Wood, P.; Berger, J.; Berger, B.J. Methionine regeneration and aspartate aminotransferase in parasitic protozoa. *J. Bacteriol.* **2001**, *183*, 4421–4434. [[CrossRef](#)] [[PubMed](#)]
174. Marciano, D.; Llorente, C.; Maugeri, D.A.; de la Fuente, C.; Opperdoes, F.; Cazzulo, J.J.; Nowicki, C. Biochemical characterization of stage-specific isoforms of aspartate aminotransferases from *Trypanosoma cruzi* and *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* **2008**, *161*, 12–20. [[CrossRef](#)] [[PubMed](#)]
175. Creek, D.J.; Mazet, M.; Achcar, F.; Anderson, J.; Kim, D.H.; Kamour, R.; Morand, P.; Millerioux, Y.; Biran, M.; Kerkhoven, E.J.; et al. Probing the metabolic network in bloodstream-form *Trypanosoma brucei* using untargeted metabolomics with stable isotope labelled glucose. *PLoS Pathog.* **2015**, *11*, 1–25. [[CrossRef](#)] [[PubMed](#)]
176. Loureiro, I.; Faria, J.; Clayton, C.; Ribeiro, S.M.; Roy, N.; Santarem, N.; Tavares, J.; Cordeiro-da-Silva, A.; Santarem, N.; Tavares, J.; et al. Knockdown of asparagine synthetase A renders *Trypanosoma brucei* auxotrophic to asparagine. *PLoS Negl. Trop. Dis.* **2013**, *7*, e2578. [[CrossRef](#)]
177. Faria, J.; Loureiro, I.; Santarém, N.; Macedo-ribeiro, S.; Tavares, J.; Cordeiro-da-Silva, A. *Leishmania infantum* asparagine synthetase A is dispensable for parasites survival and infectivity. *PLoS Negl. Trop. Dis.* **2016**, *10*, e0004365. [[CrossRef](#)] [[PubMed](#)]
178. Singh, J.; Srivastava, A.; Jha, P.; Sinha, K.K.; Kundu, B. Asparaginase as a new molecular target against leishmaniasis: Insights into the mechanism of action and structure-based inhibitor design. *Mol. Biosyst.* **2015**, *11*, 1887–1896. [[CrossRef](#)] [[PubMed](#)]



179. Singh, K.; Ali, V.; Pratap Singh, K.; Gupta, P.; Suman, S.S.; Ghosh, A.K.; Bimal, S.; Pandey, K.; Das, P. Deciphering the interplay between cysteine synthase and thiol cascade proteins in modulating Amphotericin B resistance and survival of *Leishmania donovani* under oxidative stress. *Redox Biol.* **2017**, *12*, 350–366. [[CrossRef](#)] [[PubMed](#)]
180. Finkelstein, J.D. Methionine metabolism in mammals. *J. Nutr. Biochem.* **1990**, *1*, 228–237. [[CrossRef](#)]
181. Reguera, R.M.; Redondo, C.M.; Pérez-Pertejo, Y.; Balaña-Fouce, R. S-adenosylmethionine in protozoan parasites: Functions, synthesis and regulation. *Mol. Biochem. Parasitol.* **2007**, *152*, 1–10. [[CrossRef](#)] [[PubMed](#)]
182. Ciman, M.; Siliprandi, N. On the oxidation of  $\alpha$ -oxibutyrate by isolated mammalian mitochondria. *Biochim. Biophys. Acta* **1968**, *162*, 164–169. [[CrossRef](#)]
183. Bremer, J. Pyruvate dehydrogenase, substrate specificity and product inhibition. *Eur. J. Biochem.* **1969**, *8*, 535–540. [[CrossRef](#)] [[PubMed](#)]
184. Gonzalez, J.C.; Banerjee, R.V.; Huang, S.; Sumner, J.S.; Matthews, R.G. Comparison of cobalamin-independent and cobalamin-dependent methionine synthases from *Escherichia coli*: Two solutions to the same chemical problem. *Biochemistry* **1992**, *31*, 6045–6056. [[CrossRef](#)] [[PubMed](#)]
185. Cazzulo, J.J. Amino acid and protein metabolism. In *Molecular Medical Parasitology*; Academic Press: Cambridge, MA, USA, 2003; pp. 171–195.
186. Walker, J.; Barrett, J. Parasite sulphur amino acid metabolism. *Int. J. Parasitol.* **1997**, *27*, 883–897. [[CrossRef](#)]
187. Pegg, A.E. S-Adenosylmethionine decarboxylase: A brief review. *Cell Biochem. Funct.* **1984**, *2*, 11–15. [[CrossRef](#)] [[PubMed](#)]
188. Pegg, A.E.; Xiong, H.; Feith, D.J.; Shantz, L.M. S-adenosylmethionine decarboxylase: Structure, function and regulation by polyamines. *Biochem. Soc. Trans.* **1998**, *26*, 580–586. [[CrossRef](#)] [[PubMed](#)]
189. Berger, B.J.; Dai, W.W.; Wang, H.; Stark, R.E.; Cerami, A. Aromatic amino acid transamination and methionine recycling in trypanosomatids. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 4126–4130. [[CrossRef](#)] [[PubMed](#)]
190. Moskovitz, J. Methionine sulfoxide reductases: Ubiquitous enzymes involved in antioxidant defense, protein regulation, and prevention of aging-associated diseases. *Biochim. Biophys. Acta Proteins Proteom.* **2005**, *1703*, 213–219. [[CrossRef](#)] [[PubMed](#)]
191. Reguera, R.M.; Perez-Pertejo, Y.; Ordóñez, C.; Cubría, J.C.; Tekwani, B.L.; Balaña-Fouce, R.; Ordóñez, D. S-adenosylmethionine synthesis in *Leishmania infantum*. *Cell Biol. Int.* **1999**, *23*, 579–583. [[CrossRef](#)] [[PubMed](#)]
192. Reguera, R.M.; Balaña-Fouce, R.; Pérez-Pertejo, Y.; Fernández, F.J.; García-Estrada, C.; Cubría, J.C.; Ordóñez, C.; Ordóñez, D. Cloning expression and characterization of methionine adenosyltransferase in *Leishmania infantum* promastigotes. *J. Biol. Chem.* **2002**, *277*, 3158–3167. [[CrossRef](#)] [[PubMed](#)]
193. Willert, E.K.; Fitzpatrick, R.; Phillips, M.A. Allosteric regulation of an essential trypanosome polyamine biosynthetic enzyme by a catalytically dead homolog. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 8275–8280. [[CrossRef](#)] [[PubMed](#)]
194. Willert, E.K.; Phillips, M.A. Regulated expression of an essential allosteric activator of polyamine biosynthesis in African trypanosomes. *PLoS Pathog.* **2008**, *4*, e1000183. [[CrossRef](#)] [[PubMed](#)]
195. Singh, S.P.; Agnihotri, P.; Pratap, J.V. Characterization of a novel putative S-adenosylmethionine decarboxylase-like protein from *Leishmania donovani*. *PLoS ONE* **2013**, *8*. [[CrossRef](#)] [[PubMed](#)]
196. Roberts, S.C.; Scott, J.; Gasteier, J.E.; Jiang, Y.; Brooks, B.; Jardim, A.; Carter, N.S.; Heby, O.; Ullman, B. S-adenosylmethionine decarboxylase from *Leishmania donovani*: Molecular, genetic, and biochemical characterization of null mutants and overproducers. *J. Biol. Chem.* **2002**, *277*, 5902–5909. [[CrossRef](#)] [[PubMed](#)]
197. Sansom, F.M.; Tang, L.; Ralton, J.E.; Saunders, E.C.; Naderer, T.; McConville, M.J. *Leishmania major* methionine sulfoxide reductase A Is required for resistance to oxidative stress and efficient replication in macrophages. *PLoS ONE* **2013**, *8*, 15–17. [[CrossRef](#)] [[PubMed](#)]
198. Bitonti, A.J.; Dumont, J.A.; McCann, P.P. Characterization of *Trypanosoma brucei brucei* S-adenosyl-L-methionine decarboxylase and its inhibition by berenil, pentamidine and methylglyoxal bis(guanylhydrazone). *Biochem. J.* **1986**, *237*, 685–689. [[CrossRef](#)] [[PubMed](#)]
199. Yarlett, N.; Bacchi, C.J. Effect of dl- $\alpha$ -difluoromethylornithine on methionine cycle intermediates in *Trypanosoma brucei brucei*. *Mol. Biochem. Parasitol.* **1988**, *27*, 1–10. [[CrossRef](#)]
200. Yarlett, N.; Garofalo, J.; Goldberg, B.; Ciminelli, M.A.; Ruggiero, V.; Sufrin, J.R.; Bacchi, C.J. S-Adenosylmethionine synthetase in bloodstream *Trypanosoma brucei*. *BBA—Mol. Basis Dis.* **1993**, *1181*, 68–76. [[CrossRef](#)]

201. Bacchi, C.J.; Goldberg, B.; Garofalo-Hannan, J.; Rattendi, D.; Lyte, P.; Yarlett, N. Fate of soluble methionine in African trypanosomes: Effects of metabolic inhibitors. *Biochem. J.* **1995**, *309*, 737–743. [[CrossRef](#)] [[PubMed](#)]
202. Tekwani, B.L.; Bacchi, C.J.; Pegg, A.E. Putrescine activated S-adenosylmethionine decarboxylase from *Trypanosoma brucei brucei*. *Mol. Cell. Biochem.* **1992**, *117*, 53–61. [[CrossRef](#)] [[PubMed](#)]
203. Willert, E.K.; Phillips, M.A. Cross-species activation of trypanosome S-adenosylmethionine decarboxylase by the regulatory subunit prozyme. *Mol. Biochem. Parasitol.* **2009**, *168*, 1–6. [[CrossRef](#)] [[PubMed](#)]
204. Arias, D.G.; Cabeza, M.S.; Erben, E.D.; Carranza, P.G.; Lujan, H.D.; Iñón, M.T.T.; Iglesias, A.A.; Guerrero, S.A. Functional characterization of methionine sulfoxide reductase A from *Trypanosoma* spp. *Free Radic. Biol. Med.* **2011**, *50*, 37–46. [[CrossRef](#)] [[PubMed](#)]
205. Guerrero, S.A.; Arias, D.G.; Cabeza, M.S.; Law, M.C.Y.; D'Amico, M.; Kumar, A.; Wilkinson, S.R. Functional characterisation of the methionine sulfoxide reductase repertoire in *Trypanosoma brucei*. *Free Radic. Biol. Med.* **2017**, *112*, 524–533. [[CrossRef](#)] [[PubMed](#)]
206. Kinch, L.N.; Scott, J.R.; Ullman, B.; Phillips, M.A. Cloning and kinetic characterization of the *Trypanosoma cruzi*. *Mol. Biochem. Parasitol.* **1999**, *101*, 1–11. [[CrossRef](#)]
207. Parker, N.B.; Yang, X.; Hanke, J.; Mason, K.A.; Schowen, R.L.; Borchardt, R.T.; Yin, D.H. *Trypanosoma cruzi*: Molecular cloning and characterization of the S-adenosylhomocysteine hydrolase. *Exp. Parasitol.* **2003**, *105*, 149–158. [[CrossRef](#)] [[PubMed](#)]
208. Duszenko, M.; Mühlstädt, K.; Broder, A. Cysteine is an essential growth factor for *Trypanosoma brucei* bloodstream forms. *Mol. Biochem. Parasitol.* **1992**, *50*, 269–273. [[CrossRef](#)]
209. Baltz, T.; Baltz, D.; Giroud, C.; Crockett, J. Cultivation in a semi-defined medium of animal infective forms of *Trypanosoma brucei*, *T. equiperdum*, *T. evansi*, *T. rhodesiense* and *T. gambiense*. *EMBO J.* **1985**, *4*, 1273–1277. [[PubMed](#)]
210. Williams, R.A.M.; Westrop, G.D.; Coombs, G.H. Two pathways for cysteine biosynthesis in *Leishmania major*. *Biochem. J.* **2009**, *420*, 451–462. [[CrossRef](#)] [[PubMed](#)]
211. Abendroth, J.; Choi, R.; Wall, A.; Clifton, M.C.; Lukacs, C.M.; Staker, B.L.; Van Voorhis, W.; Myler, P.; Lorimer, D.D.; Edwards, T.E. Structures of aspartate aminotransferases from *Trypanosoma brucei*, *Leishmania major* and *Giardia lamblia*. *Acta Crystallogr. Sect. F Struct. Biol. Commun.* **2015**, *71*, 566–571. [[CrossRef](#)] [[PubMed](#)]
212. Nozaki, T.; Shigeta, Y.; Saito-Nakano, Y.; Imada, M.; Kruger, W.D. Characterization of transsulfuration and cysteine biosynthetic pathways in the protozoan hemoflagellate, *Trypanosoma cruzi*: Isolation and molecular characterization of cystathionine gamma-synthase and serine acetyltransferase from trypanosoma. *J. Biol. Chem.* **2001**, *276*, 6516–6523. [[CrossRef](#)] [[PubMed](#)]
213. Marciano, D.; Santana, M.; Nowicki, C. Functional characterization of enzymes involved in cysteine biosynthesis and H<sub>2</sub>S production in *Trypanosoma cruzi*. *Mol. Biochem. Parasitol.* **2012**, *185*, 114–120. [[CrossRef](#)] [[PubMed](#)]
214. Romero, I.; Téllez, J.; Romanha, A.J.; Steindel, M.; Grisard, E.C. Upregulation of cysteine synthase and cystathionine  $\beta$ -synthase contributes to *Leishmania braziliensis* survival under oxidative stress. *Antimicrob. Agents Chemother.* **2015**, *59*, 4770–4781. [[CrossRef](#)] [[PubMed](#)]
215. Giordana, L.; Mantilla, B.S.; Santana, M.; Silber, A.M.; Nowicki, C. Cystathionine  $\gamma$ -lyase, an enzyme related to the reverse transsulfuration pathway, is functional in *Leishmania* spp. *J. Eukaryot. Microbiol.* **2014**, *61*, 204–213. [[CrossRef](#)] [[PubMed](#)]
216. Marciano, D.; Santana, M.; Mantilla, B.S.; Silber, A.M.; Marino-Buslje, C.; Nowicki, C. Biochemical characterization of serine acetyltransferase and cysteine desulhydrase from *Leishmania major*. *Mol. Biochem. Parasitol.* **2010**, *173*, 170–174. [[CrossRef](#)] [[PubMed](#)]
217. Wirtz, M.; Berkowitz, O.; Droux, M.; Hell, R. The cysteine synthase complex from plants: Mitochondrial serine acetyltransferase from *Arabidopsis thaliana* carries a bifunctional domain for catalysis and protein-protein interaction. *Eur. J. Biochem.* **2001**, *268*, 686–693. [[CrossRef](#)] [[PubMed](#)]
218. Nowicki, C.; Montemartini, M.; Duschak, V.; Santomé, J.A.; Cazzulo, J.J. Presence and subcellular localization of tyrosine aminotransferase and p-hydroxyphenyllactate dehydrogenase in epimastigotes of *Trypanosoma cruzi*. *FEMS Microbiol. Lett.* **1992**, *92*, 119–124. [[CrossRef](#)]
219. Montemartini, M.; Santomé, J.; Cazzulo, J.J.; Nowicki, C. Production of aromatic  $\alpha$ -hydroxyacids by epimastigotes of *Trypanosoma cruzi*, and its possible role in NADH reoxidation. *FEMS Microbiol. Lett.* **1994**, *118*, 89–92. [[CrossRef](#)]

220. Bontempi, E.J.; Aslund, L.; Porcel, B.M.; Segura, E.; Henriksson, J.; Örn, A.; Petterson, U.; Ruiz, A.M. Isolation and characterization of a gene from *Trypanosoma cruzi* encoding a 46-kilodalton protein with homology to human and rat tyrosine aminotransferase. *Mol. Biochem. Parasitol.* **1993**, *59*, 253–262. [[CrossRef](#)]
221. Blankenfeldt, W.; Nowicki, C.; Montemartini-Kalisz, M.; Kalisz, H.M.; Hecht, H.J. Crystal structure of *Trypanosoma cruzi* tyrosine aminotransferase: Substrate specificity is influenced by cofactor binding mode. *Protein Sci.* **1999**, *8*, 2406–2417. [[CrossRef](#)] [[PubMed](#)]
222. Nowicki, C.; Hunter, G.R.; Montemartini-Kalisz, M.; Blankenfeldt, W.; Hecht, H.J.; Kalisz, H.M. Recombinant tyrosine aminotransferase from *Trypanosoma cruzi*: Structural characterization and site directed mutagenesis of a broad substrate specificity enzyme. *Biochim. Biophys. Acta Protein Struct. Mol. Enzymol.* **2001**, *1546*, 268–281. [[CrossRef](#)]
223. Cazzulo Franke, M.C.; Vernal, J.; Cazzulo, J.J.; Nowicki, C. The NAD-linked aromatic  $\alpha$ -hydroxy acid dehydrogenase from *Trypanosoma cruzi*. A new member of the cytosolic malate dehydrogenases group without malate dehydrogenase activity. *Eur. J. Biochem.* **1999**, *266*, 903–910. [[CrossRef](#)] [[PubMed](#)]
224. Nowicki, C.; Cazzulo, J.J. Aromatic amino acid catabolism in trypanosomatids. *Comp. Biochem. Physiol. Part A Mol. Integr. Physiol.* **2008**, *151*, 381–390. [[CrossRef](#)] [[PubMed](#)]
225. Chatterjee, A.N.; Ghosh, J.J. Transaminases of *Leishmania donovani*, the causative organism of Kala-azar. *Nature* **1957**, *180*, 1425. [[CrossRef](#)] [[PubMed](#)]
226. Le Blancq, S.M.; Lanham, S.M. Aspartate aminotransferase in *Leishmania* is a broad-spectrum transaminase. *Trans. R. Soc. Trop. Med. Hyg.* **1984**, *78*, 373–375. [[CrossRef](#)]
227. Vernal, J.; Jose, J.; Nowicki, C. Isolation and partial characterization of a broad specificity aminotransferase from *Leishmania mexicana* promastigotes. *Mol. Biochem. Parasitol.* **1998**, *96*, 83–92. [[CrossRef](#)]
228. Vernal, J.; Cazzulo, J.J.; Nowicki, C. Cloning and heterologous expression of a broad specificity aminotransferase of *Leishmania mexicana* promastigotes. *FEMS Microbiol. Lett.* **2003**, *229*, 217–222. [[CrossRef](#)]
229. Lye, L.F.; Kang, S.O.; Nosanchuk, J.D.; Casadevall, A.; Beverley, S.M. Phenylalanine hydroxylase (PAH) from the lower eukaryote *Leishmania major*. *Mol. Biochem. Parasitol.* **2011**, *175*, 58–67. [[CrossRef](#)] [[PubMed](#)]
230. Stibbs, H.H.; Seed, J.R. Further studies on the metabolism of tryptophan in *Trypanosoma brucei gambiense*: Cofactors, inhibitors, and end-products. *Specialia* **1974**, *31*, 274–278.
231. Stibbs, H.H.; Seed, J.R. Short-term metabolism of (14-C) tryptophan in rats infected with *Trypanosoma brucei gambiense*. *J. Infect. Dis.* **1975**, *131*, 459–462. [[CrossRef](#)] [[PubMed](#)]
232. Stibbs, H.H.; Seed, J.R. Metabolism of tyrosine and phenylalanine in *Trypanosoma brucei gambiense*. *Int. J. Biochem.* **1975**, *6*, 197–203. [[CrossRef](#)]
233. Seed, J.R.; Hall, J.E.; Sechelski, J. Phenylalanine metabolism in *Microtus montanus* chronically infected with *Trypanosoma brucei gambiense*. *Comp. Biochem. Physiol. B* **1982**, *71*, 209–215. [[CrossRef](#)]
234. Hall, J.E.; Seed, J.R. Increased urinary excretion of aromatic amino acid catabolites by *Microtus montanus* chronically infected with *Trypanosoma brucei gambiense*. *Comparative Biochem.* **1984**, *77*, 755–760. [[CrossRef](#)]
235. El Sawalhy, A.; Seed, J.R.; Hall, J.E.; El Attar, H. Increased excretion of aromatic amino acid catabolites in animals infected with *Trypanosoma brucei evansi*. *J. Parasitol.* **1998**, *84*, 469–473. [[CrossRef](#)] [[PubMed](#)]
236. McGettrick, A.F.; Corcoran, S.E.; Barry, P.J.G.; McFarland, J.; Crès, C.; Curtis, A.M.; Franklin, E.; Corr, S.C.; Mok, K.H.; Cummins, E.P.; et al. *Trypanosoma brucei* metabolite indolepyruvate decreases HIF-1 $\alpha$  and glycolysis in macrophages as a mechanism of innate immune evasion. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, E7778–E7787. [[CrossRef](#)] [[PubMed](#)]
237. Schirch, V.; Szebenyi, D.M.E. Serine hydroxymethyltransferase revisited. *Curr. Opin. Chem. Biol.* **2005**, *9*, 482–487. [[CrossRef](#)] [[PubMed](#)]
238. Salcedo, E.; Sims, P.F.G.; Hyde, J.E. A glycine-cleavage complex as part of the folate one-carbon metabolism of *Plasmodium falciparum*. *Trends Parasitol.* **2005**, *21*, 406–411. [[CrossRef](#)] [[PubMed](#)]
239. Hampton, J.R. Serine metabolism in *Trypanosoma cruzi*: Synthesis of other amino acids. *Comp. Biochem. Physiol. B* **1971**, *39*, 999–1003. [[CrossRef](#)]
240. Nosei, C.; Avila, J. Serine hydroxymethyltransferase activity in *Trypanosoma cruzi*, *Trypanosoma rangeli* and American *Leishmania* spp. *Comp. Biochem. Physiol. Part B Biochem.* **1985**, *81*, 701–704. [[CrossRef](#)]
241. Gagnon, D.; Foucher, A.; Girard, I.; Ouellette, M. Stage specific gene expression and cellular localization of two isoforms of the serine hydroxymethyltransferase in the protozoan parasite *Leishmania*. *Mol. Biochem. Parasitol.* **2006**, *150*, 63–71. [[CrossRef](#)] [[PubMed](#)]

242. Roy, G.; Ouellette, M. Inactivation of the cytosolic and mitochondrial serine hydroxymethyl transferase genes in *Leishmania major*. *Mol. Biochem. Parasitol.* **2015**, *204*, 106–110. [[CrossRef](#)] [[PubMed](#)]
243. Capelluto, D.G.; Hellman, U.; Cazzulo, J.J.; Cannata, J.J. Purification and some properties of serine hydroxymethyltransferase from *Trypanosoma cruzi*. *Eur. J. Biochem.* **2000**, *267*, 712–719. [[CrossRef](#)] [[PubMed](#)]
244. Scott, D.A.; Hickerson, S.M.; Vickers, T.J.; Beverley, S.M. The role of the mitochondrial glycine cleavage complex in the metabolism and virulence of the protozoan parasite *Leishmania major*. *J. Biol. Chem.* **2008**, *283*, 155–165. [[CrossRef](#)] [[PubMed](#)]
245. Danson, M.J.; Conroy, K.; McQuattie, A.; Stevenson, K.J. Dihydrolipoamide dehydrogenase from *Trypanosoma brucei*. Characterization and cellular location. *Biochem. J.* **1987**, *243*, 661–665. [[CrossRef](#)] [[PubMed](#)]
246. Cook, I.D.; Jackman, S.A.; Danson, M.J.; Eisenthal, R.; Hough, D.W.; Whish, W.J. Identification of dihydrolipoamide dehydrogenase in the procyclic form of *Trypanosoma brucei*. *Biochem. Soc. Trans.* **1990**, *18*, 862–863. [[CrossRef](#)] [[PubMed](#)]
247. Jackman, S.A.; Hough, D.W.; Danson, M.J.; Stevenson, K.J.; Opperdoes, F.R. Subcellular localisation of dihydrolipoamide dehydrogenase and detection of lipoic acid in bloodstream forms of *Trypanosoma brucei*. *Eur. J. Biochem.* **1990**, *193*, 91–95. [[CrossRef](#)] [[PubMed](#)]
248. Else, A.J.; Hough, D.W.; Danson, M.J. Cloning, sequencing, and expression of *Trypanosoma brucei* dihydrolipoamide dehydrogenase. *Eur. J. Biochem.* **1993**, *212*, 423–429. [[CrossRef](#)] [[PubMed](#)]
249. Roldán, A.; Comini, M.A.; Crispo, M.; Krauth-Siegel, R.L. Lipoamide dehydrogenase is essential for both bloodstream and procyclic *Trypanosoma brucei*. *Mol. Microbiol.* **2011**, *81*, 623–639. [[CrossRef](#)] [[PubMed](#)]
250. Lohrer, H.; Krauth-Siegel, R.L. Purification and characterization of lipoamide dehydrogenase from *Trypanosoma cruzi*. *Eur. J. Biochem.* **1990**, *194*, 863–869. [[CrossRef](#)] [[PubMed](#)]
251. Else, A.J.; Clarke, J.F.; Willis, A.; Jackman, S.A.; Hough, D.W.; Danson, M.J. Dihydrolipoamide dehydrogenase in the *Trypanosoma* subgenus, Trypanozoon. *Mol. Biochem. Parasitol.* **1994**, *64*, 233–239. [[CrossRef](#)]
252. Gutiérrez-Correa, J. *Trypanosoma cruzi* dihydrolipoamide dehydrogenase as target of reactive metabolites generated by cytochrome c/hydrogen peroxide (or linoleic acid hydroperoxide)/phenol systems. *Free Radic. Res.* **2010**, *44*, 1345–1358. [[CrossRef](#)] [[PubMed](#)]
253. Dos Santos, P.F.; Moreira, D.S.; Baba, E.H.; Volpe, C.M.O.; Ruiz, J.C.; Romanha, A.J.; Murta, S.M.F. Molecular characterization of lipoamide dehydrogenase gene in *Trypanosoma cruzi* populations susceptible and resistant to benzimidazole. *Exp. Parasitol.* **2016**, *170*, 1–9. [[CrossRef](#)] [[PubMed](#)]
254. Cross, G.A.M.; Klein, R.A.; Linstead, P.J.D. Utilization of amino acids by *Trypanosoma brucei* in culture: L-threonine as a precursor for acetate. *Parasitology* **1975**, *71*, 311–313. [[CrossRef](#)] [[PubMed](#)]
255. Millerioux, Y.; Morand, P.; Biran, M.; Mazet, M.; Moreau, P.; Wargnies, M.; Ebikeme, C.; Deramchia, K.; Gales, L.; Portais, J.C.; et al. ATP synthesis-coupled and -uncoupled acetate production from acetyl-CoA by mitochondrial acetate: Succinate CoA-transferase and acetyl-CoA thioesterase in *Trypanosoma*. *J. Biol. Chem.* **2012**, *287*, 17186–17197. [[CrossRef](#)] [[PubMed](#)]
256. Klein, R.A.; Linstead, D.J. Threonine as a preferred source of 2 carbon units for lipid synthesis in *Trypanosoma brucei*. *Biochem. Soc. Trans.* **1976**, *4*, 48–50. [[CrossRef](#)] [[PubMed](#)]
257. Simon, M.W.; Jayasimhulu, K.; Mukkada, A.J. The free amino acid pool in *Leishmania tropica* promastigotes. *Mol. Biochem. Parasitol.* **1983**, *9*, 47–57. [[CrossRef](#)]
258. Saunders, E.C.; Ng, W.W.; Chambers, J.M.; Ng, M.; Naderer, T.; Krömer, J.O.; Likić, V.A.; McConville, M.J. Isotopomer profiling of *Leishmania mexicana* promastigotes reveals important roles for succinate fermentation and aspartate uptake in Tricarboxylic Acid Cycle (TCA) anaplerosis, glutamate synthesis, and growth. *J. Biol. Chem.* **2011**, *286*, 27706–27717. [[CrossRef](#)] [[PubMed](#)]
259. Ong, H.B.; Lee, W.S.; Patterson, S.; Wyllie, S.; Fairlamb, A.H. Homoserine and quorum-sensing acyl homoserine lactones as alternative sources of threonine: A potential role for homoserine kinase in insect-stage *Trypanosoma brucei*. *Mol. Microbiol.* **2015**, *95*, 143–156. [[CrossRef](#)] [[PubMed](#)]
260. Williamson, J.; Desowitz, R.S. Chemical composition of Trypanosomes.1. protein, amino acid and sugar analysis. *Exp. Parasitol.* **1961**, *11*, 161–175. [[CrossRef](#)]
261. Chappell, B.Y.L.H.; Southworth, G.C.; Read, C.P. Short-interval absorption and metabolism of some amino acids in *Trypanosoma gambiense*. *Parasitology* **1972**, *64*, 379–387. [[CrossRef](#)] [[PubMed](#)]
262. Panizzutti, R.; De Souza Leite, M.; Pinheiro, C.M.; Meyer-Fernandes, J.R. The occurrence of free D-alanine and an alanine racemase activity in *Leishmania amazonensis*. *FEMS Microbiol. Lett.* **2006**, *256*, 16–21. [[CrossRef](#)] [[PubMed](#)]



263. Frydman, B.; de los Santos, C.; Cannata, J.J.B.; Cazzulo, J.J. Carbon-13 nuclear magnetic resonance analysis of [1-13C]glucose metabolism in *Trypanosoma cruzi*. *Eur. J. Biochem.* **1990**, *192*, 363–368. [[CrossRef](#)] [[PubMed](#)]
264. Westrop, G.D.; Williams, R.A.M.; Wang, L.; Zhang, T.; Watson, D.G.; Silva, A.M.; Coombs, G.H. Metabolomic analyses of *Leishmania* reveal multiple species differences and large differences in amino acid metabolism. *PLoS ONE* **2015**, *10*. [[CrossRef](#)] [[PubMed](#)]
265. Newport, G.R.; Page, C.R. Free amino acids in brain, liver, and skeletal muscle tissue of voles infected with *Trypanosoma brucei gambiense*. *J. Parasitol.* **1977**, *63*, 1060–1064. [[CrossRef](#)] [[PubMed](#)]
266. Newport, G.R.; Page, C.R.; Ashman, P.U.; Stibbs, H.H.; Seed, J.R. Alteration of free serum amino acids in voles infected with *Trypanosoma brucei gambiense*. *J. Parasitol.* **1977**, *63*, 15–24. [[CrossRef](#)] [[PubMed](#)]
267. Isoun, T.T.; Isoun, M.J.; Anosa, V.O. Free plasma amino acid profiles of normal and *Trypanosoma vivax* infected sheep. *Tropenmed. Parasitol.* **1978**, *29*, 330–334. [[PubMed](#)]
268. Bursell, E. Aspects of the metabolism of amino acids in the tsetse fly, *Glossina* (Diptera). *J. Insect Physiol.* **1963**, *9*, 439–452. [[CrossRef](#)]
269. Spitznagel, D.; Ebikeme, C.; Biran, M.; Nicabháird, N.; Bringaud, F.; Henehan, G.T.M.; Nolan, D.P. Alanine aminotransferase of *Trypanosoma brucei*- a key role in proline metabolism in procyclic life forms. *FEBS J.* **2009**, *276*, 7187–7199. [[CrossRef](#)] [[PubMed](#)]
270. Bentel, M.; Harder, S.; Wiesgig, M.; Heukeshoven, J.; Gelhaus, C.; Krause, E.; Clos, J.; Bruchhaus, I. Developmentally induced changes of the proteome in the protozoan parasite *Leishmania donovani*. *Proteomics* **2003**, *3*, 1811–1829. [[CrossRef](#)] [[PubMed](#)]
271. Antunes, L.C.M.; Han, J.; Pan, J.; Moreira, C.J.C.; Azambuja, P.; Borchers, C.H.; Carels, N. Metabolic signatures of triatomine vectors of *Trypanosoma cruzi* unveiled by metabolomics. *PLoS ONE* **2013**, *8*, e77283. [[CrossRef](#)] [[PubMed](#)]
272. Harington, J.S. Histamine and Histidine in excreta of the blood-sucking bug *Rhodnius prolixus*. *Nature* **1956**, *178*, 268. [[CrossRef](#)] [[PubMed](#)]
273. Michael Barrett, F. Changes in the concentration of free amino acids in the haemolymph of *Rhodnius prolixus* during the fifth instar. *Comp. Biochem. Physiol. Part B Biochem.* **1974**, *48*, 241–250. [[CrossRef](#)]
274. Silber, A.M.; Colli, W.; Ulrich, H.; Alves, M.J.M.; Pereira, C.A.; Manso Alves, M.; Pereira, C.A. Amino acid metabolic routes in *Trypanosoma cruzi*: Possible therapeutic targets against Chagas' disease. *Curr. Drug Target Infect. Disord.* **2005**, *5*, 53–64. [[CrossRef](#)]
275. Silva Paes, L.; Mantilla, B.A.; Barison, M.J.; Wrenger, C.; Silber, A.M. The uniqueness of the *Trypanosoma cruzi* mitochondrion: Opportunities to target new drugs against Chagas' disease. *Curr. Pharm. Des.* **2011**, *17*, 2074–2099. [[CrossRef](#)]
276. Magdaleno, A.; Ahn, I.Y.; Paes, L.S.; Silber, A.M. Actions of a proline analogue, L-thiazolidine-4-carboxylic acid (T4C), on *Trypanosoma cruzi*. *PLoS ONE* **2009**, *4*. [[CrossRef](#)] [[PubMed](#)]
277. Magdaleno, A.; Suárez Mantilla, B.; Rocha, S.C.; Pral, E.M.F.; Silber, A.M. The involvement of glutamate metabolism in the resistance to thermal, nutritional, and oxidative stress in *Trypanosoma cruzi*. *Enzym. Res.* **2011**, *2011*, 1–13. [[CrossRef](#)] [[PubMed](#)]
278. Krassner, S.M.; Granger, B.; Phermsangngnam, P.; Le, T.; Linden, V. Further studies on substrates inducing metacyclogenesis in *Trypanosoma cruzi*. *J. Protozool.* **1990**, *37*, 128–132. [[CrossRef](#)] [[PubMed](#)]
279. Martins, R.M.; Covarrubias, C.; Rojas, R.G.; Silber, A.M.; Yoshida, N. Use of L-proline and ATP production by *Trypanosoma cruzi* metacyclic forms as requirements for host cell invasion. *Infect. Immun.* **2009**, *77*, 3023–3032. [[CrossRef](#)] [[PubMed](#)]
280. Schenkman, S.; Robbins, E.S.; Nussenzweig, V. Attachment of *Trypanosoma cruzi* to mammalian cells requires parasite energy, and invasion can be independent of the target cell cytoskeleton. *Infect. Immun.* **1991**, *59*, 645–654. [[PubMed](#)]
281. Silber, A.M.; Tonelli, R.R.; Lopes, C.G.; Cunha-e-Silva, N.; Torrecilhas, A.C.T.; Schumacher, R.I.; Colli, W.; Alves, M.J.M. Glucose uptake in the mammalian stages of *Trypanosoma cruzi*. *Mol. Biochem. Parasitol.* **2009**, *168*, 102–108. [[CrossRef](#)] [[PubMed](#)]
282. Shah-Simpson, S.; Lentini, G.; Dumoulin, P.C.; Burleigh, B.A. Modulation of host central carbon metabolism and in situ glucose uptake by intracellular *Trypanosoma cruzi* amastigotes. *PLoS Pathog.* **2017**, *13*, 1–23. [[CrossRef](#)] [[PubMed](#)]



283. Toledo, D.A.M.; Roque, N.R.; Teixeira, L.; Milán-Garcés, E.A.; Carneiro, A.B.; Almeida, M.R.; Andrade, G.F.S.; Martins, J.S.; Pinho, R.R.; Freire-de-Lima, C.G.; et al. Lipid body organelles within the parasite *Trypanosoma cruzi*: A role for intracellular arachidonic acid metabolism. *PLoS ONE* **2016**, *11*, 1–22. [[CrossRef](#)] [[PubMed](#)]
284. Gazos-Lopes, F.; Martin, J.L.; Dumoulin, P.C.; Burleigh, B.A. Host triacylglycerols shape the lipidome of intracellular trypanosomes and modulate their growth. *PLoS Pathog.* **2017**, *13*, 1–22. [[CrossRef](#)] [[PubMed](#)]
285. Ley, V.; Robbins, E.S.; Nussenzweig, V.; Andrews, N.W.; Andrews, N.W. The exit of *Trypanosoma cruzi* from the phagosome is inhibited by raising the pH of acidic compartments. *J. Exp. Med.* **1990**, *171*, 401–413. [[CrossRef](#)] [[PubMed](#)]
286. Cruz-Bustos, T.; Potapenko, E.; Storey, M.; Docampo, R. An intracellular ammonium transporter is necessary for replication, differentiation, and resistance to starvation and osmotic stress in *Trypanosoma cruzi*. *mSphere* **2018**, *3*, e00377-17. [[CrossRef](#)] [[PubMed](#)]
287. Coutinho, L.; Ferreira, M.A.; Cosson, A.; Batista, M.M.; Batista Dda, G.; Minoprio, P.; Degraeve, W.M.; Berneman, A.; Soeiro Mde, N. Inhibition of *Trypanosoma cruzi* proline racemase affects host-parasite interactions and the outcome of in vitro infection. *Mem. Inst. Oswaldo Cruz* **2009**, *104*, 1055–1062. [[CrossRef](#)] [[PubMed](#)]
288. Coatnoan, N.; Berneman, A.; Chamond, N.; Minoprio, P. Proline racemases: Insights into *Trypanosoma cruzi* peptides containing D-proline. *Mem. Inst. Oswaldo Cruz* **2009**, *104*, 295–300. [[CrossRef](#)] [[PubMed](#)]
289. Buschiazzi, A.; Goytia, M.; Schaeffer, F.; Degraeve, W.; Shepard, W.; Grégoire, C.; Chamond, N.; Cosson, A.; Berneman, A.; Coatnoan, N.; et al. Crystal structure, catalytic mechanism, and mitogenic properties of *Trypanosoma cruzi* proline racemase. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 1705–1710. [[CrossRef](#)] [[PubMed](#)]
290. Ryley, J.F. Studies on the metabolism of the protozoa. 9. Comparative metabolism of bloodstream and culture forms of *Trypanosoma rhodiense*. *Biochemistry* **1962**, *85*, 211–223. [[CrossRef](#)]
291. Hannaert, V.; Michels, P.A.M. Structure, function, and biogenesis of glycosomes in Kinetoplastida. *J. Bioenerg. Biomembr.* **1994**, *26*, 205–212. [[CrossRef](#)] [[PubMed](#)]
292. Vassella, E.; Reuner, B.; Yutzy, B.; Boshart, M. Differentiation of African trypanosomes is controlled by a density sensing mechanism which signals cell cycle arrest via the cAMP pathway. *J. Cell Sci.* **1997**, *110*, 2661–2671. [[PubMed](#)]
293. Van Grinsven, K.W.A.; Van Den Abbeele, J.; Van Den Bossche, P.; Van Hellemond, J.J.; Tielens, A.G.M. Adaptations in the glucose metabolism of procyclic *Trypanosoma brucei* isolates from tsetse flies and during differentiation of bloodstream forms. *Eukaryot. Cell* **2009**, *8*, 1307–1311. [[CrossRef](#)] [[PubMed](#)]
294. Maudlin, I. Infection of tsetse with *Trypanosoma brucei rhodesiense* and *T. b. gambiense*. In *The Molecular Biology of Insect Disease Vectors*; Springer: Dordrecht, The Netherlands, 1997; pp. 136–145.
295. Overath, P.; Czichos, J.; Haas, C. The effect of citrate/cis-aconitate on oxidative metabolism during transformation of *Trypanosoma brucei*. *Eur. J. Biochem.* **1986**, *160*, 175–182. [[CrossRef](#)] [[PubMed](#)]
296. Ziegelbauer, K.; Quinten, M.; Schwarz, H.; Pearson, T.W.; Overath, P. Synchronous differentiation of *Trypanosoma brucei* from bloodstream to procyclic forms in vitro. *Eur. J. Biochem.* **1990**, *192*, 373–378. [[CrossRef](#)] [[PubMed](#)]
297. Chakraborty, B.; Biswas, S.; Mondal, S.; Bera, T. Stage specific developmental changes in the mitochondrial and surface membrane associated redox systems of *Leishmania donovani* promastigote and amastigote. *Biochemistry* **2010**, *75*, 494–518. [[CrossRef](#)] [[PubMed](#)]
298. Warburg, A.; Schlein, Y. The effect of post-bloodmeal nutrition of *Phlebotomus papatasi* on the transmission of *Leishmania major*. *Am. J. Trop. Med. Hyg.* **1986**, *35*, 926–930. [[CrossRef](#)] [[PubMed](#)]
299. Saunders, E.C.; Ng, W.W.; Kloehn, J.; Chambers, J.M.; Ng, M.; McConville, M.J. Induction of a stringent metabolic response in intracellular stages of *Leishmania mexicana* leads to increased dependence on mitochondrial metabolism. *PLoS Pathog.* **2014**, *10*. [[CrossRef](#)] [[PubMed](#)]
300. McConville, M.J.; Saunders, E.C.; Kloehn, J.; Dagley, M.J. *Leishmania* carbon metabolism in the macrophage phagolysosome—feast or famine? *F1000Research* **2015**, *4*, 1–11. [[CrossRef](#)] [[PubMed](#)]
301. Saunders, E.C.; Naderer, T.; Chambers, J.; Landfear, S.M.; McConville, M.J. *Leishmania mexicana* can utilize amino acids as major carbon sources in macrophages but not in animal models. *Mol. Microbiol.* **2018**, 1–29. [[CrossRef](#)] [[PubMed](#)]
302. Debrabant, A.; Joshi, M.B.; Pimenta, P.F.P.; Dwyer, D.M. Generation of *Leishmania donovani* axenic amastigotes: Their growth and biological characteristics. *Int. J. Parasitol.* **2004**, *34*, 205–217. [[CrossRef](#)] [[PubMed](#)]

303. Diaz, E.; Zacarias, A.K.; Pérez, S.; Vanegas, O.; Köhidai, L.; Padrón-Nieves, M.; Ponte-Sucre, A. Effect of aliphatic, monocarboxylic, dicarboxylic, heterocyclic and sulphur-containing amino acids on *Leishmania* spp. chemotaxis. *Parasitology* **2015**, *142*, 1621–1630. [[CrossRef](#)] [[PubMed](#)]
304. Green, S.J.; Crawford, R.M.; Hockmeyer, J.T.; Meltzer, M.S.; Nacy, C.A. *Leishmania major* amastigotes initiate the L-arginine-dependent killing mechanism in INF-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. *J. Immunol.* **1990**, *90*, 4290–4297.
305. Acuña, S.M.; Aoki, J.I.; Laranjeira-Silva, M.F.; Zampieri, R.A.; Fernandes, J.C.R.; Muxel, S.M.; Floeter-Winter, L.M. Arginase expression modulates nitric oxide production in *Leishmania (Leishmania) amazonensis*. *PLoS ONE* **2017**, *12*, 1–21. [[CrossRef](#)] [[PubMed](#)]
306. Rath, M.; Müller, I.; Kropf, P.; Closs, E.I.; Munder, M. Metabolism via arginase or nitric oxide synthase: Two competing arginine pathways in macrophages. *Front. Immunol.* **2014**, *5*, 1–10. [[CrossRef](#)] [[PubMed](#)]
307. Da Silva, M.F.L.; Floeter-Winter, L.M. Arginase in *Leishmania*. In *Proteins and Proteomics of Leishmania and Trypanosoma*; Springer: Dordrecht, The Netherlands, 2014; Volume 74, pp. 103–117.
308. Goldman-Pinkovich, A.; Balno, C.; Strasser, R.; Zeituni-Molad, M.; Bendelak, K.; Rentsch, D.; Ephros, M.; Wiese, M.; Jardim, A.; Myler, P.J.; et al. An arginine deprivation response pathway is induced in *Leishmania* during macrophage invasion. *PLoS Pathog.* **2016**, *12*, 1–18. [[CrossRef](#)] [[PubMed](#)]
309. Muxel, S.M.; Laranjeira-Silva, M.F.; Zampieri, R.A.; Floeter-Winter, L.M. *Leishmania (Leishmania) amazonensis* induces macrophage miR-294 and miR-721 expression and modulates infection by targeting NOS<sub>2</sub> and L-arginine metabolism. *Sci. Rep.* **2017**, *7*, 1–15. [[CrossRef](#)] [[PubMed](#)]
310. Kropf, P.; Fuentes, J.M.; Fahrnich, E.; Arpa, L.; Herath, S.; Weber, V.; Soler, G.; Celada, A.; Modolell, M.; Muller, I. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. *FASEB J.* **2005**, *19*, 1000–1002. [[CrossRef](#)] [[PubMed](#)]
311. Stuehr, D.J. Mammalian nitric oxide synthases. *Biochim. Biophys. Acta Bioenerg.* **1999**, *1411*, 217–230. [[CrossRef](#)]
312. Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: Structure, function and inhibition. *Biochem. J.* **2001**, *357*, 593–615. [[CrossRef](#)] [[PubMed](#)]
313. Duszzenko, M.; Ginger, M.L.; Brennand, A.; Gualdrón-López, M.; Colombo, M.I.; Coombs, G.H.; Coppens, I.; Jayabalasingham, B.; Langsley, G.; De Castro, S.L.; et al. Autophagy in protists. *Autophagy* **2011**, *7*, 127–158. [[CrossRef](#)] [[PubMed](#)]
314. Brennand, A.; Gualdrón-López, M.; Coppens, I.; Rigden, D.J.; Ginger, M.L.; Michels, P.A.M. Autophagy in parasitic protists: Unique features and drug targets. *Mol. Biochem. Parasitol.* **2011**, *177*, 83–99. [[CrossRef](#)] [[PubMed](#)]
315. Kim, K.H.; Lee, M. Autophagy—A key player in cellular and body metabolism. *Nat. Rev. Endocrinol.* **2014**, *10*, 322–337. [[CrossRef](#)] [[PubMed](#)]
316. Schmidt, R.S.; Butikofer, P. Autophagy in *Trypanosoma brucei*: Amino acid requirement and regulation during different growth phases. *PLoS ONE* **2014**, *9*, 1–10. [[CrossRef](#)] [[PubMed](#)]
317. Li, F.-J.; Xu, Z.-S.; Soo, A.D.S.; Lun, Z.-R.; He, C.Y. ATP-driven and AMPK-independent autophagy in an early branching eukaryotic parasite. *Autophagy* **2017**, *13*, 715–729. [[CrossRef](#)] [[PubMed](#)]
318. Li, F.; He, C.Y. Autophagy in protozoan parasites: *Trypanosoma brucei* as a model. *Future Microbiol.* **2017**, *12*, 1337–1340. [[CrossRef](#)] [[PubMed](#)]
319. Albina, J.E.; Cui, S.; Mateo, R.B.; Reichner, J.S. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. *J. Immunol.* **1993**, *150*, 5080–5085. [[PubMed](#)]
320. Piacenza, L.; Peluffo, G.; Radi, R. L-arginine-dependent suppression of apoptosis in *Trypanosoma cruzi*: Contribution of the nitric oxide and polyamine pathways. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 7301–7306. [[CrossRef](#)] [[PubMed](#)]
321. Mandal, A.; Das, S.; Roy, S.; Ghosh, A.K.; Sardar, A.H.; Verma, S.; Saini, S.; Singh, R.; Abhishek, K.; Kumar, A.; et al. Deprivation of L-arginine induces oxidative stress mediated apoptosis in *Leishmania donovani* promastigotes: Contribution of the polyamine pathway. *PLoS Negl. Trop. Dis.* **2016**, *10*, 1–26. [[CrossRef](#)] [[PubMed](#)]
322. Darling, T.N.; Blum, J.J. Changes in the shape of *Leishmania major* promastigotes in response to hexoses, proline, and hypo-osmotic stress. *J. Protozool.* **1990**, *37*, 267–272. [[CrossRef](#)] [[PubMed](#)]
323. Kollien, A.H.; Schaub, G.A. The development of *Trypanosoma cruzi* in triatominae. *Parasitol. Today* **2000**, *16*, 381–387. [[CrossRef](#)]

324. Kollien, A.H.; Grospietsch, T.; Kleffmann, T.; Zerbst-Boroffka, I.; Schaub, G.A. Ionic composition of the rectal contents and excreta of the reduviid bug *Triatoma infestans*. *J. Insect Physiol.* **2001**, *47*, 739–747. [[CrossRef](#)]
325. Louradour, I.; Monteiro, C.C.; Inbar, E.; Ghosh, K.; Merkhofer, R.; Lawyer, P.; Paun, A.; Smelkinson, M.; Secundino, N.; Lewis, M.; et al. The midgut microbiota plays an essential role in sand fly vector competence for *Leishmania major*. *Cell. Microbiol.* **2017**, *19*. [[CrossRef](#)] [[PubMed](#)]
326. Lang, F. Mechanisms and significance of cell volume regulation. *J. Am. Coll. Nutr.* **2007**, *26*, 613S–623S. [[CrossRef](#)] [[PubMed](#)]
327. Brocker, C.; Thompson, D.C.; Vasilio, V. The role of hyperosmotic stress in inflammation and disease. *Biomol. Concepts* **2012**, *3*, 345–364. [[CrossRef](#)] [[PubMed](#)]
328. Rohloff, P.; Docampo, R. A contractile vacuole complex is involved in osmoregulation in *Trypanosoma cruzi*. *Exp. Parasitol.* **2008**, *118*, 17–24. [[CrossRef](#)] [[PubMed](#)]
329. Docampo, R.; Ulrich, P.; Moreno, S.N.J. Evolution of acidocalcisomes and their role in polyphosphate storage and osmoregulation in eukaryotic microbes. *Philos. Trans. R. Soc. B Biol. Sci.* **2010**, *365*, 775–784. [[CrossRef](#)] [[PubMed](#)]
330. Docampo, R.; de Souza, W.; Miranda, K.; Rohloff, P.; Moreno, S.N.J. Acidocalcisomes—Conserved from bacteria to man. *Nat. Rev. Microbiol.* **2005**, *3*, 251–261. [[CrossRef](#)] [[PubMed](#)]
331. Allen, R.D.; Naitoh, Y. Osmoregulation and contractile vacuoles of protozoa. *Int. Rev. Cytol.* **2002**, *215*, 351–394. [[PubMed](#)]
332. Docampo, R.; Jimenez, V.; Lander, N.; Li, Z.H.; Niyogi, S. New insights into roles of acidocalcisomes and contractile vacuole complex in osmoregulation in protists. *Int. Rev. Cell Mol. Biol.* **2013**, *305*, 69–113. [[PubMed](#)]
333. Ruiz, F.A.; Rodrigues, C.O.; Docampo, R. Rapid changes in polyphosphate content within acidocalcisomes in response to cell growth, differentiation, and environmental stress in *Trypanosoma cruzi*. *J. Biol. Chem.* **2001**, *276*, 26114–26121. [[CrossRef](#)] [[PubMed](#)]
334. LeFurgey, A.; Ingram, P.; Blum, J.J. Compartmental responses to acute osmotic stress in *Leishmania major* result in rapid loss of Na<sup>+</sup> and Cl<sup>−</sup>. *Comp. Biochem. Physiol. A Mol. Integr. Physiol.* **2001**, *128*, 385–394. [[CrossRef](#)]
335. Lemerrier, G.; Espiau, B.; Ruiz, F.A.; Vieira, M.; Luo, S.; Baltz, T.; Docampo, R.; Bakalara, N. A pyrophosphatase regulating polyphosphate metabolism in acidocalcisomes is essential for *Trypanosoma brucei* virulence in mice. *J. Biol. Chem.* **2004**, *279*, 3420–3425. [[CrossRef](#)] [[PubMed](#)]
336. Vieira, L.L.; Lafuente, E.; Gamarro, F.; Cabantchik, Z. An amino acid channel activated by hypotonically induced swelling of *Leishmania major* promastigotes. *Biochem. J.* **1996**, *319*, 691–697. [[CrossRef](#)] [[PubMed](#)]
337. Rohloff, P.; Rodrigues, C.O.; Docampo, R. Regulatory volume decrease in *Trypanosoma cruzi* involves amino acid efflux and changes in intracellular calcium. *Mol. Biochem. Parasitol.* **2003**, *126*, 219–230. [[CrossRef](#)]
338. LeFurgey, A.; Gannon, M.; Blum, J.; Ingram, P. *Leishmania donovani* amastigotes mobilize organic and inorganic osmolytes during regulatory volume decrease. *J. Eukaryot. Microbiol.* **2005**, *52*, 277–289. [[CrossRef](#)] [[PubMed](#)]
339. Rohloff, P.; Docampo, R. Ammonium production during hypo-osmotic stress leads to alkalization of acidocalcisomes and cytosolic acidification in *Trypanosoma cruzi*. *Mol. Biochem. Parasitol.* **2006**, *150*, 249–255. [[CrossRef](#)] [[PubMed](#)]
340. Li, Z.-H.; Alvarez, V.E.; De Gaudenzi, J.G.; Sant’Anna, C.; Frasch, A.C.C.; Cazzulo, J.J.; Docampo, R. Hyperosmotic stress induces aquaporin-dependent cell shrinkage, polyphosphate synthesis, amino acid accumulation, and global gene expression changes in *Trypanosoma cruzi*. *J. Biol. Chem.* **2011**, *286*, 43959–43971. [[CrossRef](#)] [[PubMed](#)]

